

Brumback
836576

08/836576

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:13:22 ON 15 DEC 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 12 DEC 97 HIGHEST RN 198622-31-0
DICTIONARY FILE UPDATES: 12 DEC 97 HIGHEST RN 198541-26-3

TSCA INFORMATION NOW CURRENT THROUGH JUNE 1997

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

=> e "cholesteryl-3.beta.-carboxamidoethylenetrimethylammonium iodide"/cn 5

E1 1 CHOLESTERYL VINYL SUCCINATE POLYMER/CN
E2 1 CHOLESTERYL-.BETA.-D-GLUCOSIDE-6-MONOPALMITATE/CN
E3 0 --> CHOLESTERYL-3.BETA.-CARBOXAMIDOETHYLENETRIMETHYLAMMONIUM IODIDE/CN
E4 1 CHOLESTERYL-4-14C ARACHIDONATE/CN
E5 1 CHOLESTERYL-4-14C LINOLEATE/CN

=> s ?carboxamidoethylenamine?/cns

L1 0 ?CARBOXAMIDOETHYLENAMINE?/CNS

=> s ?oxysuccinamidoethylene?/cns

L2 0 ?OXYSUCCINAMIDOETHYLENE?/CNS

=> s ?"dimethylaminoethane)carbamoyl]cholester"?/cns

6 ?"DIMETHYLAMINOETHANE"/CNS
13797 "CARBAMOYL"/CNS
1584 "CHOLESTER"?/CNS
L3 0 ?"DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTER"?/CNS
((??"DIMETHYLAMINOETHANE" (W) "CARBAMOYL" (W) "CHOLESTER"?)/C
NS)

=> fil ca,caplus

FILE 'CA' ENTERED AT 16:15:26 ON 15 DEC 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:15:26 ON 15 DEC 1997
Searcher : Shears 308-4994

08/836576

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L4 (2952) SEA CHOLESTER? (S) (3 (W) (BETA OR B))
L5 49 SEA L4 (S) (CARBAM? OR CARBOXAMID? OR CARBOX? AMID?)

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 25 DUP REM L5 (24 DUPLICATES REMOVED)

=> d 1-25 .bevstr1

L6 ANSWER 1 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 1
AN 127:298774 CA
TI Spray-dried microparticles as therapeutic vehicles for use in gene therapy
IN Sutton, Andrew Derek; Ogden, Jill Elizabeth; Johnson, Richard Alan
PA Andaris Ltd., UK; Sutton, Andrew Derek; Ogden, Jill Elizabeth; Johnson, Richard Alan
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
PI WO 9736578 A1 971009
DS W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE,
GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-GB953 970403
PRAI GB 96-7035 960403
WO 96-GB1379 960607
DT Patent
LA English
AB Microparticles, which are smooth and spherical, and at least 90 % of which have a vol. median particle size of 1 to 10 .mu.m, comprise a substantially uniform mixt. of an agent for gene therapy and an excipient. For example, a naked or encapsulated gene can thus be administered, using a dry powder inhaler. A plasmid pCMV promoter:luciferase gene was reconstituted with 3. **beta.-[N-(N,N-dimethylaminoethyl)carbamoyl]cholesterol/dioleoylphosphatidylethanolamine** at a charge ratio of 5:1 and spray dried.
IT Encapsulation

Searcher : Shears 308-4994

Gene therapy
 Inhalants (drug delivery systems)
 Inhalers (medical)
 Microparticles (drug delivery systems)
 Particle size
 Spray drying
 Virus
 (spray-dried microparticles as therapeutic vehicles for gene therapy)
 IT Carbohydrates, biological studies
 RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (spray-dried microparticles as therapeutic vehicles for gene therapy)
 IT DNA
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (spray-dried microparticles as therapeutic vehicles for gene therapy)
 IT Genes (animal)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (spray-dried microparticles as therapeutic vehicles for gene therapy)
 IT 57-50-1, Sucrose, biological studies 63-42-3, Lactose 87-78-5,
 Mannitol
 RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (spray-dried microparticles as therapeutic vehicles for gene therapy)

L6 ANSWER 2 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 2
 AN 127:144710 CA
 TI Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer
 AU Nomura, Takehiko; Nakajima, Shin; Kawabata, Kenji; Yamashita, Fumiyo; Takakura, Yoshinobu; Hashida, Mitsuru
 CS Department Drug Delivery Research, Faculty Pharmaceutical Sciences, Kyoto University, Kyoto, 606-01, Japan
 SO Cancer Res. (1997), 57(13), 2681-2686
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 AB The pharmacokinetic properties and gene expression of naked plasmid DNA and its cationic liposome complexes were studied after direct
 Searcher : Shears 308-4994

intratumoral injection. Using a Walker 256 tissue-isolated tumor perfusion system, we quantified the recovery of naked plasmid DNA and cationic liposome complexes in the tumor, leakage from the tumor surface, and the venous outflow after intratumoral injection.

Approx. 50% of naked plasmid DNA had been eliminated from the tumor 2 h after injection, whereas more than 90% of plasmid DNA was retained in the tumor when it was complexed with cationic liposomes. However, the distribution of these complexes in the tumor was restricted to the tissue surrounding the injection site.

Pharmacokinetic anal. of the venous outflow profiles suggested that the rate-limiting process that dets. the retention of plasmid DNA in the tumor is transferred from the injection site in the tumor tissue and that complexation with cationic liposomes may retard this process. Furthermore, we examd. the gene expression of chloramphenicol acetyltransferase DNA constructs (naked pCMV-CAT) and the corresponding cationic liposome [3,.beta
.-(N,-(N',N'-dimethylaminoethane)carbamoyl)

cholesterol] complexes. A similar level of gene expression was obsd. in vivo after direct intratumoral injection of naked DNA and its cationic liposome complexes. In both cases, a great variation was obsd. between tumors, and localization of gene-transduced cells in the tumor tissue was limited to the area in the vicinity of the injection site. Thus, these pharmacokinetic and gene expression studies have demonstrated that cationic liposomes can enhance the retention of injected DNA in the tumor model, whereas cationic liposome complex does not necessarily improve gene expression because of its poor dissemination in this tumor. The present study also suggested that there is a need to control the behavior of the injected naked plasmid DNA and its cationic liposome complexes to ensure better distribution throughout the tumor.

IT Antitumor agents
Gene therapy
Liposomes (drug delivery systems)
Plasmids
(pharmacokinetics and gene expression of naked plasmid DNA and its cationic liposome complexes in Walker 256 tumor)

IT DNA
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(pharmacokinetics and gene expression of naked plasmid DNA and its cationic liposome complexes in Walker 256 tumor)

IT 9040-07-7, Chloramphenicol acetyltransferase 137056-72-5
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmacokinetics and gene expression of naked plasmid DNA and its cationic liposome complexes in Walker 256 tumor)

TI Optimization of liposome mediated transfection of a neuronal cell line
AU Mcquillin, Andrew; Murray, Karl D.; Etheridge, Christopher J.; Stewart, Luisa; Cooper, Robert G.; Brett, Peter M.; Miller, Andrew D.; Gurling, Hugh M. D.
CS Molecular Psychiatry Laboratory, Department of Psychiatry and Behavioural Sciences, Windeyer Institute of Medical, UCL Medical School, London, W1P 6DB, UK
SO NeuroReport (1997), 8(6), 1481-1484
CODEN: NERPEZ; ISSN: 0959-4965
PB Rapid Science Publishers
DT Journal
LA English
AB A cell line derived from sensory neurons was transfected with high efficiency using cationic liposomes, formulated from 3.
beta.-[N-(N',N'-dimethylaminoethyl)carbamoyl]
cholesterol (DC-Chol) and dioleoyl L-.alpha.-phosphatidylethanolamine (DOPE). This is the first time that cationic liposomes of this type have been reported to transfect a neuronal cell line. We used a reporter gene construct expressing .beta.-galactosidase under the control of the cytomegalovirus immediate early promoter and routinely obsd. transfection efficiencies >40%. Parameters affecting transfection efficiency were examd. and the ratio of DNA to liposome proved to be crucial. Liposome formulation procedures and cell transfection protocols devised here will be used as a basis for further in vivo and in vitro work.
IT Animal cell line
(ND7; optimization of liposome mediated transfection of a neuronal cell line)
IT Cytomegalovirus
Gene therapy
Liposomes (drug delivery systems)
Neurons
Transformation (genetic)
(optimization of liposome mediated transfection of a neuronal cell line)
IT DNA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(optimization of liposome mediated transfection of a neuronal cell line)
IT 4004-05-1, Dioleoylphosphatidylethanolamine 137056-72-5
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(optimization of liposome mediated transfection of a neuronal cell line)

AN 127:76698 CA
 TI Transfection of avian LMH-2A hepatoma cells with cationic lipids
 AU Walzem, R. L.; Hickman, M. A.; German, J. B.; Hansen, R. J.
 CS Departments of Molecular Biosciences, School of Veterinary Medicine,
 University of California-Davis, Davis, CA, 95616, USA
 SO Poult. Sci. (1997), 76(6), 882-886
 CODEN: POSCAL; ISSN: 0032-5791
 PB Poultry Science Association, Inc.
 DT Journal
 LA English
 AB LMH-2A is an estrogen-responsive avian hepatoma cell line whose
 susceptibility to cationic-lipid-mediated transfection is poorly
 described. **3.beta.[N-N',N'-**
 (dimethylaminoethane)-**carbamoyl cholesterol**
 (DCC) requires a one-step synthesis, and can be used to formulate
 transfection-grade liposomes when combined with
 dioleoylphosphatidylethanolamine (DOPE) 1/1 (wt./wt.). Luciferase
 activities in LMH-2A cells were 8.5-fold and 87.5-fold greater than
 those in HepG2 and FTO2B cells, resp., following
 DCC-liposome-mediated transfection with a reporter consisting of the
 human cytomegalovirus immediate-early promoter (CMV), joined to
 Photinus pyralis luciferase (L) cDNA, designated pCMVL. Using
 pCMVL, N-(2-bromoethyl)-N,N-dimethyl-2,3-bis(9-octadecenoxy)-
 propanaminium bromide (BMOP)/DOPE 1/1 (wt./wt.), at a 7.5:1 ratio
 with DNA, produced luciferase activities that were 2.9-fold higher
 than those of DCC-liposomes, at an optimal 10:1 lipid:DNA ratio. At
 optimal lipid:DNA ratios, com. available liposomes, Transfectam.RTM.
 Lipofectamine.RTM., and Lipofectin.RTM. produced luciferase
 activities that were 1.39, 1.03, and 0.47-fold those of
 DCC-liposomes. The effect of 0, 10, 100, or 500 nM/L
 17.beta.-estradiol on the expression of pCMVL and a second
 luciferase reporter contg. the -593/+48 promoter region of the
 estrogen-responsive avian apo VLDL-II gene, designated pApoL, was
 tested in cells cultured in the presence or absence of 10% chicken
 serum. The CMV promoter supported a high level of expression in
 LMH-2A cells that was unaffected by serum alone, but was weakly
 responsive to estrogen. Estrogen responses of both reporters
 reached a plateau at 10 nM/L. Estrogen increased the expression of
 pApoL 24-fold and 79-fold in the absence and presence of serum,
 resp. The -593/+48 region of the apo VLDL-II promoter may not
 contain previously reported neg. insulin response elements, but
 chicken serum contains factors that enhance estrogen responsiveness
 of this region.
 IT Animal cell line
 (LMH-2A; transfection of avian LMH-2A hepatoma cells with
 cationic lipids)
 IT Liposomes
 (cationic; transfection of avian LMH-2A hepatoma cells with
 cationic lipids)

Searcher : Shears 308-4994

IT Plasmid vectors
 (pCMVL and pApOL; transfection of avian LMH-2A hepatoma cells with cationic lipids)

IT Transformation (genetic)
 (transfection of avian LMH-2A hepatoma cells with cationic lipids)

IT 50-28-2, 17. β -Estradiol, biological studies
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (estrogen responsiveness of expression; transfection of avian LMH-2A hepatoma cells with cationic lipids)

IT 137056-72-5 156180-28-8
 RL: BUU (Biological use, unclassified); BIOL (Biological study);
 USES (Uses)
 (transfection of avian LMH-2A hepatoma cells with cationic lipids)

L6 ANSWER 5 OF 25 CAPLUS COPYRIGHT 1997 ACS
 AN 1997:646908 CAPLUS
 TI Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes
 AU Schreier, Hans; Gagne, Lucie; Bock, Thomas; Erdos, Gregory W.; Druzgala, Pascal; Conary, Jon T.; Mueller, Bernd W.
 CS Advanced Therapies Inc., Suite 210A, 371 Bel Marin Keys, Novato, CA, 94949, USA
 SO Pharm. Acta Helv. (1997), 72(4), 215-223
 CODEN: PAHEAA; ISSN: 0031-6865
 PB Elsevier
 DT Journal
 LA English
 AB The purpose of this study was to elucidate the interaction of cationic liposomes and plasmid cDNA by examg. their ultrastructure, zeta potential, stability in aq. media and protection from DNaseI digestion; their potential for hemolysis and platelet aggregation was evaluated as it may serve as an in vitro toxicity screen.
 Liposomes consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) or 3. β -trimethylammonium chloride (DOTMA) or 3. β -[N-(N',N'-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and dioleylphosphatidylethanolamine (DOPE) were complexed with plasmid constructs of ovine prostaglandin G/H synthase (pCMV4-PGH) or human .alpha.1-antitrypsin (pCMV4-AAT) at lipid:plasmid (L/P) ratios of 3:1-8:1 (wt./wt.). The electron micrographs showed bead-like attachment of liposomes to cDNA and coating of plasmid strands. The zeta potential showed isoelec. points at L/P ratios of 3.5-4 (DOTMA/DOPE) and 5.5-6.5, corresponding to a pKa of 6.45 (DC-Chol/DOPE). Liposome cDNA complexes were stable in water, saline and 5% dextrose for 48 h, but pptd. instantaneously in PBS. An increase in the L/P ratio corresponded with increased protection from DNaseI digestion.

Searcher : Shears 308-4994

DOTMA/DOPE liposomes alone were highly hemolytic and DC-Chol/DOPE liposomes moderately hemolytic; hemolysis was abolished by cDNA complexation, with the exception of very high (.gtoreq.7:1) L/P ratios. Both liposomes alone and cDNA complexes caused transient serum turbidity, while none caused platelet aggregation. It was concluded that current cationic lipid cDNA formulations are metastable and appear to have very little if any toxicity with respect to hemolytic potential and untoward interaction with other blood components. The results are discussed in relation to the use of cationic liposomal formulations to deliver plasmid vectors in gene therapy.

IT Drug toxicity
 Gene therapy
 Liposomes (drug delivery systems)
 Plasmid vectors
 (physicochem. properties and in vitro toxicity of cationic liposome cDNA complexes in relation to delivery of plasmid vectors in gene therapy)

IT cDNA
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (physicochem. properties and in vitro toxicity of cationic liposome cDNA complexes in relation to delivery of plasmid vectors in gene therapy)

IT 4004-05-1, DOPE 104162-48-3, DOTMA 137056-72-5
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (physicochem. properties and in vitro toxicity of cationic liposome cDNA complexes in relation to delivery of plasmid vectors in gene therapy)

L6 ANSWER 6 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 5
 AN 127:298617 CA
 TI Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin
 AU Zuidam, Nicolaas J.; Barenholz, Yechezkel
 CS Department of Biochemistry, The Hebrew University, Hadassah Medical School, P.O. Box 12272, Jerusalem, Israel
 SO Biochim. Biophys. Acta (1997), 1329(2), 211-222
 CODEN: BBACAQ; ISSN: 0006-3002
 PB Elsevier
 DT Journal
 LA English
 AB Cationic liposomes are used to deliver genes into cells in vitro and in vivo. The present study is aimed to characterize the electrostatic parameters of cationic, large unilamellar vesicles, 110.+-20 nm in size, composed of DOTAP/DOPE (mole ratio 1/1), DOTAP/DOPC (mole ratio 1/1), 100% DOTAP, DMRIE/DOPE 1/1, or DC-CHOL/DOPE (mole ratio 1/1). {Abbreviations: DOTAP, Searcher : Shears 308-4994

N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DMRIE, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide; DC-CHOL, 3.**beta.** [N-(N',N'-dimethylaminoethane) carbamoyl] cholesterol}. The cationic liposomes had a large pos. surface potential and a high pH at the liposomal surface in 20 mM Hepes buffer (pH 7.4) as monitored by the pH-sensitive fluorophore 4-heptadecyl-7-hydroxycoumarin. In contrast to DOTAP and DMRIE which were 100% charged, DC-CHOL in DC-CHOL/DOPE (1/1) liposomes was only about 50% charged in 20 mM Hepes buffer (pH 7.4). This might result in an easier dissociation of bilayers contg. DC-CHOL from the plasmid DNA (which is necessary to enable transcription), in a decrease of the charge on the external surfaces of the liposomes or DNA-lipid complexes, and in an increase in release of the DNA-lipid complex into the cytosol from the endosomes. Other electrostatic characteristics found were that the primary amine group of DOPE in cationic liposomes dissociated at high (>7.9) pH_{bulk} and that a salt bridge was likely between the quaternary amine of DOTAP or DMRIE and the phosphate group of DOPE or DOPC, but not between the tertiary amine of DC-CHOL and the phosphate group of DOPE. The liposomes contg. DOTAP were unstable upon diln., probably due to the high crit. aggregation concn. of DOTAP, 7. times. 10⁻⁵ M. This might also be a mechanism of the dissociation of bilayers contg. DOTAP from the plasmid DNA.

IT Liposomes (drug delivery systems)
 (cationic; electrostatic parameters of cationic liposomes commonly used for gene delivery as detd. by 4-heptadecyl-7-hydroxycoumarin)

IT Gene therapy
 Genetic engineering
 (electrostatic parameters of cationic liposomes commonly used for gene delivery as detd. by 4-heptadecyl-7-hydroxycoumarin)

IT Electricity
 (electrostatics; electrostatic parameters of cationic liposomes commonly used for gene delivery as detd. by 4-heptadecyl-7-hydroxycoumarin)

IT 4004-05-1, 1,2-Dioleoyl-sn-glycero-3-phosphatidylethanolamine
 4235-95-4 132172-61-3 137056-72-5 153312-64-2
 RL: DEV (Device component use); PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process); USES (Uses)
 (electrostatic parameters of cationic liposomes commonly used for gene delivery as detd. by 4-heptadecyl-7-hydroxycoumarin)

L6 ANSWER 7 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 6

AN 127:131699 CA

TI Gene transfection by cationic liposomes: comparison of the transfection efficiency of liposomes prepared from various positively charged lipids

Searcher : Shears 308-4994

AU Zhao, Dan-Dan; Watarai, Shinobu; Lee, Jin-Tae; Kouchi, Shuuichi;
 Ohmori, Hitishi; Yasuda, Tatsuji
 CS Department of Cell Chemistry, Institute of Cellular and Molecular
 Biology, Okayama University Medical School, Okayama, 700, Japan
 SO Acta Med. Okayama (1997), 51(3), 149-154
 CODEN: AMOKAG; ISSN: 0386-300X
 PB Okayama University Medical School
 DT Journal
 LA English
 AB We compared the transfection efficiency of four types of pos.
 charged liposomes composed of (i) N-(.alpha.-trimethylammonioacetyl)-
 didodecyl-D-glutamate chloride (TMAG), dilauroylphosphatidylcholine
 (DLPC), and dioleoylphosphatidylethanolamine (DOPE) (1:2:2 molar
 ratio); (ii) **3.*beta.* [N-(N',
 N'-dimethylaminoethane)-carbamoyl] cholesterol**
 (DC-Chol) and DOPE (3:2 molar ratio); (iii)
 dimethyldioctadecylammonium bromide (DDAB) and DOPE (1:2.2 molar
 ratio); (i.v.) N-[1- (2,3-dioleyloxy) propyl]-N,N,N-
 trimethylammonium chloride (DOTMA) and DOPE (1: 1, wt./wt.);
 lipofectin). Luciferase gene was used as a reporter gene. Among
 the cationic liposomes used, the liposomes composed of TMAG, DOPE
 and DLPC showed a much higher efficiency of plasmid DNA entrapment
 than the other cationic liposomes tested. In the absence of serum,
 the cationic multilamellar vesicles (MLV) and small unilamellar
 vesicles (SUV) composed of TMAG, DOPE and DLPC gave highly efficient
 transfection. MLV, dehydration-rehydration vesicles (DRV), and SUV
 liposomes prep'd. with the mixts. of DC-Chol and DOPE showed similar
 levels of transfection efficiency. However, the cationic liposomes
 composed of DDAB and DOPE showed inferior efficiency, whether in the
 form of DRV, SUV or MLV. The transfection efficiency of lipofectin
 was also low. In the presence of serum, a considerable (about
 30-50%) amt. of transfection activity was still obsd. at 10% fetal
 calf serum in the cationic MLV and SUV composed of TMAG, DOPE and
 DLPC. Cationic MLV, composed of TMAG, DOPE and DLPC, can transfet
 plasmid DNA, not only in the adherent cell lines but also in the
 suspension cell lines. These findings indicate that the
 transfection efficiency of cationic liposomes is affected by the
 lipid compn., the type of liposome, or the presence or absence of
 serum. They also indicate that the cationic liposomes contg. TMAG,
 DOPE and DLPC are efficient vectors for gene transfer into cells.
 IT Liposomes
 (cationic; gene transfection by cationic liposomes: comparison of
 transfection efficiency of liposomes prep'd. from various pos.
 charged lipids)
 IT Transformation (genetic)
 (liposome-mediated; gene transfection by cationic liposomes:
 comparison of transfection efficiency of liposomes prep'd. from
 various pos. charged lipids)
 IT Genes

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (transfer of,; gene transfection by cationic liposomes: comparison of transfection efficiency of liposomes prep'd. from various pos. charged lipids)

IT 18194-25-7, Dilauroylphosphatidylcholine
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (gene transfection by cationic liposomes and comparison of transfection efficiency of liposomes prep'd. from various pos. charged lipids)

IT 2462-63-7, Dioleoylphosphatidylethanolamine 131897-06-8, N-(.alpha.-Trimethylammonioacetyl)-didodecyl-D-glutamate chloride
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (gene transfection by cationic liposomes: comparison of transfection efficiency of liposomes prep'd. from various pos. charged lipids)

L6 ANSWER 8 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 7
 AN 127:2669 CA
 TI Lipid-mediated transfection of normal adult human hepatocytes in primary culture
 AU Ourlin, Jean Claude; Vilarem, Marie-Jose; Daujat, Martine; Harricane, Marie-Cecile; Domergue, Jacques; Joyeux, Henri; Baulieux, Jean; Maurel, Patrick
 CS INSERM U-128, CNRS, Montpellier, 34033, Fr.
 SO Anal. Biochem. (1997), 247(1), 34-44
 CODEN: ANBCA2; ISSN: 0003-2697
 PB Academic
 DT Journal
 LA English
 AB The aim of this work was to develop a procedure for the lipid-mediated transfection of DNA into normal adult human hepatocytes in culture. Cells were plated in a serum-free culture medium at various cell densities, on plastic or collagen-coated dishes, both in the absence and in the presence of epidermal growth factor (EGF). The cells were incubated for various periods of time with mixts. of DNA-lipofectin or DNA-3.**beta**.[N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol) liposomes, and the efficiency of transfection was assessed by measuring the activity of reporter genes, .beta.-galactosidase or chloramphenicol acetyltransferase (CAT). For comparison, similar expts. were carried out with human cell lines including HepG2, Caco-2, and WRL68. The efficiency of transfection (in percentage of cells) was not significantly different after transfection with lipofectin or DC-chol and
 Searcher : Shears 308-4994

comprised between 0.04 and 1.7% (extreme values) for different cultures. The efficiency of transfection decreased as the age or d. of the culture increased and increased in cultures treated with EGF. Direct measurement of the rate of DNA synthesis suggested that the efficiency of transfection was related to the no. of cells entering the S phase. Under the same conditions, the efficiency of transfection was 1-2 orders of magnitude greater in the 3 cell lines. A plasmid harboring 660 bp of the 5'-flanking region of CYP1A1 (contg. two xenobiotic enhancer elements) fused upstream of the promoter of thymidine kinase and the CAT reporter gene was constructed. When this plasmid was transfected in human hepatocytes, CAT activity was induced as expected. We conclude that normal adult human hepatocytes can be transfected with exogenous DNA and that the transfected construct is regulated in the manner expected from in vivo studies.

IT DNA
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 ([(dimethylaminoethane)carbamoyl]cholesterol complexes;
 lipid-mediated transfection of normal adult human hepatocytes in primary culture)

IT Hepatocyte
 Liposomes
 Plasmids
 Primary tissue culture (animal)
 Transformation (genetic)
 (lipid-mediated transfection of normal adult human hepatocytes in primary culture)

IT Lipids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (lipid-mediated transfection of normal adult human hepatocytes in primary culture)

IT 62229-50-9, Epidermal growth factor 128835-92-7, Lipofectin 137056-72-5D, DNA complexes
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (lipid-mediated transfection of normal adult human hepatocytes in primary culture)

L6 ANSWER 9 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 8
 AN 126:122476 CA
 TI Cationic lipid acid salt of 3.**beta**
 .-[N-(N,N-dimethylaminoethyl)carbamoyl]cholesterol
 IN Wyse, Joseph W.; Warner, Charles D.
 PA Aronex Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 PI WO 9640067 A1 961219
 Searcher : Shears 308-4994

DS W: CA, JP
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
 SE

AI WO 96-US9954 960607
 PRAI US 95-485866 950607
 DT Patent
 LA English

AB This invention discloses a novel cationic lipid acid salt of
3.bet.a.-[N-(N,N-dimethylaminoethyl)carbamoyl]cholesterol (I). Also disclosed is a
 transmembrane compatible body suitable for transfection of animals
 and animal cells with nucleotides such as DNA, RNA, and synthetic
 nucleotides. Such transmembrane compatible bodies arise from
 hydratable non-liposomal halogenated solvent-free lyophilizate
 comprising I and DOPE. This invention yet further discloses a
 halogenated solvent-free aq. soln., suitable for lyophilization into
 a preliposomal powder, wherein the soln. comprises I wherein
 substantially all I is dissolved.

IT DNA
 Gene therapy
 Liposomes (drug delivery systems)
 Nucleotides, biological studies
 RNA
 Transformation (genetic)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic lipid acid salt of dimethylaminoethylcarbamoyl
 cholesterol)

IT 137056-72-5P 166023-21-8P
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (cationic lipid acid salt of dimethylaminoethylcarbamoyl
 cholesterol)

IT 50-99-7, D-Glucose, biological studies 57-50-1, Sucrose,
 biological studies 58-86-6, D-Xylose, biological studies 63-42-3
 69-65-8, D-Mannitol 2462-63-7, Dioleoylphosphatidylethanolamine
 3458-28-4, D-Mannose 68737-67-7, Dioleoylphosphatidylcholine
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cationic lipid acid salt of dimethylaminoethylcarbamoyl
 cholesterol)

IT 108-00-9, N,N-Dimethylethylenediamine 7144-08-3, Cholesteryl
 chloroformate
 RL: RCT (Reactant)
 (cationic lipid acid salt of dimethylaminoethylcarbamoyl
 cholesterol)

L6 ANSWER 10 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 9
 AN 125:96041 CA

Searcher : Shears 308-4994

TI Adjuvant for vaccines comprising a sterol-derived lipophilic group bound to a cationic group
 IN Haensler, Jean; Trannoy, Emmanuelle; Ronco, Jorge
 PA Pasteur Merieux Serums et Vaccins, Fr.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 PI WO 9614831 A1 960523
 DS W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 95-FR1495 951114
 PRAI FR 94-13606 941114
 DT Patent
 LA French
 AB An amphipathic compd. including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine compn. In a particular embodiment, the lipophilic grouping is a cholesterol deriv. and the cations grouping is a quaternary ammonium or a protonable amine. A vaccine compn. including one or more antigens with at least one amphipathic compd. having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed. A soln. of 2.25 g **cholesteryl** chloroformate in 5 mL chloroform was stirred with a soln. of 2 mL N,N-dimethylethylenediamine in 3 mL chloroform at 0.degree. followed by evapn. of the solvent and the purifn. of **3.*beta* -[N-(N'N'-dimethylaminoethane)-carbamoyl]-cholesterol** (I) by recrystn. Thus, 300 mg I was dissolved in 100 .mu.L ethanol and 75 .mu.L of this soln was injected to 3 mL of water at 45.degree. and stirred for 5 min. The micellar suspension thus obtained was mixed with 200 .mu.L of a monovalent influenza vaccine and divided in 0.3 mL doses. The immunol. response of guinea pigs to the above vaccine was studied.
 IT Vaccines
 Lipids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adjuvant for vaccines comprising sterol-derived lipophilic group bound to cationic group)
 IT Quaternary ammonium compounds, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (conjugates with sterols; adjuvant for vaccines comprising sterol-derived lipophilic group bound to cationic group)
 IT Virus, animal
 (influenza, adjuvant for vaccines comprising sterol-derived lipophilic group bound to cationic group)
 IT Pharmaceutical dosage forms
 (liposomes, adjuvant for vaccines comprising sterol-derived lipophilic group bound to cationic group)
 Searcher : Shears 308-4994

IT 108-00-9, N,N-Dimethylethylenediamine 7144-08-3, Cholesteryl
chloroformate
RL: RCT (Reactant)
(adjuvant for vaccines comprising sterol-derived lipophilic group
bound to cationic group)

IT 137056-72-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(adjuvant for vaccines comprising sterol-derived lipophilic group
bound to cationic group)

IT 2462-63-7 10015-85-7, Dioleoyl phosphatidylcholine 123628-75-1
144108-36-1 154440-71-8 178823-15-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant for vaccines comprising sterol-derived lipophilic group
bound to cationic group)

L6 ANSWER 11 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 10
AN 125:134786 CA
TI Cholesterol (dimethylaminoethane)carbamoyl deriv. preparation and
use for liposome-mediated gene transfer
IN Reszka, Regina
PA Max-Delbrueck-Centrum fuer Molekulare Medizin, Germany
SO Ger. Offen., 5 pp.
CODEN: GWXXBX
PI DE 4446937 A1 960704
AI DE 94-4446937 941228
DT Patent
LA German
AB A new cholesterol deriv. for liposome-mediated gene transfer was
prepd. and has applications in medicine and gene transfer. The
cholesterol deriv., **3.beta**
. - [N- (N,N'-dimethylaminoethane)**carbamoyl**]
cholesterol (DAC-Chol), was prepd. from reaction of
N,N'-dimethylethylenediamine and chloroformate **cholesterol**
in equal amts. and purified by chromatog. DAC-Chol is not toxic and
can be used for direct liposome-mediated gene transfer. A new
method for direct liposome-mediated gene transfer *in vivo* is also
described. This method uses a pump system or automatic system to
continually apply liposome/DNA complexes at timed intervals.
IT Liposome
(DOPE/DAC-Chol liposome; cholesterol
(dimethylaminoethane)carbamoyl deriv. prepn. and use for
liposome-mediated gene transfer)
IT Apparatus
Genetic engineering
Pumps
Transformation, genetic
(cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use
for liposome-mediated gene transfer)
Searcher : Shears 308-4994

IT Antibodies
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Deoxyribonucleic acids
 RL: BPR (Biological process); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Gene, animal
 RL: BPR (Biological process); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Virus, animal
 (fusion proteins; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Phosphoproteins
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HMG1, cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Proteins, specific or class
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (core, cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Proteins, specific or class
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fusion products, viral; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT Therapeutics
 (geno-, cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT 2462-63-7
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (DOPE/DAC-Chol liposome; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

Searcher : Shears 308-4994

IT 137056-72-5P
 RL: BUU (Biological use, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT 110-70-3, N,N'-Dimethylethylenediamine
 RL: RCT (Reactant)
 (reaction with chloroformate cholesterol; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT 7144-08-3, Cholesterol, chloroformate
 RL: RCT (Reactant)
 (reaction with dimethylethylenediamine; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

IT 67-56-1, Methanol, uses 67-66-3, Trichloromethane, uses 7631-86-9, Silica, uses
 RL: NUU (Nonbiological use, unclassified); USES (Uses)
 (silica gel and tricholormethane/methanol for purifn.; cholesterol (dimethylaminoethane)carbamoyl deriv. prepn. and use for liposome-mediated gene transfer)

L6 ANSWER 12 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 11
 AN 126:44183 CA
 TI DNA-Induced Lateral Segregation of Cationic Amphiphiles in Lipid Bilayer Membranes as Detected via 2H NMR
 AU Mitrakos, Peter; Macdonald, Peter M.
 CS Department of Chemistry, University of Toronto, Mississauga, ON, L5L 1C6, Can.
 SO Biochemistry (1996), 35(51), 16714-16722
 CODEN: BICHAW; ISSN: 0006-2960
 PB American Chemical Society
 DT Journal
 LA English
 OS CJACS-IMAGE; CJACS
 AB *2H NMR spectroscopy was used to investigate the response of specifically choline-deuterated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) to changes in surface electrostatic charge in membranes consisting of mixts. of POPC plus various cationic amphiphiles plus polyadenylic acid (Polys). Three different cationic amphiphiles were investigated: cetyltrimethylammonium bromide (CTAB), dioleyldimethylaminopropane (DODAP), and 3.
 .beta. [N-(N',N'-dimethylaminoethane)carbamoyl]
 cholesterol (DC-CHOL). Each of the cationic amphiphiles elicited a concn.-dependent decrease (increase) in the quadrupolar splitting from POPC-.alpha.-d2 (POPC-.beta.-d2), as expected for the accumulation of cationic charges at the surface of a lipid bilayer. However, the strength of the response varied with the cationic*

Searcher : Shears 308-4994

amphiphile in the order CTAB > DODAP > DC-CHOL. When polyA was added to the cationic amphiphile-contg. lipid bilayers, the 2H NMR spectrum consisted of two overlapping Pake patterns, indicating the presence of two lipid domains with different effective surface charges and only slow exchange of lipids between the two domains. There was no evidence of any non-bilayer lipid arrangements. Anal. of the quadrupolar splittings of the two 2H NMR spectral components demonstrated that the polyA-contg. domain was enriched with respect to cationic amphiphiles while the polyA-free domain was depleted with respect to cationic amphiphiles. We conclude that polyA is able to laterally segregate cationic amphiphiles into long-lived lipid domains of distinct compn.

IT Amphiphiles
 Bilayer (biological membrane)
 (DNA-induced lateral segregation of cationic amphiphiles in lipid bilayer membranes as detected via 2H NMR)

IT 24937-83-5, Poly(A)
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (DNA-induced lateral segregation of cationic amphiphiles in lipid bilayer membranes as detected via 2H NMR)

IT 57-09-0, Cetyltrimethylammonium bromide 127512-29-2 137056-72-5
 RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
 (DNA-induced lateral segregation of cationic amphiphiles in lipid bilayer membranes as detected via 2H NMR)

L6 ANSWER 13 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 12
 AN 124:252118 CA
 TI Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
 AU Lee, Robert J.; Huang, Leaf
 CS Lab. Drug Targeting, Dep. Pharm., Univ. Pittsburgh Sch. Med., Pittsburgh, PA, 15261, USA
 SO J. Biol. Chem. (1996), 271(14), 8481-7
 CODEN: JBCHA3; ISSN: 0021-9258
 DT Journal
 LA English
 AB We have developed a lipidic gene transfer vector, LPDII, where DNA was first complexed to polylysine at a ratio of 1:0.75 (wt./wt.) and then entrapped into folate-targeted pH-sensitive anionic liposomes composed of dioleoyl phosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate/folate-polyethylene glycol-DOPE (6:4:0.01 mol/mol) via charge interaction. LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid compn. At low lipid to DNA ratios (e.g. 4 and 6), LPDII particles were pos. charged; transfection and cellular uptake levels were independent of the folate receptor and did not require a pH-sensitive lipid compn.

Searcher : Shears 308-4994

Meanwhile, transfection and uptake of neg. charged LPDII particles, i.e. those with high lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid compn. The transfection activity of LPDII was lost when the inverted cone-shaped DOPE was replaced by dioleoyl phosphatidylcholine. LPDII particles with lipid to DNA ratios of 4, 6, 10, and 12 were .apprx.20-30 times more active than DNA.cntdot.3-.

beta.-[N-(N',N'-dimethylethane)carbamoyl]

cholesterol cationic liposome complexes in KB cells and were much less cytotoxic. On the sucrose gradient, LPDII particles had a migration rate in between those of the free DNA and the DNA.cntdot.polylysine complex. An electron micrograph of LPDII showed a structure of spherical particles with a pos. stained core enclosed in a lipidic envelope with a mean diam. of 74 .+- . 14 nm. This novel gene transfer vector may potentially be useful in gene therapy for tumor-specific delivery.

- IT Liposome
 - (anionic; folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)
- IT Neoplasm
 - (cell; folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)
- IT Transformation, genetic
 - (folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)
- IT Deoxyribonucleic acids
 - RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 - (folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)
- IT Lipids, biological studies
 - RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 - (lipidic gene transfer vector LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid compn.)
- IT pH
 - (tumor cell transfection and uptake of neg. charged LPDII particles, i.e. those with high lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid compn.)
- IT Animal cell line
 - (KB, lipidic gene transfer vector LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid compn.)
- IT Receptors
 - RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 - (folic acid, tumor cell transfection and uptake of neg. charged

Searcher : Shears 308-4994

LPDII particles, i.e. those with high lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid compn.)

IT 1510-21-0, Cholesteryl hemisuccinate 2462-63-7, Dioleoyl phosphatidylethanolamine 25322-68-3, Polyethylene glycol
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses (anionic liposomes composed of dioleoyl phosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate/folate-polyethylene glycol-DOPE (6:4:0.01 mol/mol) for tumor cell-specific gene transfer)

IT 25104-18-1, Polylysine
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses (folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)

IT 59-30-3, Folic acid, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer)

L6 ANSWER 14 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 13
 AN 126:162137 CA
 TI New cationic lipid formulations for gene transfer
 AU Liu, Feng; Yang, Jingping; Huang, Leaf; Liu, Dexi
 CS Dep. Pharmaceutical Sciences, SchoolPharmacy, Univ. Pittsburgh, Pittsburgh, PA, 15261, USA
 SO Pharm. Res. (1996), 13(12), 1856-1860
 CODEN: PHREEB; ISSN: 0724-8741
 PB Plenum
 DT Journal
 LA English
 AB An attempt was made to develop dosage forms of DNA for gene delivery. **3.beta. [N-(N',N' imethylaminoethane) carbamoyl]cholesterol** (DC-Chol) was mixed either with Tween 80 alone, or with addnl. lipid components including castor oil and phosphatidylcholine (PC) or dioleoylphosphatidylethanolamine (DOPE) to make different lipid formulations. The particle size and the phys. stability of the formulations upon mixing with plasmid DNA contg. the luciferase cDNA were examd. using laser light scattering measurement. The transfection activity of the DNA/lipid complexes was tested in presence or absence of serum using a cell culture system. Many favorable properties as a gene carrier could be achieved by formulating DNA into new dosage forms using Tween 80 as the major emulsifier. Compared to the cationic liposomes, these new formulations transfected different cell lines with an equiv. or higher efficiency. Not only are they resistant to serum, but also form stable DNA complexes which could be stored for longer periods

Searcher : Shears 308-4994

of time without losing transfection activity. Cationic lipids formulated into different lipid formulations using Tween 80 as a surfactant appeared to have more favorable phys. and biol. activities than traditional cationic liposomes as a carrier for gene delivery.

IT Gene therapy
 Liposomes (drug delivery systems)
 Particle size
 Serum (blood)
 Transformation (genetic)
 (cationic lipid formulations for gene transfer)
 IT Castor oil
 DNA
 Lipids, biological studies
 Phosphatidylcholines, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic lipid formulations for gene transfer)
 IT 2462-63-7, Dioleoylphosphatidylethanolamine 9005-65-6, Tween 80
 137056-72-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic lipid formulations for gene transfer)

L6 ANSWER 15 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 14
 AN 126:108822 CA
 TI Effect of non-ionic surfactants on the formation of DNA/Emulsion complexes and emulsion-mediated gene transfer
 AU Liu, Feng; Yang, Jingping; Huang, Leaf; Liu, Dexi
 CS School of Pharmacy, Univ. Pittsburgh, Pittsburgh, PA, 15261, USA
 SO Pharm. Res. (1996), 13(11), 1642-1646
 CODEN: PHREEB; ISSN: 0724-8741
 PB Plenum
 DT Journal
 LA English
 AB The structure-function relationship of non-ionic surfactants in emulsion-mediated gene delivery is studied. Four different types of non-ionic surfactants including Tween, Span, Brij and pluronic copolymers were used as co-emulsifiers for prepn. of emulsions composed of castor oil, dioleoylphosphatidylethanolamine (DOPE) and 3.**beta.**[N-(N',N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol). The effect of different surfactants on the formation of DNA/emulsion complexes and transfection activity were analyzed using plasmid DNA contg. luciferase cDNA as a reporter gene. Non-ionic surfactants contg. branched polyoxyethylene chains as the hydrophilic head group were more effective in preventing the formation of large DNA/emulsion complexes than those contg. one or no polyoxyethylene chain. All emulsion formulations except those contg. Brij 700 exhibited high activity in transfecting mouse BL-6 cells in the absence of serum. In the presence of serum, however, transfection activity of each
 Searcher : Shears 308-4994

formulation varied significantly. Emulsions contg. Tween Brij 72, pluronic F68 and F127 demonstrated increased activity in transfecting cells in the presence of 20% serum. In contrast to emulsions contg. Span, long chain polyoxyethylene of Brji showed decreased transfection activity. The particle size of the DNA/emulsion complexes and their ability to transfect cells are dependent on the concn. of non-ionic surfactant in the formulation. Conclusions. The structure of the hydrophilic head group of the nonionic surfactants in the emulsion is important in detg. how DNA mols. interact with emulsions and the extent to which DNA is transferred inside the cell.

IT Emulsifying agents
 Emulsions (drug delivery systems)
 Nonionic surfactants
 Particle size
 Transformation (genetic)
 (effect of non-ionic surfactants on formation of DNA/emulsion complexes and emulsion-mediated gene transfer)

IT Castor oil
 DNA
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effect of non-ionic surfactants on formation of DNA/emulsion complexes and emulsion-mediated gene transfer)

IT 1338-39-2, Span 20 1338-41-6, Span 60 1338-43-8, Span 80
 2462-63-7, Dioleoylphosphatidylethanolamine 9005-00-9, Brij 72
 9005-64-5, Tween 20 9005-65-6, Tween 80 9005-66-7, Tween 40
 9005-67-8, Tween 60 26266-57-9, Span 40 106392-12-5, Pluronic f68 137056-72-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effect of non-ionic surfactants on formation of DNA/emulsion complexes and emulsion-mediated gene transfer)

L6 ANSWER 16 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 15
 AN 126:69795 CA
 TI The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors
 AU Szala, S.; Missol, E.; Sochanik, A.; Strozyk, M.
 CS Dep. Tumor Biol., Inst. Oncol., Gliwice, 44-100, Pol.
 SO Gene Ther. (1996), 3(11), 1026-1031
 CODEN: GETHEC; ISSN: 0969-7128
 PB Stockton
 DT Journal
 LA English
 AB An attempt was made to use simple cationic liposomes DC-Chol/DOPE and DDAB/DOPE (DC-Chol is **3.beta** .-(N(N',N'-dimethylaminoethane) **carbamoyl**) **cholesterol**, DDAB is dimethyldioctadecyl ammonium bromide and DOPE is dioleoylphosphatidylethanolamine) for transfer of
 Searcher : Shears 308-4994

Escherichia coli cytosine deaminase 'suicide' gene under the control of tissue-specific tyrosinase gene promoter directly into the murine melanoma B16(F10) tumor. Several repeated intratumoral injections of DNA-liposome complexes followed by i.p. administrations of 5-fluorocytosine, which is converted to 5-fluorouracil, caused strong retardation of murine melanoma B16(F10) tumor growth and, in some cases, rejection of the pre-established tumor. The inhibition of tumor growth expressed as the increased survival of mice is better seen in the case of using DNA-DDAB/DOPE complexes as compared to DNA-DC-Chol/DOPE ones. It seems that the obsd. therapeutic effect appears to result from several factors; 5-fluorouracil generation by transfected cells, liposome toxicity (DDAB is more toxic than DC-Chol and hence more tumor cells are killed), increased transfection efficiency of surviving cancer cells (in this case DDAB is a better transfection agent than DC-Chol) and, finally, the bystander effect which causes destruction of cells untransfected with CD gene by easily diffusible 5-fluorouracil.

IT Escherichia coli

Gene therapy

Liposomes (drug delivery systems)

Melanoma inhibitors

(the use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors)

IT Genes (animal)

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(the use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors)

IT 9002-10-2, Tyrosinase 9025-05-2, Cytosine deaminase

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(the use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors)

IT 51-21-8, 5-Fluorouracil 2022-85-7, 5-Fluorocytosine 2462-63-7, Dioleoylphosphatidylethanolamine 3700-67-2, Dimethyldioctadecyl ammonium bromide 137056-72-5

RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(the use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors)

L6 ANSWER 17 OF 25 CA COPYRIGHT 1997 ACS

DUPLICATE 16

AN 125:95723 CA

TI Fate of cationic liposomes and their complex with oligonucleotide in vivo

Searcher : Shears 308-4994

AU Litzinger, David C.; Brown, Jeffrey M.; Wala, Iwona; Kaufman, Stephen A.; Van, Gwyneth Y.; Farrell, Catherine L.; Collins, David
CS Department of Pharmacology, Amgen, Inc., Thousand Oaks, CA, 91320,
USA
SO Biochim. Biophys. Acta (1996), 1281(2), 139-149
CODEN: BBACAO; ISSN: 0006-3002
DT Journal
LA English
AB The present studies describe the biodistribution of cationic liposomes and cationic liposome/oligonucleotide complex following i.v. injection into mice via the tail vein. ^{111}In -diethylenetriaminepentaacetic acid stearylamide (^{111}In -DTPA-SA) was used as a lipid-phase radiolabel. Inclusion of up to 5 mol DTPA-SA in liposomes composed of 3.**beta**-(N-(N',N'-dimethylaminoethane)**carbamoyl**)**cholesterol** (DC-Chol) and dioleoylphosphatidylethanolamine (DOPE) did not influence liposome formation or size, nor the binding/uptake or fusion of the cationic liposomes with CHO cells in vitro. Moreover, nuclear delivery of oligonucleotide to CHO cells was unaffected by the probe. The biodistribution of liposomes with increasing concn. of DC-Chol (1:4-4:1, DC-Chol/DOPE, mol/mol) at 24 h post-injection revealed no dependence on lipid compn. Uptake was primarily by liver, and accumulation in spleen and skin was also obsd. Comparatively little accumulation occurred in lung. Clearance of injected liposomes by liver was very rapid (.apprx.84.5 of the injected dose by 7.5 h post-injection). Liposome uptake by liver and spleen were equally efficient in the dose range of 3.33 to 33.33 mg/kg body wt., yet possible satn. of liver uptake at a dose of 66.80 mg/kg may have allowed for increased spleen accumulation. Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic yet transient accumulation of the lipid in lung which gradually redistributed to liver. Similar results were obsd. when monitoring iodinated oligonucleotide in the complex. Immuno-histochem. studies revealed large aggregates of oligonucleotide within pulmonary capillaries at 15 min post-injection, suggesting the early accumulation in lung was due to embolism. Immuno-histochem. studies further revealed labeled oligonucleotide to be localized primarily to Kupffer cells at 24 h post-injection. Immuno-electron microscopy revealed localization of oligonucleotide primarily to the lumen of pulmonary capillaries at 15 min post-injection, and to phagocytic vacuoles of Kupffer cells at 24 h post-injection. By these methods, nuclear delivery of oligonucleotide in vivo was not obsd. Increasing concn. of mouse serum inhibited cellular binding/uptake of cationic liposomes in vitro, without or with complexed oligonucleotide. We therefore postulate that interaction with plasma components, including opsonin(s), inhibits cellular uptake of the injected liposomes as well as the liposome/oligonucleotide complex, and mediates rapid uptake by Kupffer cells of the liver. These results are relevant to

Searcher : Shears 308-4994

the design of cationic liposomes for efficient delivery of nucleic acid in vivo.

IT Nucleic acids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (delivery of; pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Lung
 Spleen
 (pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Opsonins
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Liver
 (Kupffer cell, pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Pharmaceutical dosage forms
 (liposomes, cationic; pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Nucleotides, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oligo-, pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT Nucleotides, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oligo-, deoxyribo-, thiophosphate-linked, pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

IT 2462-63-7, Dioleoylphosphatidylethanolamine 137056-72-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacokinetics of cationic liposomes for delivery of antisense oligonucleotides)

L6 ANSWER 18 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 17
 AN 126:122406 CA
 TI Large scale production of DC-Chol cationic liposomes by microfluidization
 AU Sorgi, Frank L.; Huang, Leaf
 CS Departments of Pharmaceutical Sciences and Pharmacology, The Laboratory of Drug Targeting, The University of Pittsburgh, Pittsburgh, PA, 15261, USA
 SO Int. J. Pharm. (1996), 144(2), 131-139
 CODEN: IJPHDE; ISSN: 0378-5173
 PB Elsevier
 DT Journal
 LA English
 AB In this report, we describe the large scale prodn. and testing of DC-Chol [3.**beta.**-[N-(N,N-dimethylaminoethyl)

Searcher : Shears 308-4994



carbamoyl] cholesterol] cationic liposomes by microfluidization. These liposomes are produced in a good manufg. practice acceptable manner to a 500 mL batch size and are shown to be sterile. Further, when stored at 4.degree.C, DC-Chol liposomes will retain their original size, remain suspended in soln., and retain activity for a period exceeding 1.5 yr. In-process quality assurance and quality control procedures have identified problems in processing and methods to produce a final product of pharmaceutical quality have been developed to overcome these obstacles. Assays for product content (DC-Chol and DOPE assays), size, sterility, endotoxin detn., storage conditions and shelf life have been developed. Successful lots have been used in a human gene therapy clin. trial for cystic fibrosis at Oxford University as well as many pre-clin. expts. throughout the world. Implications for application to further gene therapy clin. trials as well as the development of liposome vector programs are discussed in detail.

IT Liposomes (drug delivery systems)
 (large scale prodn. of DC-Chol cationic liposomes by microfluidization)

IT Fluidization
 (microfluidization; large scale prodn. of DC-Chol cationic liposomes by microfluidization)

IT 4004-05-1, Dioleoylphosphatidylethanolamine 144108-30-5
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (large scale prodn. of DC-Chol cationic liposomes by microfluidization)

L6 ANSWER 19 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 18
 AN 124:260850 CA
 TI 4-(Carbamoyloxy)piperidine-1-carboxylic acid esters as inhibitors of cholesterol absorption
 IN LaClair, Christa Marie; Laclair, Christa Marie
 PA American Home Products Corp., USA
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 PI WO 9534539 A1 951221
 DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 95-US4938 950418
 PRAI US 94-259229 940613
 DT Patent
 LA English
 OS MARPAT 124:260850
 GI



11

AB The title compds. inhibit the enzyme cholesterol ester hydrolase (CEH), and thus inhibit the formation of esterified cholesterol. Since esterified cholesterol is absorbed through the intestine, inhibition of the enzyme results in inhibition of cholesterol absorption. The compds. have formula I [wherein p=0-4; Z = -Ar1, -Ar1Ar2, -Ar1OAr2, -Ar1SAr2, -Ar1OCOAr2, -Ar1COOAr2, -Ar1COAr2, -Ar1(CH2)1-20Ar2, -Ar1(CH2)1-20OAr2, -Ar1O(CH2)1-20Ar2, -Ar1(CR6:CR6)1-3Ar2, or -Ar1NR7Ar2; Ar1, Ar2 = various arom. and heteroarom ring systems; A = hydrocarbon linking group which may be interrupted by heteroatom or cycloalkyl, aryl, heterocycloalkyl, or azacycloalkyl; R1 = H, alkyl, (un)substituted Ph; or Ar1 forms heterocyclic ring; R2, R3 = alkyl, alkoxy, alkylcarbonyl, OH, cyano, etc.; R4, R5 = H, alkyl, alkenyl, acyl, alkoxy carbonyl, etc.; or NR4R5 = satd. heterocyclic ring; R6 = H, alkyl; R7 = H, alkyl, alkanoyl, alkoxy carbonyl]. For example, 4-phenoxyphenol was converted to its 4-nitrophenyl carbonate ester (73%), which was amidated with 6-amino-1-hexanol (70%). The obtained alc. carbamate was again converted to a 4-nitrophenyl carbonate ester (61%), which was again amidated, this time with 4-hydroxypiperidine (71%). Repeating the same cycle with the product and six different amines gave six title compds., e.g. (using piperidine), II. At 10 mg/kg orally in normal rats, II gave an 81% decrease in absorption of radiolabeled cholesterol.

IT Intestine

(absorption through; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT Anticholesteremics and Hypolipemics

(prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT Antiarteriosclerotics
 (antiatherosclerotics, prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 112-80-1, Oleic acid, reactions
 RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study)
 (esterification; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 303-43-5P, Cholesteryl oleate
 RL: PNU (Preparation, unclassified); PREP (Preparation)
 (inhibition of formation; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 9026-00-0, Cholesteryl ester hydrolase
 RL: BPR (Biological process); CAT (Catalyst use); BIOL (Biological study); PROC (Process); USES (Uses)
 (inhibition; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 162321-08-6P, Carbonic acid 4-nitrophenyl 4-phenoxyphenyl ester
 174960-44-2P, (6-Hydroxyhexyl)carbamic acid 4-phenoxyphenyl ester
 174960-45-3P 174960-46-4P 174960-47-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (intermediate; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 174960-38-4P 174960-39-5P 174960-40-8P 174960-41-9P
 174960-42-0P 174960-43-1P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 57-88-5, Cholest-5-en-3-ol (3.**beta.**)-, reactions
 RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study)
 (prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

IT 108-91-8, Cyclohexylamine, reactions 110-89-4, Piperidine, reactions 111-26-2, 1-Hexanamine 831-82-3, 4-Phenoxyphenol 1123-30-4, 8-Azapiro[4.5]decane hydrochloride 2016-57-1, Decylamine 4048-33-3, 6-Amino-1-hexanol 5382-16-1, 4-Hydroxypiperidine 7693-46-1, 4-Nitrophenyl chloroformate 13214-66-9, 4-Phenylbutylamine
 RL: RCT (Reactant)
 (starting material; prepn. of (carbamoyloxy)piperidinecarboxylate esters as cholesterol absorption inhibitors)

L6 ANSWER 20 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 19

AN 123:6532 CA

TI Fusion of cationic liposomes with mammalian cells occurs after endocytosis

Searcher : Shears 308-4994

AU Wrobel, Iwona; Collins, David
CS Department of Pharmaceutics and Drug Delivery, Mail stop 8-1-A-215,
Amgen, Inc., 1840 DeHavilland Drive, Thousand Oaks, CA, 91320, USA
SO Biochim. Biophys. Acta (1995), 1235(2), 296-304
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English
AB The interaction of cationic liposomes prep'd. using either dioleoyltrimethylammonium propane (DOTAP) or 3.
beta.-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-CHOL) with model membranes and with cultured mammalian cells was examd. using an assay developed for monitoring virus-cell fusion (Stegmann et al. (1993) Biochem. 32, 11330-11337). Lipid mixing between cationic liposomes and liposomes composed of DOPE/dioleoylphosphatidylglycerol (DOPG) or dioleoylphosphatidylcholine (DOPC)/DOPG was insensitive to pH in the range of pH 4.5-7.0 and was not affected by sodium chloride concn. in the range of 0-150 mM. Lipid mixing was dependent on dioleoylphosphatidylethanolamine (DOPE), since cationic liposomes prep'd. using dioleoylphosphatidylcholine (DOPC) were incapable of lipid mixing with DOPC/DOPG liposomes. The interaction of cationic liposomes with Hep G-2 and CHO D- cells was also studied. For both cell types, liposome-cell lipid mixing was rapid at 37.degree.C, beginning within minutes and continuing for up to 1 h after uptake. The extent of lipid mixing was decreased at 15.degree.C, esp. at later (.gtoreq.20 min) time points. This suggests that at least part of the obsd. lipid mixing occurred after reaching cellular lysosomes. No lipid mixing was seen at 4.degree.C. Monensin inhibited lipid mixing between cationic liposomes and the cells, despite having no effect on liposome uptake. Inhibition of endocytic uptake of liposomes, either by incubation in hypertonic media or by depletion of cellular ATP with sodium azide and 2-deoxyglucose abolished liposome-cell fusion in both cell types. These data demonstrate that binding to the cell surface is insufficient for cationic liposome-cell fusion and that uptake into the endocytic pathway is required for fusion to occur.
IT Liposome
(cationic; fusion of cationic liposomes with mammalian cells occurs after endocytosis)
IT Animal cell
Fusion, biological
(fusion of cationic liposomes with mammalian cells occurs after endocytosis)
IT Biological transport
(endocytosis, fusion of cationic liposomes with mammalian cells occurs after endocytosis)
IT 2462-63-7, Dioleoylphosphatidylethanolamine 62700-69-0,
Dioleoylphosphatidylglycerol 113669-21-9, DOTAP 137056-72-5
RL: BPR (Biological process); BIOL (Biological study); PROC
Searcher : Shears 308-4994

(Process)

(fusion of cationic liposomes with mammalian cells occurs after endocytosis)

L6 ANSWER 21 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 20
 AN 122:307619 CA
 TI The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer
 AU Farhood, Hassan; Serbina, Natalya; Huang, Leaf
 CS Department of Pharmacology, University of Pittsburgh School of Medicine, 13th Floor, Biomedical Science Tower, Pittsburgh, PA, 15261, USA
 SO Biochim. Biophys. Acta (1995), 1235(2), 289-95
 CODEN: BBACAO; ISSN: 0006-3002
 DT Journal
 LA English
 AB In a reporter gene assay, cationic liposomes contg. the cationic lipid **3.beta.- (N-(N',N'-dimethylaminoethane) carbamoyl)cholesterol** (DC-Chol) and a neutral phospholipid dioleoylphosphatidylethanolamine (DOPE) showed high transfection activity. DNA/liposome complex which contained low amt. of liposomes could bind to the cell surface but failed to transfect the cells. We have designed a two-step protocol to examine this phenomenon in more detail. A431 human cells were incubated on ice (pulse) with DNA complexed to a low level of cationic liposomes. The cells were washed and incubated at 37.degree.C (chase) with or without free cationic liposomes of various compn. (helper liposomes). Only liposomes enriched with DOPE showed helper activity; liposomes contg. dioleoylphosphatidylcholine (DOPC), a structural analog of DOPE, had no helper activity. The delivery was inhibited by the lysosomotropic agent chloroquine and was optimal if the helper liposome chase was initiated immediately after the pulse. An endocytosis model of DNA delivery by cationic liposomes is proposed in which the principal function of the chase liposomes is to destabilize the endosome membrane and allow the release of DNA into the cytosol. This model is consistent with the known activity of DOPE to assume non-bilayer structures, hence destabilizing the endosome membrane.
 IT Deoxyribonucleic acids
 RL: BPR (Biological process); BIOL (Biological study); PROC
 (Process)
 (A431 human cells were incubated on ice (pulse) with DNA complexed to a low level of cationic liposomes, and only liposomes enriched with dioleoylphosphatidylethanolamine showed helper activity for genetic transformation)
 IT Cell membrane
 (an endocytosis model of DNA delivery by cationic liposomes is proposed in which the principal function of the chase liposomes
 Searcher : Shears 308-4994

is to destabilize the endosome membrane and allow the release of DNA into the cytosol)

IT Liposome
 Transformation, genetic
 (role of dioleoylphosphatidylethanolamine in cationic liposome mediated gene transfer)

IT Animal cell line
 (A431, role of dioleoylphosphatidylethanolamine in cationic liposome mediated gene transfer in human A431 cells)

IT Biological transport
 (endocytosis, an endocytosis model of DNA delivery by cationic liposomes is proposed in which the principal function of the chase liposomes is to destabilize the endosome membrane and allow the release of DNA into the cytosol)

IT 54-05-7, Chloroquine
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (an endocytosis model of DNA delivery by cationic liposomes is proposed in which the principal function of the chase liposomes is to destabilize the endosome membrane and allow the release of DNA into the cytosol)

IT 137056-72-5
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cationic liposomes contg. the cationic lipid **3**
.beta.-(N-(N',N'-dimethylaminoethane)carbamoyl
cholesterol (DC-Chol) and a neutral phospholipid
 dioleoylphosphatidylethanolamine (DOPE) showed high transfection activity)

IT 2462-63-7, Dioleoylphosphatidylethanolamine
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (role of dioleoylphosphatidylethanolamine in cationic liposome mediated gene transfer)

L6 ANSWER 22 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 21
 AN 121:28017 CA
 TI A sustained, cytoplasmic transgene expression system delivered by cationic liposomes
 AU Gao, Xiang; Jaffurs, Daniel; Robbins, Paul D.; Huang, Leaf
 CS Sch. Med., Univ. Pittsburgh, Pittsburgh, PA, 15261, USA
 SO Biochem. Biophys. Res. Commun. (1994), 200(3), 1201-6
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal
 LA English
 AB A plasmid contg. the reporter gene, chloramphenicol acetyltransferase (CAT), driven by the bacteriophage T7 promoter was co-delivered with purified T7 RNA polymerase by the **3**.
.beta.-[N-(N',N'-dimethylaminoethane)-carbamoyl
cholesterol cationic liposomes into human embryonic kidney
 Searcher : Shears 308-4994

293 cells to obtain a transient (2 days) CAT gene expression. To prolong the expression, a T7 autogene which contains the T7 RNA polymerase gene driven by the T7 promoter was included in the transfection complex as a self-amplifying regeneration mechanism for the polymerase. High level CAT gene expression was obstd. up to 5 days after transfection. This strong and sustained expression system should be useful in gene transfer expts.

IT Plasmid and Episome
(bacteriophage T7 promoter and RNA polymerase gene in, for cationic liposome delivery to human cell, in gene expression system)

IT Transformation, genetic
(cationic liposome delivery of plasmid contg. bacteriophage T7 RNA polymerase and other gene in, of human cell, as gene expression system)

IT Liposome
(dimethylaminoethane-carbamoyl cholesterol, plasmid contg. bacteriophage T7 promoter and RNA polymerase gene delivery by, for gene expression in transfected human cell)

IT Gene
RL: BIOL (Biological study)
(expression of, in transfected human cell, plasmid contg. bacteriophage T7 promoter and RNA polymerase gene delivered by cationic liposome for)

IT Gene, microbial
RL: BIOL (Biological study)
(for RNA polymerase, in plasmid, cationic liposome for delivery of, in gene expression in transfected human cell)

IT Animal cell
(transfection of human, as gene expression system, cationic liposome delivery of plasmid contg. bacteriophage T7 RNA polymerase and other gene in)

IT Virus, bacterial
(T7, promoter of, gene for RNA polymerase and other gene regulation by, in human cell transfected by plasmid delivered by cationic liposome)

IT Genetic element
RL: BIOL (Biological study)
(promoter, gene for RNA polymerase and other gene regulation by, of bacteriophage T7, in human cell transfected by plasmid delivered by cationic liposome)

IT 137056-72-5
RL: USES (Uses)
(liposome, plasmid contg. bacteriophage T7 promoter and RNA polymerase gene delivery by, for gene expression in transfected human cell)

IT 9014-24-8, RNA polymerase
RL: USES (Uses)
(plasmid contg. bacteriophage T7 promoter and gene for, cationic Searcher : Shears 308-4994

liposome for delivery of, in gene expression in transfected human cell)

L6 ANSWER 23 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 22
 AN 121:42651 CA
 TI Direct gene transfer by liposomes
 AU Singhal, Arun; Huang, Leaf
 CS Dep. Pharmacol., Univ. Pittsburgh, PA, 15261, USA
 SO J. Liposome Res. (1994), 4(1), 289-99
 CODEN: JLREE7; ISSN: 0898-2104
 DT Journal
 LA English
 AB Cationic liposomes are widely used for the delivery of genes both in vivo and in clin. trials. Thus, a **3.βeta** .-[N-(N',N'-dimethylaminoethyl)carbamoyl] **cholesterol** (DC-chol) liposome formulation was developed by the authors for relatively high activity of transfection and low level of toxicity for most cell types. Different strategies are described for achieving regulated transgene expression as well as expression for a prolonged period of time using DC-chol liposomes.
 IT Gene, animal
 RL: PRP (Properties)
 (transfer of, by cationic liposomes)
 IT Pharmaceutical dosage forms
 (liposomes, cationic, direct gene transfer by)
 IT 137056-72-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical liposomes contg., direct gene transfer by)

L6 ANSWER 24 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 23
 AN 123:47107 CA
 TI DC-chol liposomes as DNA carriers for gene therapy
 AU Singhal, Arun; Huang, Leaf
 CS Department Pharmacology, University Pittsburgh School Medicine, Pittsburgh, PA, 15261, USA
 SO Gene Ther. (1994), 107-29. Editor(s): Hui, Kam Man. Publisher: World Sci., Singapore, Singapore.
 CODEN: 61JCAW
 DT Conference; General Review
 LA English
 AB A review, with 38 refs., discussing the authors' work with various liposomes as DNA carriers for gene therapy. In particular, liposomes contg. DC-chol (**3.βeta** .-[N-(N',N-dimethylaminoethane)carbamoyl] **cholesterol**) have shown versatility in administering DNA-liposome complexes in vivo and have been proven to be a safe reagent in clin. uses.. The liposomes can be manufd. in large quantities with pharmaceutical quality.
 IT Deoxyribonucleic acids

Searcher : Shears 308-4994

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (liposomes contg. [(dimethylaminoethane)carbamoyl]cholesterol as DNA carriers for gene therapy)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (liposomes contg. [(dimethylaminoethane)carbamoyl]cholesterol as DNA carriers for gene therapy)

IT Therapeutics
 (geno-, liposomes contg. [(dimethylaminoethane)carbamoyl]cholesterol as DNA carriers for gene therapy)

IT Pharmaceutical dosage forms
 (liposomes, liposomes contg. [(dimethylaminoethane)carbamoyl]cholesterol as DNA carriers for gene therapy)

IT 137056-72-5
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liposomes contg. [(dimethylaminoethane)carbamoyl]cholesterol as DNA carriers for gene therapy)

L6 ANSWER 25 OF 25 CA COPYRIGHT 1997 ACS DUPLICATE 24
 AN 115:225390 CA
 TI A novel cationic liposome reagent for efficient transfection of mammalian cells
 AU Gao, Xiang; Huang, Leaf
 CS Dep. Biochem., Univ. Tennessee, Knoxville, TN, 37996-0840, USA
 SO Biochem. Biophys. Res. Commun. (1991), 179(1), 280-5
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal
 LA English
 AB A novel cationic deriv. of **cholesterol**, 3.
beta.[N-(N',N'-dimethylaminoethane)-**carbamoyl**]
cholesterol (DC-Chol), has been synthesized and used to prep. sonicated liposomes with dioleoylphosphatidylethanolamine. This novel cationic liposome reagent facilitates efficient DNA mediated transfection in A431 human epidermoid carcinoma cells, A549 human lung carcinoma cells, L929 mouse fibroblast cells, and YPT minipig primary endothelial cells. The activity was greater than that of a com. reagent, Lipofectin, and was approx. 4-fold less toxic than Lipofectin when assayed with A431 cells. The reagent is easy to synthesize and stable for at least 6 wk.
 IT Liposome
 (cationic, DC-cholesterol reagent for, for efficient transfection of mammalian cells)
 IT Transformation, genetic
 (using cationic liposomes, DC-cholesterol reagent for)
 IT 2462-63-7, Dioleoylphosphatidylethanolamine
 RL: PRP (Properties)
 (as cationic liposome reagent with DC-cholesterol, for efficient Searcher : Shears 308-4994

08/836576

transfection of mammalian cells)
IT 137056-72-5P
RL: PREP (Preparation)
(prepn. of, as cationic liposome reagent for efficient
transfection of mammalian cells)
IT 108-00-9 7144-08-3, Cholesteryl chloroformate
RL: RCT (Reactant)
(reaction of, in prepn. of DC-cholesterol)

=

=> d his 17-

(FILE 'BIOSIS, MEDLINE, EMBASE, LIFESCI, BIOTECHDS, WPIDS, CONFSCI,
DISSABS, SCISEARCH, JICST-EPLUS, PROMT, TOXLIT, TOXLINE, DRUGU,
DRUGNL, DRUGB, DRUGLAUNCH' ENTERED AT 16:17:32 ON 15 DEC 1997)

L7 4572 S L4
L8 87 S L7(S) (CARBAM? OR CARBOXAMID? OR CARBOX? AMID?)

=> dup rem 18

DUPLICATE IS NOT AVAILABLE IN 'DRUGLAUNCH'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8
L9 39 DUP REM L8 (48 DUPLICATES REMOVED)

=> d 1-39 bib abs; fil uspat; s 18

L9 ANSWER 1 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS
AN 97:347639 BIOSIS
DN 99646842
TI Intratumoral pharmacokinetics and in vivo gene expression of naked
plasmid DNA and its cationic liposome complexes after direct gene
transfer.
AU Nomura T; Nakajima S; Kawabata K; Yamashita F; Takakura Y; Hashida M
CS Dep. Drug Delivery Res., Fac. Pharmaceutical Sci., Kyoto Univ.,
Sakyo-ku, Kyoto 606-01, Japan
SO Cancer Research 57 (13). 1997. 2686-2686. ISSN: 0008-5472
LA English
AB The pharmacokinetic properties and gene expression of naked plasmid
DNA and its cationic liposome complexes were studied after direct
intratumoral injection. Using a Walker 256 tissue-isolated tumor
perfusion system, we quantified the recovery of naked plasmid DNA and
cationic liposome complexes in the tumor, leakage from the tumor
surface, and the venous outflow after intratumoral injection.
Approximately 50% of naked plasmid DNA had been eliminated from the
tumor 2 h after injection, whereas more than 90% of plasmid DNA was

Searcher : Shears 308-4994

retained in the tumor when it was complexed with cationic liposomes. However, the distribution of these complexes in the tumor was restricted to the tissue surrounding the injection site.

Pharmacokinetic analysis of the venous outflow profiles suggested that the rate-limiting process that determines the retention of plasmid DNA in the tumor is transferred from the injection site in the tumor tissue and that complexation with cationic liposomes may retard this process. Furthermore, we examined the gene expression of chloramphenicol acetyltransferase DNA constructs (naked pCMV-CAT) and the corresponding cationic liposome (3-**beta**-
- (N-(N',N'-dimethylaminoethane)carbamoyl)

cholesterol) complexes. A similar level of gene expression was observed in vivo after direct intratumoral injection of naked DNA and its cationic liposome complexes. In both cases, a great variation was observed between tumors, and localization of gene-transduced cells in the tumor tissue was limited to the area in the vicinity of the injection site. Thus, these pharmacokinetic and gene expression studies have demonstrated that cationic liposomes can enhance the retention of injected DNA in the tumor model, whereas cationic liposome complex does not necessarily improve gene expression because of its poor dissemination in this tumor. The present study also suggested that there is a need to control the behavior of the injected naked plasmid DNA and its cationic liposome complexes to ensure better distribution throughout the tumor.

L9 ANSWER 2 OF 39 MEDLINE DUPLICATE 1
AN 97349073 MEDLINE
TI Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer.
AU Nomura T; Nakajima S; Kawabata K; Yamashita F; Takakura Y; Hashida M
CS Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Japan.
SO CANCER RESEARCH, (1997 Jul 1) 57 (13) 2681-6.
Journal code: CNF. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 9710
EW 19971001
AB The pharmacokinetic properties and gene expression of naked plasmid DNA and its cationic liposome complexes were studied after direct intratumoral injection. Using a Walker 256 tissue-isolated tumor perfusion system, we quantified the recovery of naked plasmid DNA and cationic liposome complexes in the tumor, leakage from the tumor surface, and the venous outflow after intratumoral injection. Approximately 50% of naked plasmid DNA had been eliminated from the tumor 2 h after injection, whereas more than 90% of plasmid DNA was

Searcher : Shears 308-4994

retained in the tumor when it was complexed with cationic liposomes. However, the distribution of these complexes in the tumor was restricted to the tissue surrounding the injection site. Pharmacokinetic analysis of the venous outflow profiles suggested that the rate-limiting process that determines the retention of plasmid DNA in the tumor is transferred from the injection site in the tumor tissue and that complexation with cationic liposomes may retard this process. Furthermore, we examined the gene expression of chloramphenicol acetyltransferase DNA constructs (naked pCMV-CAT) and the corresponding cationic liposome [3β -**beta**-(N-(N',N'-dimethylaminoethane)**carbamoyl**)**cholesterol**] complexes. A similar level of gene expression was observed in vivo after direct intratumoral injection of naked DNA and its cationic liposome complexes. In both cases, a great variation was observed between tumors, and localization of gene-transduced cells in the tumor tissue was limited to the area in the vicinity of the injection site. Thus, these pharmacokinetic and gene expression studies have demonstrated that cationic liposomes can enhance the retention of injected DNA in the tumor model, whereas cationic liposome complex does not necessarily improve gene expression because of its poor dissemination in this tumor. The present study also suggested that there is a need to control the behavior of the injected naked plasmid DNA and its cationic liposome complexes to ensure better distribution throughout the tumor.

L9 ANSWER 3 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 2
 AN 97:299525 BIOSIS
 DN 99598728
 TI Optimization of liposome mediated transfection of a neuronal cell line.
 AU McQuillin A; Murray K D; Etheridge C J; Stewart L; Cooper R G; Brett P M; Miller A D; Gurling H M D
 CS Molecular Psychiatry Lab., Dep. Psychiatry Behavioural Sci., UCL Med. Sch., Windeyer Inst. Med. Sci., 46 Cleveland St., London W1P 6DB, UK
 SO Neuroreport 8 (6). 1997. 1481-1484. ISSN: 0959-4965
 LA English
 AB A cell line derived from sensory neurons was transfected with high efficiency using cationic liposomes, formulated from 3β -**beta**-(N-(N,N'-dimethylaminoethane)**carbamoyl**)**cholesterol** (DC-Chol) and dioleoyl L-alpha-phosphatidylethanolamine (DOPE). This is the first time that cationic liposomes of this type have been reported to transfect a neuronal cell line. We used a reporter gene construct expressing β -galactosidase under the control of the cytomegalovirus immediate early promoter and routinely observed transfection efficiencies > 40%. Parameters affecting transfection efficiency were examined and the ratio of DNA to liposome proved to be crucial. Liposome formulation procedures and cell transfection protocols devised here will be used as a basis for further in vivo and in vitro work.

Searcher : Shears 308-4994

L9 ANSWER 4 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 3
 AN 97:292762 BIOSIS
 DN 99591965
 TI Transfection of avian LMH-2A hepatoma cells with cationic lipids.
 AU Walzem R L; Hickman M A; German J B; Hansen R J
 CS Dep. Molecular Biosciences, Sch. Veterinary Med., Coll. Agricultural Environmental Sciences, Univ. California-Davis, Davis, CA 95616, USA
 SO Poultry Science 76 (6). 1997. 882-886. ISSN: 0032-5791
 LA English
 AB LMH-2A is an estrogen-responsive avian hepatoma cell line whose susceptibility to cationic-lipid-mediated transfection is poorly described. 3-**beta**(N-N',N'-dimethylaminoethane)-carbamoyl) cholesterol (DCC) requires a one-step synthesis, and can be used to formulate transfection-grade liposomes when combined with dioleoylphosphatidyl-ethanolamine (DOPE) 1/1 (wt/wt). Luciferase activities in LMH-2A cells were 8.5-fold and 87.5-fold greater than those in HepG2 and FTO2B cells, respectively, following DCC-liposome-mediated transfection with a reporter consisting of the human cytomegalovirus immediate-early promoter (CMV), joined to Photinus pyralis luciferase (L) cDNA, designated pCMVL. Using pCMVL, N-(2-bromoethyl)-N,N-dimethyl-2,3-bis(9-octadecenoxy)-propanaminium bromide) (BMOP)/DOPE 1/1 (wt/wt), at a 7.5:1 ratio with DNA, produced luciferase activities that were 2.9-fold higher than those of DCC-liposomes, at an optimal 10:1 lipid:DNA ratio. At optimal lipid:DNA ratios, commercially available liposomes, Transfectam, Lipofectamine, and Lipofectin, produced luciferase activities that were 1.39, 1.03, and 0.47-fold those of DCC-liposomes. The effect of 0, 10, 100, or 500 nM/L 17-beta-estradiol on the expression of pCMVL and a second luciferase reporter containing the -593/+48 promoter region of the estrogen-responsive avian apo VLDL-II gene, designated pApoL, was tested in cells cultured in the presence or absence of 10% chicken serum. The CMV promoter supported a high level of expression in LMH-2A cells that was unaffected by serum alone, but was weakly responsive to estrogen. Estrogen responses of both reporters reached a plateau at 10 nM/L. Estrogen increased the expression of pApoL 24-fold and 79-fold in the absence and presence of serum, respectively. The -593/+48 region of the apo VLDL-II promoter may not contain previously reported negative insulin response elements, but chicken serum contains factors that enhance estrogen responsiveness of this region.

L9 ANSWER 5 OF 39 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
 AN 97328161 EMBASE
 TI Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes.
 AU Schreier H.; Gagne L.; Bock T.; Erdos G.W.; Druzgala P.; Conary J.T.; Muller B.W.

Searcher : Shears 308-4994

CS H. Schreier, Advanced Therapies Inc., 371 Bel Marin Keys, Novato, CA
94949, United States. mls86a@prodigy.com
SO Pharmaceutica Acta Helvetiae, (1997) 72/4 (215-223).
ISSN: 0031-6865 CODEN: PAHEAA
PUI S 0031-6865(97)00019-8
CY Netherlands
DT Journal
FS 022 Human Genetics
025 Hematology
029 Clinical Biochemistry
LA English
SL English
AB The purpose of this study was to elucidate the interaction of cationic liposomes and plasmid cDNA by examining their ultrastructure, zeta potential, stability in aqueous media and protection from DNaseI digestion; their potential for hemolysis and platelet aggregation was evaluated as it may serve as an in vitro toxicity screen. Liposomes consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) or 3.**beta**.-[N-(N',N'-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and dioleylophosphatidylethanolamine (DOPE) were complexes with plasmid constructs of ovine prostaglandin G/H synthase (pCMV4-PGH) or human α .1-antitrypsin (pCMV4-AAT) at lipid:plasmid (L/P) ratios of 3:1-8:1 (w/w). The electron micrographs showed bead-like attachment of liposomes to cDNA and coating of plasmid strands. The zeta potential showed isoelectric points at L/P ratios of 3.5-4 (DOTMA/DOPE) and 5.5-6.5, corresponding to a pK(a) of 6.45 (DC-Chol/DOPE). Liposome cDNA complexes were stable in water, saline and 5% dextrose for 48 h, but precipitated instantaneously in PBS. An increase in the L/P ratio corresponded with increased protection from DNaseI digestion. DOTMA/DOPE liposomes alone were highly hemolytic and DC-Chol/DOPE liposomes moderately hemolytic; hemolysis was abolished by cDNA complexation, with the exception of very high (.ltoreq.7:1) L/P ratios. Both liposomes alone and cDNA complexes caused transient serum turbidity, while none caused platelet aggregation. It was concluded that current cationic lipid cDNA formulations are metastable and appear to have very little if any toxicity with respect to hemolytic potential and untoward interaction with other blood components.

L9 ANSWER 6 OF 39 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.DUPLICATE 4
AN 97335961 EMBASE
TI Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin.
AU Zuidam N.J.; Barenholz Y.
CS Y. Barenholz, Department of Biochemistry, Hebrew University, Hadassah Medical School, P.O. Box 12272, Jerusalem 91120, Israel.
yb@cc.huji.ac.il

Searcher : Shears 308-4994

SO Biochimica et Biophysica Acta - Biomembranes, (1997) 1329/2
 (211-222).
 ISSN: 0005-2736 CODEN: BBBMBS
 PUI S 0005-2736 (97)00110-7
 CY Netherlands
 DT Journal
 FS 039 Pharmacy
 037 Drug Literature Index
 LA English
 SL English
 AB Cationic liposomes are used to deliver genes into cells in vitro and in vivo. The present study is aimed to characterize the electrostatic parameters of cationic, large unilamellar vesicles, 110 .+- . 20 nm in size, composed of DOTAP/DOPE (mole ratio 1/1), BOTAP/DOPC (mole ratio 1/1), 100% DOTAP, DMRIE/DOPE 1/1, or DC-CHOL/DOPE (mole ratio 1/1). {Abbreviations: DOTAP, N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DMRIE, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide; DC-CHOL, 3.**beta.**[N-(N',N'-dimethylaminoethane) carbamoyl]cholesterol}. The cationic liposomes had a large positive surface potential and a high pH at the liposomal surface in 20 mM Hepes buffer (pH 7.4) as monitored by the pH-sensitive fluorophore 4-heptadecyl-7-hydroxycoumarin. In contrast to DOTAP and DMRIE which were 100% charged, DC-CHOL in DC-CHOL/DOPE (1/1) liposomes was only about 50% charged in 20 mM Hepes buffer (pH 7.4). This might result in an easier dissociation of bilayers containing DC-CHOL from the plasmid DNA (which is necessary to enable transcription), in a decrease of the charge on the external surfaces of the liposomes or DNA-lipid complexes, and in an increase in release of the DNA-lipid complex into the cytosol from the endosomes. Other electrostatic characteristics found were that the primary amine group of DOPE in cationic liposomes dissociated at high (> 7.9) PH(bulk) and that a salt bridge was likely between the quaternary amine of DOTAP or DMRIE and the phosphate group of DOPE or DOPC, but not between the tertiary amine of DC-CHOL and the phosphate group of DOPE. The liposomes containing DOTAP were unstable upon dilution, probably due to the high critical aggregation concentration of DOTAP, 7 x 10-5 M. This might also be a mechanism of the dissociation of bilayers containing DOTAP from the plasmid DNA.

L9 ANSWER 7 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 5
 AN 97:366351 BIOSIS
 DN 99658284
 TI Gene transfection by cationic liposomes: Comparison of the transfection efficiency of liposomes prepared from various positively charged lipids.

Searcher : Shears 308-4994

AU Zhao D-D; Watarai S; Lee J-T; Kouchi S; Ohmori H; Yasuda T
 CS Dep. Cell Chem., Inst. Cell. Mol. Biol., Okayama Univ. Med. Sch.,
 Okayama 700, Japan
 SO Acta Medica Okayama 51 (3). 1997. 149-154. ISSN: 0386-300X
 LA English
 AB We compared the transfection efficiency of four types of positively charged liposomes composed of (i) N-(alpha-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dilauroylphosphatidylcholine (DLPC), and dioleylphosphatidylethanolamine (DOPE) (1:2:2 molar ratio); (ii) **3-beta** (N-(N', N'-dimethylaminoethane)-carbamoyl) cholesterol (DC-Chol) and DOPE (3:2 molar ratio); (iii) dimethyldioctadecylammonium bromide (DDAB) and DOPE (1:2.2 molar ratio); (iv) N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA) and DOPE (1:1, w/w; lipofectin). Luciferase gene was used as a reporter gene. Among the cationic liposomes used, the liposomes composed of TMAG, DOPE and DLPC showed a much higher efficiency of plasmid DNA entrapment than the other cationic liposomes tested. In the absence of serum, the cationic multilamellar vesicles (MLV) and small unilamellar vesicles (SUV) composed of TMAG, DOPE and DLPC gave highly efficient transfection. On the other hand, MLV, dehydration-rehydration vesicles (DRV), and SUV liposomes prepared with the mixtures of DC-Chol and DOPE showed similar levels of transfection efficiency. However, the cationic liposomes composed of DDAB and DOPE showed inferior efficiency, whether in the form of DRV, SUV or MLV. The transfection efficiency of lipofectin was also low. In the presence of serum, on the other hand, a considerable (about 30-50%) amount of transfection activity was still observed at 10% fetal calf serum in the cationic MLV and SUV composed of TMAG, DOPE and DLPC. Cationic MLV, composed of TMAG, DOPE and DLPC, can transfet plasmid DNA, not only in the adherent cell lines but also in the suspension cell lines. These findings indicate that the transfection efficiency of cationic liposomes is affected by the lipid composition, the type of liposome, or the presence or absence of serum. They also indicate that the cationic liposomes containing TMAG, DOPE and DLPC are efficient vectors for gene transfer into cells.

L9 ANSWER 8 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 6
 AN 97:219317 BIOSIS
 DN 99525821
 TI Lipid-mediated transfection of normal adult human hepatocytes in primary culture.
 AU Ourlin J C; Vilarem M-J; Daujat M; Harricane M-C; Domergue J; Joyeux H; Baulieux J; Maurel P
 CS Biozentrum der Univ. Basel Abt. Pharmakol., Klingelbergstr. 70,
 CH-4056 Basel, Switzerland
 SO Analytical Biochemistry 247 (1). 1997. 34-44. ISSN: 0003-2697
 LA English

Searcher : Shears 308-4994

AB The aim of this work was to develop a procedure for the lipid-mediated transfection of DNA into normal adult human hepatocytes in culture. Cells were plated in a serum-free culture medium at various cell densities, on plastic or collagen-coated dishes, both in the absence and in the presence of epidermal growth factor (EGF). The cells were incubated for various periods of time with mixtures of DNA-lipofectin or DNA-3-beta (N-(B',N'-dimethylaminoethane)-carbamoyl) cholesterol (DC-chol) liposomes, and the efficiency of transfection was assessed by measuring the activity of reporter genes, beta-galactosidase or chloramphenicol acetyltransferase (CAT). For comparison, similar experiments were carried out with human cell lines including HepG2, Caco-2, and WRL68. The efficiency of transfection (in percentage of cells) was not significantly different after transfection with lipofectin or DC-chol and comprised between 0.04 and 1.7% (extreme values) for different cultures. The efficiency of transfection decreased as the age or density of the culture increased and increased in cultures treated with EGF. Direct measurement of the rate of DNA synthesis suggested that the efficiency of transfection was related to the number of cells entering the S phase. Under the same conditions, the efficiency of transfection was one to two orders of magnitude greater in the three cell lines. A plasmid harboring 660 bp of the 5'-flanking region of CYP1A1 (containing two xenobiotic enhancer elements) fused upstream of the promoter of thymidine kinase and the CAT reporter gene was constructed. When this plasmid was transfected in human hepatocytes, CAT activity was induced as expected. We conclude that normal adult human hepatocytes can be transfected with exogenous DNA and that the transfected construct is regulated in the manner expected from in vivo studies.

L9 ANSWER 9 OF 39 PROMT COPYRIGHT 1997 IAC

AN 97:443621 PROMT

TI Cancer Gene Therapy "Intratumoral Pharmacokinetics and in vivo Gene Expression of Naked Plasmid DNA and Its Cationic Liposome Complexes after Direct Gene Transfer."

SO Cancer Weekly Plus, (18 Aug 1997) pp. N/A.

WC 381

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Nomura, T.; Nakajima, S.; Kawabata, K.; Yamashita, F.; Takakura, Y.; Hashida, M.

Cancer Research, July 1, 1997;57(13):2681-2686.

According to the authors' abstract of an article published in Cancer Research, "The pharmacokinetic properties and gene expression of naked plasmid DNA and its cationic liposome complexes were studied after direct intratumoral injection. Using a Walker 256 tissue-isolated tumor perfusion system, we quantified the recovery of naked plasmid DNA and cationic liposome complexes in the tumor,

Searcher : Shears 308-4994

leakage from the tumor surface, and the venous outflow after intratumoral injection. Approximately 50% of naked plasmid DNA had been eliminated from the tumor 2 h after injection, whereas more than 90% of plasmid DNA was retained in the tumor when it was complexed with cationic liposomes. However, the distribution of these complexes in the tumor was restricted to the tissue surrounding the injection site. Pharmacokinetic analysis of the venous outflow profiles suggested that the rate-limiting process that determines the retention of plasmid DNA in the tumor is transferred from the injection site in the tumor tissue and that complexation with cationic liposomes may retard this process. Furthermore, we examined the gene expression of chloramphenicol acetyltransferase DNA constructs (naked pCMV-CAT) and the corresponding cationic liposome [³-beta - (N-(N',N'-dimethylaminoethane)carbamoyl) cholesterol] complexes. A similar level of gene expression was observed in vivo after direct intratumoral injection of naked DNA and its cationic liposome complexes. In both cases, a great variation was observed between tumors, and localization of gene-transduced cells in the tumor tissue was limited to the area in the vicinity of the injection site. Thus, these pharmacokinetic and gene expression studies have demonstrated that cationic liposomes can enhance the retention of injected DNA in the tumor model, whereas cationic liposome complex does not necessarily improve gene expression because of its poor dissemination in this tumor. The present study also suggested that there is a need to control the behavior of the injected naked plasmid DNA and its cationic liposome complexes to ensure better distribution throughout the tumor." The corresponding author for this study is: M Hashida, Kyoto Univ, Dept Drug Delivery Res, Fac Pharmaceut Sci, Sakyo Ku, Kyoto 60601, Japan.

THIS IS AN EXCERPT: COPYRIGHT 1997 Charles W Henderson

L9 ANSWER 10 OF 39 PROMT COPYRIGHT 1997 IAC

AN 97:443578 PROMT

TI Cancer Gene Therapy Naked Plasmid DNA and Cationic Liposome Complexes Behave Differently In Vivo

SO Cancer Weekly Plus, (18 Aug 1997) pp. N/A.

WC 600

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Intratumoral pharmacokinetics and in vivo gene expression differ between the direct injection of naked plasmid DNA and plasmid DNA/cationic liposome complexes.

Multiple vector systems are available for in vivo gene delivery systems. Most delivery vehicles currently in use are viral in nature. Although efficient in delivering DNA, viral vectors have several disadvantages. Nonviral vectors such as naked plasmid DNA and cationic liposome systems avoid the complications of viral

Searcher : Shears 308-4994

vectors, however, little is actually known about the pharmacokinetics of genes after intratumoral injection with these vectors, especially in relation to gene expression.

Japanese researchers Takehiko Nomura and colleagues quantified the recovery of naked plasmid DNA and cationic liposome complexes, leakage from tumor surface, and the venous outflow after direct tumor injection using a Walker 256 tissue-isolated tumor perfusion system ("Intratumoral Pharmacokinetics and In Vivo Gene Expression of Naked Plasmid DNA and Its Cationic Liposome Complexes After Direct Gene Transfer," Cancer Research, July 1, 1997;57(13):2681-6). "The first objective of the present study was to evaluate the intratumoral behavior of naked plasmid DNA and its cationic liposome complex at an early phase after intratumoral injection using this perfusion system," stated Nomura et al. "The second aim of the study was to investigate the relationships between disposition characteristics and gene expression after in vivo gene transfer." Walker 256 carcinoma tumors and female SPF Wistar rats were used the in vivo perfusion experiments, which were conducted with either naked plasmid DNA expressing the bacterial CAT gene under the control of the human CMV immediate early promoter, a plasmid control, or a corresponding cationic liposome complex 3-(β)-(N -(N' - N' -dimethylaminoethan- e)carbamoyl)cholesterol.

Within two hours of tumor injection, approximately 50 percent of the naked plasmid DNA had been eliminated from the tumor. The tumor injected with complexed cationic liposomes, however, retained more than 90 percent after the same time period. Unfortunately, the distribution of the complexes in the tumor was restricted to the tissue surrounding the injection site.

Pharmacokinetic analysis of the venous outflow profiles suggested that the rate-limiting process that determined the retention of plasmid DNA in the tumor was transferred from the injection site in the tumor tissue, noted the researchers.

THIS IS AN EXCERPT: COPYRIGHT 1997 Charles W Henderson

L9 ANSWER 11 OF 39 DISSABS COPYRIGHT 1997 UMI Company
 AN 97:40717 DISSABS Order Number: AAR9717367
 TI INTERACTIONS OF LIPOSOMES AND PROTEOLIPOSOMES WITH CULTURED CELLS:
 APPLICATION TO THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE
 REGULATOR (DOPE, DOTAP, CFTR)
 AU HIGGINBOTHAM, CAROL ANN [PH.D.]
 CS MONTANA STATE UNIVERSITY (0137)
 SO Dissertation Abstracts International, (1996) Vol. 57, No. 12B, p.
 7506. Order No.: AAR9717367. 162 pages.
 DT Dissertation
 FS DAI
 LA English
 AB Cystic Fibrosis (CF) is the most common fatal genetic disease
 affecting caucasians. Potential approaches to therapy seek to
 Searcher : Shears 308-4994

decrease or avoid disease symptoms by correction of the genetic defect. Included in these approaches are attempts to deliver a normal copy of the defective gene, and attempts to deliver normal protein, to the affected cells of CF patients.

Liposomes composed of artificial, cationic compounds have been found to be effective DNA delivery vehicles, producing expression of the gene products introduced in a significant percentage of treated cells. This study investigated the feasibility of using liposomes for delivery of integral membrane proteins, and particularly the protein defective in CF, to cultured eukaryotic cells. Because of their demonstrated usefulness in DNA transfection, cationic liposome delivery vehicles were examined in detail.

Fluorescence microscopy was used, in conjunction with fluorescence resonance energy transfer, to characterize the interaction occurring between liposomes or proteoliposomes and cultured cells. Studies of cationic liposomes composed of dioleoylphosphatidylethanolamine (DOPE) and 1,2-bis(oleoxy)-3-(trimethylammonio) propane (DOTAP), and DOPE and β -N,N-dimethylaminoethane)-carbamoyl) cholesterol (DC Chol) revealed that these liposomes adhered strongly to cell surfaces, but that dilution of the probes did not occur, to a measurable degree. These results suggest that these cationic liposomes would not be suitable for integral membrane protein delivery to the cell lines studied. Other liposome formulations tested did not exhibit interaction with cultured cells.

Systems employing viral envelopes (virosomes) and receptor mediated uptake of liposomes were also studied, to see if these systems might be significantly more efficient at delivery of foreign material. In the experiments performed, no evidence of lipid transfer to target cells was obtained.

The protein defective in CF is reported to undergo rapid endocytosis from the plasma membrane. To investigate the trafficking of this protein, we identified the CFTR protein by immunoblot from vesicle enriched cell fractions. Cell fractions containing clathrin, a marker protein for coated vesicles, were found also to contain a protein of approximately 170 kD which was reactive to anti-CFTR antibodies.

L9 ANSWER 12 OF 39 DISSABS COPYRIGHT 1997 UMI Company
AN 97:39721 DISSABS Order Number: AAR9715495
TI CATIONIC LIPOSOME- AND POLYMER- MEDIATED GENE TRANSFER
AU GAO, XIANG [PH.D.]; HUANG, LEAF [adviser]
CS UNIVERSITY OF PITTSBURGH (0178)
SO Dissertation Abstracts International, (1996) Vol. 57, No. 12B, p.
7360. Order No.: AAR9715495. 132 pages.
DT Dissertation
FS DAI
LA English
AB Various aspects related to the development of cationic liposome
Searcher : Shears 308-4994

and polymer based gene delivery systems were studied. A novel cationic lipid, 3 \$\beta\$ (N-(N\$^{\prime}\$-dimethylaminoethane) carbamoyl) cholesterol (DC-chol) was synthesized from a simple reaction with high yield. Cationic liposomes composed of DC-chol and dioleoylphosphatidylethanolamine (DOPE) showed higher transfection efficient and lower toxicity than a commercial reagent.

An excess of liposomes formed stable complexes with DNA, even at very high concentrations of both components. The complexes were purified and concentrated from the DNA/liposome mixture by ultracentrifugation on a sucrose density gradient that resulted in a single-vial, ready-to-use DNA/liposome formulation. These purified complexes were as efficient in transfection as the freshly prepared DNA/liposome complexes.

Cationic polymers dramatically reduced the particle size of the lipid/DNA complexes, rendered the DNA resistant to the nuclease activity, and enhanced the transfection activity of several types of cationic liposomes by 2-28 fold in vitro. Fractionation by ultracentrifugation obtained complexes of different amounts of lipid and different levels of transfection activity. The lipid-poor complexes were less active, unless additional free liposomes were supplemented. The lipid-enriched complexes were highly active by themselves. The purified complexes were about 3-9-fold more active than the unpurified complexes. Negative stain EM studies revealed that the purified, active complexes were all under 100 nm in size; some were associated with lipid membranes.

Finally, a potent cytoplasmic gene expression system based on a purified T7 RNA polymerase and a reporter gene driven by a T7 promoter was delivered into cells by cationic liposomes. A T7 RNA polymerase specific expression was observed that reached its peak level about eight hours sooner and 2-fold higher than a nucleus-dependent gene expression system using SV 40 enhance/promoter. The expression declined after 30 hour post-transfection. The level and the duration of the gene expression were significantly improved by the addition of a polymerase self-regenerating plasmid.

In summary, we have developed and further improved a cationic liposome based delivery technology through a series of chemical, formulation and molecular biological studies from both delivery and expression aspects.

L9 ANSWER 13 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 7
 AN 97:82126 BIOSIS
 DN 99373839
 TI DNA-induced lateral segregation of cationic amphiphiles in lipid bilayer membranes as detected via ^2H NMR.
 AU Mitrakos P; MacDonald P M
 CS Dep. Chem. Erindale Coll., Univ. Toronto, 3359 Mississauga Road
 North, Mississauga, ON, L5L 1C6, Canada
 Searcher : Shears 308-4994

SO Biochemistry 35 (51). 1996. 16714-16722. ISSN: 0006-2960
 LA English
 AB ²H NMR spectroscopy was used to investigate the response of specifically choline-deuterated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) to changes in surface electrostatic charge in membranes consisting of mixtures of POPC plus various cationic amphiphiles plus polyadenylic acid (polyA). Three different cationic amphiphiles were investigated: cetyltrimethylammonium bromide (CTAB), dioleoyldimethylaminopropane (DODAP), and **3-beta** (N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-CHOL). Each of the cationic amphiphiles elicited a concentration-dependent decrease (increase) in the quadrupolar splitting from POPC-alpha-d-2 (POPC-beta-d-2), as expected for the accumulation of cationic charges at the surface of a lipid bilayer. However, the strength of the response varied with the cationic amphiphile in the order CTAB > DODAP > DC-CHOL. When polyA was added to the cationic amphiphile-containing lipid bilayers, the ²H NMR spectrum consisted of two overlapping Pake patterns, indicating the presence of two lipid domains with different effective surface charges and only slow exchange of lipids between the two domains. There was no evidence of any non-bilayer lipid arrangements. Analysis of the quadrupolar splittings of the two ²H NMR spectral components demonstrated that the polyA-containing domain was enriched with respect to cationic amphiphiles while the polyA-free domain was depleted with respect to cationic amphiphiles. We conclude that polyA is able to laterally segregate cationic amphiphiles into long-lived lipid domains of distinct composition.

L9 ANSWER 14 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 8
 AN 96:230304 BIOSIS
 DN 98794433
 TI Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer.
 AU Lee R J; Huang L
 CS Lab. Drug Targeting, Dep. Pharmacol., Univ. Pittsburgh Sch. Med., Pittsburgh, PA 15261, USA
 SO Journal of Biological Chemistry 271 (14). 1996. 8481-8487. ISSN: 0021-9258
 LA English
 AB We have developed a lipidic gene transfer vector, LPD-II, where DNA was first complexed to polylysine at a ratio of 1:0.75 (w/w) and then entrapped into folate-targeted pH-sensitive anionic liposomes composed of dioleoyl phosphatidylethanolamine (DOPE)/**cholesteryl** hemisuccinate/polyethylene glycol-DOPE (6:4:0.01 mol/mol) via charge interaction. LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid composition. At low lipid to DNA ratios (eg. 4 and 6), LPDII particles were positively charged; transfection and cellular uptake

Searcher : Shears 308-4994

levels were independent of the folate receptor and did not require a pH-sensitive lipid composition. Meanwhile, transfection and uptake of negatively charged LPDII particles, i.e. those with high lipid to DNA ratios (eg. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid composition. The transfection activity of LPDII was lost when the inverted cone-shaped DOPE was replaced by dioleoyl phosphatidylcholine. LPDII particles with lipid to DNA ratios of 4, 6, 10, and 12 were apprx 20-30 times more active than DNA cndot

3-beta-(N-(N',N'-dimethylethane)carbamoyl

)cholesterol cationic liposome complexes in KB cells and were much less cytotoxic. On the sucrose gradient, LPDII particles had a migration rate in between those of the free DNA and the DNA cndot polylysine complex. An electron micrograph of LPDII showed a structure of spherical particles with a positively stained core enclosed in a lipidic envelope with a mean diameter of 74 +- 14 nm. This novel gene transfer vector may potentially be useful in gene therapy for tumor-specific delivery.

L9 ANSWER 15 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 9
 AN 97:65259 BIOSIS
 DN 99364462
 TI New cationic lipid formulations for gene transfer.
 AU Liu F; Yang J; Huang L; Liu D
 CS Dep. Pharm. Sci., Sch. Pharm., Univ. Pittsburgh, Pittsburgh, PA
 15261, USA
 SO Pharmaceutical Research (New York) 13 (12). 1996. 1856-1860. ISSN:
 0724-8741
 LA English
 AB Purpose: To develop appropriate dosage forms of DNA for gene delivery. Methods: 3-beta-(N-(N',N'-dimethylaminoethane) carbamoyl) cholesterol (DC-Chol) was mixed either with Tween 80 alone, or with additional lipid components including castor oil and phosphatidylcholine (PC) or dioleoylphosphatidylethanolamine (DOPE) to make different lipid formulations. The particle size and the physical stability of the formulations upon mixing with plasmid DNA containing the luciferase cDNA were examined using laser light scattering measurement. The transfection activity of the DNA/lipid complexes was tested in presence or absence of serum using a cell culture system. Results: We demonstrated that many favorable properties as a gene carrier could be achieved by formulating DNA into new dosage forms using Tween 80 as the major emulsifier. Compared to the cationic liposomes, these new formulations transfected different cell lines with an equivalent or higher efficiency. Not only are they resistant to serum, but also form stable DNA complexes which could be stored for longer periods of time without losing transfection activity. Conclusions: Cationic lipids formulated into different lipid formulations using Tween 80 as a surfactant appeared to have more favorable physical and biological activities than traditional cationic liposomes as a carrier for gene

Searcher : Shears 308-4994

delivery.

L9 ANSWER 16 OF 39 MEDLINE DUPLICATE 10
 AN 97114594 MEDLINE
 TI Effect of non-ionic surfactants on the formation of DNA/emulsion complexes and emulsion-mediated gene transfer.
 AU Liu F; Yang J; Huang L; Liu D
 CS Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania 15261, USA.
 SO PHARMACEUTICAL RESEARCH, (1996 Nov) 13 (11) 1642-6.
 Journal code: PHS. ISSN: 0724-8741.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 9705
 EW 19970503
 AB PURPOSE: To study the structure-function relationship of non-ionic surfactants in emulsion-mediated gene delivery. METHODS: Four different types of non-ionic surfactants including Tween, Span, Brij and pluronic copolymers were used as co-emulsifiers for preparation of emulsions composed of Castor oil, dioleoylphosphatidylethanolamine (DOPE) and **3 beta** [N-(N', N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol). The effect of different surfactants on the formation of DNA/emulsion complexes and transfection activity were analyzed using plasmid DNA containing luciferase cDNA as a reporter gene. RESULTS: Non-ionic surfactants containing branched polyoxyethylene chains as the hydrophilic head group were more effective in preventing the formation of large DNA/emulsion complexes than those containing one or no polyoxyethylene chain. All emulsion formulations except those containing Brij 700 exhibited high activity in transfecting mouse BL-6 cells in the absence of serum. In the presence of serum, however, transfection activity of each formulation varied significantly. Emulsions containing Tween, Brij 72, pluronic F68 and F127 demonstrated increased activity in transfecting cells in the presence of 20% serum. In contrast to emulsions containing Span, long chain polyoxyethylene of Brij showed decreased transfection activity. The particle size of the DNA/emulsion complexes and their ability to transfect cells are dependent on the concentration of non-ionic surfactant in the formulation. CONCLUSIONS: The structure of the hydrophilic head group of the non-ionic surfactants in the emulsion is important in determining how DNA molecules interact with emulsions and the extent to which DNA is transferred inside the cell.

L9 ANSWER 17 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS
 AN 97:42817 BIOSIS
 DN 99334805

Searcher : Shears 308-4994

TI Effect of non-ionic surfactants on the formation of DNA-emulsions complexes and emulsion-mediated gene transfer.
 AU Liu F; Yang J; Huang L; Liu D
 CS Dep. Pharm. Sci., Sch. Pharm., Univ. Pittsb., Pittsburgh, PA 15261, USA
 SO Pharmaceutical Research (New York) 113 (11). 1996. 1642-1646. ISSN: 0724-8741
 LA English
 AB Purpose. To study the structure-function relationship of non-ionic surfactants in emulsion-mediated gene delivery. Methods. Four different types of non-ionic surfactants including Tween, Span, Brij and pluronic copolymers were used as co-emulsifiers for preparation of emulsions composed of Castor oil, dioleoylphosphatidylethanolamine (DOPE) and **3-beta**(N-(N',N'-dimethylaminoethane) **carbamoyl**) **cholesterol** (DC-Chol). The effect of different surfactants on the formation of DNA/emulsion complexes and transfection activity were analyzed using plasmid DNA containing luciferase cDNA as a reporter gene. Results. Non-ionic surfactants containing branched polyoxyethylene chains as the hydrophilic head group were more effective in preventing the formation of large DNA/emulsion complexes than those containing one or no polyoxyethylene chain. All emulsion formulations except those containing Brij 700 exhibited high activity in transfecting mouse BL-6 cells in the absence of serum. In the presence of serum, however, transfection activity of each formulation varied significantly. Emulsions containing Tween, Brij 72, pluronic F68 and F127 demonstrated increased activity in transfecting cells in the presence of 20% serum. In contrast to emulsions containing Span, long chain polyoxyethylene of Brij showed decreased transfection activity. The particle size of the DNA/emulsion complexes and their ability to transfect cells are dependent on the concentration of non-ionic surfactant in the formulation. Conclusions. The structure of the hydrophilic head group of the nonionic surfactants in the emulsion is important in determining how DNA molecules interact with emulsions and the extent to which DNA is transferred inside the cell.

L9 ANSWER 18 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 11
 AN 96:564032 BIOSIS
 DN 99293388
 TI The use of cationic liposomes DC-CHOL-DOPE and DDAB-DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors.
 AU Szala S; Missol E; Sochanik A; Strozyk M
 CS Dep. Tumor Biol., Inst. Oncol., 44-100 Gliwice, Poland
 SO Gene Therapy 3 (11). 1996. 1026-1031. ISSN: 0969-7128
 LA English
 AB An attempt was made to use simple cationic liposomes DC-Chol/DOPE and DDAB/DOPE (DC-Chol is **3-beta** (N(N',N'-dimethylaminoethane) **carbamoyl**) **cholesterol**, DDAB
 Searcher : Shears 308-4994

is dimethyldioctadecyl ammonium bromide and DOPE is dioleoylphosphatidylethanolamine) for transfer of Escherichia coli cytosine deaminase 'suicide' gene under the control of tissue-specific tyrosinase gene promoter directly into the murine melanoma B16(F10) tumor. Several repeated intratumoral injections of DNA-liposome complexes followed by intraperitoneal administrations of 5-fluorocytosine, which is converted to 5-fluorouracil, caused strong retardation of murine melanoma B16(F10) tumor growth and, in some cases, rejection of the pre-established tumor. The inhibition of tumor growth expressed as the increased survival of mice is better seen in the case of using DNA-DDAB/DOPE complexes as compared to DNA-DC-Chol/DOPE ones. It seems that the observed therapeutic effect appears to result from several factors: 5-fluorouracil generation by transfected cells, liposome toxicity (DDAB is more toxic than DC-Chol and hence more tumor cells are killed), increased transfection efficiency of surviving cancer cells (in this case DDAB is a better transfection agent than DC-Chol) and, finally, the bystander effect which causes destruction of cells untransfected with CD gene by easily diffusible 5-fluorouracil.

L9 ANSWER 19 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 12
 AN 96:370369 BIOSIS
 DN 99092725
 TI Fate of cationic liposomes and their complex with oligonucleotide in vivo.
 AU Litzinger D C; Brown J M; Wala I; Kaufman S A; Van G Y; Farrell C L; Collins D
 CS Dep. Pharmacol., Amgen Inc., Thousand Oaks, CA 91320, USA
 SO Biochimica et Biophysica Acta 1281 (2). 1996. 139-149. ISSN: 0006-3002
 LA English
 AB The present studies describe the biodistribution of cationic liposomes and cationic liposome/oligonucleotide complex following intravenous injection into mice via the tail vein. ^{111}In -diethylenetriaminepentaacetic acid stearylamide (^{111}In -DTPA-SA) was used as a lipid-phase radiolabel. Inclusion of up to 5 mol% DTPA-SA in liposomes composed of 3-beta - (N-(N',N'-dimethylamino-ethane)carbamoyl) cholesterol (DC-Chol) and dioleoylphosphatidylethanolamine (DOPE) did not influence liposome formation or size, nor the binding/uptake or fusion of the cationic liposomes with CHO cells in vitro. Moreover, nuclear delivery of oligonucleotide to CHO cells was unaffected by the probe. The biodistribution of liposomes with increasing concentration of DC-Chol (1:4-4:1, DC-Chol/DOPE, mol/mol) at 24 h post-injection revealed no dependence on lipid composition. Uptake was primarily by liver, and accumulation in spleen and skin was also observed. Comparatively little accumulation occurred in lung. Clearance of injected liposomes by liver was very rapid (apprx 84.5% of the injected dose by 7.5 h post-injection). Liposome uptake

Searcher : Shears 308-4994

by liver and spleen were equally efficient in the dose range of 3.33 to 33.33 mg/kg body weight, yet possible saturation of liver uptake at a dose of 66.80 mg/kg may have allowed for increased spleen accumulation. Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic yet transient accumulation of the lipid in lung which gradually redistributed to liver. Similar results were observed when monitoring iodinated oligonucleotide in the complex. Immuno-histochemical studies revealed large aggregates of oligonucleotide within pulmonary capillaries at 15 min post-injection, suggesting the early accumulation in lung was due to embolism. Immuno-histochemical studies further revealed labeled oligonucleotide to be localized primarily to Kupffer cells at 24 h post-injection. Immuno-electron microscopy revealed localization of oligonucleotide primarily to the lumen of pulmonary capillaries at 15 min post-injection, and to phagocytic vacuoles of Kupffer cells at 24 h post-injection. By these methods, nuclear delivery of oligonucleotide in vivo was not observed. Increasing concentration of mouse serum inhibited cellular binding/uptake of cationic liposomes in vitro, without or with complexed oligonucleotide. We therefore postulate that interaction with plasma components, including opsonin(s), inhibits cellular uptake of the injected liposomes as well as the liposome/oligonucleotide complex, and mediates rapid uptake by Kupffer cells of the liver. These results are relevant to the design of cationic liposomes for efficient delivery of nucleic acid in vivo.

L9 ANSWER 20 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS
AN 97:115153 BIOSIS
DN 99414356
TI Large scale production of DC-Chol cationic liposomes by microfluidization.
AU Sorgi F L; Huang L
CS W1351 Biomed. Sci. Tower, Univ. Pittsburgh, Pittsburgh, PA 15261, USA
SO International Journal of Pharmaceutics (Amsterdam) 144 (2). 1996.
131-139. ISSN: 0378-5173
LA English
AB In this report, we describe the large scale production and testing of DC-Chol cationic liposomes by microfluidization. These liposomes are produced in a GMP acceptable manner to a 500 ml batch size and are shown to be sterile. Further, when stored at 4 degree C, DC-Chol liposomes will retain their original size, remain suspended in solution. and retain activity for a period exceeding 1.5 years. In-process QA and QC procedures have identified problems in processing and methods to produce a final product of pharmaceutical quality have been developed to overcome these obstacles. Assays for product content (DC-Chol and DOPE assays). size. sterility. endotoxin determination, storage conditions and shelf life have been developed. Successful lots have been used in a human gene therapy clinical trial for cystic fibrosis at Oxford University as well as many pre-clinical
Searcher : Shears 308-4994

experiments throughout the world. Implications for application to further gene therapy clinical trials as well as the development of liposome vector programs are discussed in detail.

L9 ANSWER 21 OF 39 BIOTECHDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 95-15760 BIOTECHDS
 TI Efficient gene transfer to EGF receptor-overexpressing cancer cells by means of EGF-liposomes;
 cationic liposome-mediated epidermal growth factor
 recpetor-mediated gene transfer into human endometrial
 carcinoma, choriocarcinoma, ovary carcinoma cell (conference
 abstract)
 AU Kikuchi A; Sugaya S; Ueda H; Tanaka K; Aramaki Y; Hara T; Arima H;
 Tsuchiya S
 CS Univ.Niigata; Univ.Tokyo-Pharm.
 LO Department of Obstetrics and Gynecology, Niigata University School
 of Medicine, Niigata 951, Japan.
 SO Gene Ther.; (1995) 2, 9, 687
 CODEN: 4352W ISSN: 0969-7128
 Japanese Society of Gene Therapy 1st Annual Meeting, Tokyo, Japan,
 21 May, 1995.
 DT Journal
 LA English
 AN 95-15760 BIOTECHDS
 AB Epidermal growth factor (EGF)-labeled cationic liposomes
 (EGF-liposomes) including **3-beta**
 -(N-(N',N'-dimethylaminoethane) **carbamoyl**)
 cholesterol (DC-chol) were prepared in order to enhance
 liposome transfection efficiency. In HEC-1-A (human endometrial
 carcinoma) cells and GCH-1 (m) (human choriocarcinoma) cells, both
 of which have high expression of EGF receptors, EGF-liposomes
 induced about 2- and 4-fold higher luciferase activities than
 non-labeled liposomes, respectively. HRA (human ovarian carcinoma)
 cells, which have a low level of expression of EGF receptors,
 transfected with EGF-liposomes containing the luciferase gene,
 exhibited almost the same activities as those transfected with
 non-labeled liposomes. The transfection activity of the
 EGF-liposomes was not completely suppressed by competition with
 excess-free EGF, suggesting that the enhancement of the
 transfection activity is not only due to the increase of liposome
 uptake via receptor mediated endocytosis, but other mechanisms as
 well. (0 ref)

L9 ANSWER 22 OF 39 BIOTECHDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 95-03921 BIOTECHDS
 TI Inhibition of human ovarian carcinoma cell proliferation by
 liposome-plasmid DNA complex;
 plasmid pUC19 and DC-chol liposome complex lipofection for
 cancer gene therapy in severe combined immunodeficiency mice
 Searcher : Shears 308-4994

AU Hofland H; *Huang L
 CS Univ.Pittsburgh
 LO Department of Pharmacology, University of Pittsburgh School of
 Medicine, Pittsburgh, PA 15261, USA.
 SO Biochem.Biophys.Res.Commun.; (1995) 207, 2, 492-96
 CODEN: BBRCA9 ISSN: 0006-291X
 DT Journal
 LA English
 AN 95-03921 BIOTECHDS
 AB Severe combined immunodeficiency (SCID) mice were injected i.p. with 200 ul medium containing 30 mil human ovary carcinoma cells (2008). Treatment was initiated 2 days later at a frequency of 3 injections per wk. The mice were injected with 200 ul liposome plasmid DNA complex, which contained 50 ug plasmid pUC19 and 250 nmol **3-beta(N-(N'N'-dimethylaminoethane)-carbamoyl) cholesterol** (DC-chol) liposomes in 5% glucose. Mice injected with 250 nmol DC-chol liposomes alone, 50 ug plasmid pUC19 alone, or 5% dextrose controls. Liposome-plasmid DNA complexes appeared to inhibit the cell growth of ascites tumor cells specifically in the peritoneal cavity, while they were not toxic to the normal tissues. The inhibition of tumor growth by liposome-plasmid DNA complex was independent of the DNA sequence. Similar results were obtained using different plasmids such as plasmid pUCSV2CAT or plasmid pBR322. The sequence independent inhibition of tumor cell proliferation in vivo may augment the anti-cancer therapeutic effect of gene therapy, which depends on the gene product produced by the specific DNA sequence delivered by the liposomes. (12 ref)

L9 ANSWER 23 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS
 AN 95:288149 BIOSIS
 DN 98302449
 TI Liposome mediated gene transfer in the gut and liver of the adult rat: Functional mapping of a eukaryotic promoter.
 AU Katsel P; Mobbs C C; Greenstein R J
 CS VAMC, Bronx, NY, USA
 SO Clinical Research Meeting, San Diego, California, USA, May 5-8, 1995. Journal of Investigative Medicine 43 (SUPPL. 2). 1995. 331A.
 DT Conference
 LA English

L9 ANSWER 24 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 13
 AN 95:310885 BIOSIS
 DN 98325185
 TI Fusion of cationic liposomes with mammalian cells occurs after endocytosis.
 AU Wrobel I; Collins D
 CS Dep. Pharmaceutics Drug Delivery, Mail Stop 8-1-A-215, Amgen Inc., 1840 Dehavenland Drive, Thousand Oaks, CA 91320, USA
 Searcher : Shears 308-4994

SO Biochimica et Biophysica Acta 1235 (2). 1995. 296-304. ISSN:
 0006-3002
 LA English
 AB The interaction of cationic liposomes prepared using either dioleoyltrimethylammonium propane (DOTAP) or **3-beta**-
 -(N-(N',N'-dimethylaminoethane)**carbamoyl**)
cholesterol (DC-CHOL) with model membranes and with cultured
 mammalian cells was examined using an assay developed for monitoring
 virus-cell fusion (Stegmann et al. (1993) Biochemistry 32,
 11330-11337). Lipid mixing between cationic liposomes and liposomes
 composed of DOPE/dioleoylphosphatidylglycerol (DOPG) or
 dioleoylphosphatidylcholine (DOPC)/DOPG was insensitive to pH in the
 range of pH 4.5-7.0 and was not affected by sodium chloride
 concentration in the range of 0-150 mM. Lipid mixing was dependent on
 dioleoylphosphatidylethanolamine (DOPE), since cationic liposomes
 prepared using dioleoylphosphatidylcholine (DOPC) were incapable of
 lipid mixing with DOPC/DOPG liposomes. The interaction of cationic
 liposomes with Hep G-2 and CHO D- cells was also studied. For both
 cell types, liposome-cell lipid mixing was rapid at 37 degree C,
 beginning within minutes and continuing for up to 1 hour after
 uptake. The extent of lipid mixing was decreased at 15 degree C,
 especially at later (gt 20 min) time points. This suggests that at
 least part of the observed lipid mixing occurred after reaching
 cellular lysosomes. No lipid mixing was seen at 4 degree C. Monensin
 inhibited lipid mixing between cationic liposomes and the cells,
 despite having no effect on liposome uptake. Inhibition of endocytic
 uptake of liposomes, either by incubation in hypertonic media or by
 depletion of cellular ATP with sodium azide and 2-deoxyglucose
 abolished liposome-cell fusion in both cell types. These data
 demonstrate that binding to the cell surface is insufficient for
 cationic liposome-cell fusion and that uptake into the endocytic
 pathway is required for fusion to occur.

L9 ANSWER 25 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 14
 AN 95:313935 BIOSIS
 DN 98328235
 TI The role of dioleoyl phosphatidylethanolamine in cationic liposome
 mediated gene transfer.
 AU Farhood H; Serbina N; Huang L
 CS Dep. Pharmacol., Univ. Pittsburgh Sch. Med., 13th Floor, Biomed. Sci.
 Tower, Pittsburgh, PA 15261, USA
 SO Biochimica et Biophysica Acta 1235 (2). 1995. 289-295. ISSN:
 0006-3002
 LA English
 AB In a reporter gene assay, cationic liposomes containing the cationic
 lipid **3-beta**-(N-(N',N'-dimethylaminoethane)
carbamoyl)**cholesterol** (DC-Chol) and a neutral
 phospholipid dioleoylphosphatidylethanolamine (DOPE) showed high
 transfection activity. DNA/liposome complex which contained low
 Searcher : Shears 308-4994

amount of liposomes could bind to the cell surface but failed to transfect the cells. We have designed a two-step protocol to examine this phenomenon in more detail. A431 human cells were incubated on ice (pulse) with DNA complexed to a low level of cationic liposomes. The cells were washed and incubated at 37 degree C (chase) with or without free cationic liposomes of various composition (helper liposomes). Only liposomes enriched with DOPE showed helper activity; liposomes containing dioleoylphosphatidylcholine (DOPC), a structural analog of DOPE, had no helper activity. The delivery was inhibited by the lysosomotropic agent chloroquine and was optimal if the helper liposome chase was initiated immediately after the pulse. An endocytosis model of DNA delivery by cationic liposomes is proposed in which the principal function of the chase liposomes is to destabilize the endosome membrane and allow the release of DNA into the cytosol. This model is consistent with the known activity of DOPE to assume non-bilayer structures, hence destabilizing the endosome membrane.

L9 ANSWER 26 OF 39 MEDLINE DUPLICATE 15
AN 96170339 MEDLINE
TI Pleotropic effects of dietary DHEA.
AU Milewich L; Catalina F; Bennett M
CS Department of Obstetrics-Gynecology and Pathology, University of Texas, Southwestern Medical Center at Dallas 75235, USA.
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Dec 29) 774 149-70.
Journal code: 5NM. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 9606
AB We present data pertaining to some of the in vivo effects associated with dietary DHEA administration to mice and rats. Dietary DHEA leads to: (1) decrease in body weight gain; (2) relative increases in liver weight; (3) liver color change; (4) induction of hepatic peroxisomal enzymes; (5) proliferation of hepatic peroxisomes with increased cross-sectional area; (6) decreased hepatic mitochondrial cross-sectional area; (7) elevated levels of hepatic cytosolic malic enzyme; (8) slight decreases, significant decreases, or significant increases in serum triglyceride levels, depending on mouse strain; (9) increases in total serum **cholesterol** levels; (10) significant decreases in the hepatic rates of fatty acid synthesis; (11) significant increases in the hepatic rates of **cholesterol** synthesis; (12) decreases in both protein content and specific activity of hepatic mitochondrial carbamoyl phosphate synthetase-I without concomitant changes in serum urea nitrogen; (13) induction of glutathione S-transferase activity in liver; (14) decrease in hepatic endogenous protein

phosphorylation; (15) increase in hepatic AMPase and GTPase activities; (16) formation of 5-androstene-3 **beta**,17 beta-diol as a major metabolite of DHEA by subcellular fractions of liver, which is reflected in serum and tissue levels; and (17) reduction in serum prolactin levels.

L9 ANSWER 27 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS
 AN 95:77825 BIOSIS
 DN 98092125
 TI New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy.
 AU Sternberg B; Sorgi F L; Huang L
 CS Inst. Ultrastructure Res., Med. Sch., Friedrich-Schiller-Univ. Jena, Ziegelmuhlenweg 1, Jena D-07743, Germany
 SO FEBS Letters 356 (2-3). 1994. 361-366. ISSN: 0014-5793
 LA English
 AB Structures formed during interaction of cationic liposomes and plasmid DNA were studied by freeze-fracture electron microscopy and their morphology was found to be dependent on incubation time and DNA concentration. These structures were formed with liposomes composed of DC-Chol and DOPE after 30 min incubation at DNA: lipid concentrations encompassing maximal transfection activity. They resembled liposome complexes (meatballs) and additionally bilayer-covered DNA tubules (spaghetti), whereby the DNA-tubules were found to be connected to the liposome complexes as well as occurring free in the suspension. At later times and higher DNA-to-liposome ratios the complexes grow larger while their membranes become discontinuous, allowing the self-encapsulation of the DNA. The relative transfection potency of the various morphologically distinct structures is discussed.

L9 ANSWER 28 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 16
 AN 94:300521 BIOSIS
 DN 97313521
 TI Direct gene transfer by liposomes.
 AU Singhal A; Huang L
 CS Dep. Pharmacology, Lab. Drug Targeting, Univ. Pittsburgh, Pittsburgh, PA 15261, USA
 SO Journal of Liposome Research 4 (1). 1994. 289-299. ISSN: 0898-2104
 LA English
 AB Cationic liposomes are widely used for the delivery of genes both in vivo and in clinical trials. DC-chol liposome formulation was developed by us for relatively high activity of transfection and low level of toxicity for most cell types. Different strategies are described for achieving regulated transgene expression as well as expression for a prolonged period of time using DC-chol liposomes.

L9 ANSWER 29 OF 39 BIOTECHDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 95-02113 BIOTECHDS
 Searcher : Shears 308-4994

TI Cationic liposomes for direct gene transfer in therapy of cancer and other diseases;
 lipofection for melanoma therapy (conference paper)
 AU Farhood H; Gao X; Son K; Yang Y Y; Lazo J S; Huang L; Barsoum J;
 Bottega R; Epand R M
 CS Univ.Pittsburgh; Biogen; Univ.McMaster
 LO Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
 SO Ann.N.Y.Acad.Sci.; (1994) 716, 23-35
 CODEN: ANYAA9 ISSN: 0077-8923
 Gene Therapy for Neoplastic Diseases, Washington DC, USA, 27-29 June, 1993.
 DT Journal
 LA English
 AN 95-02113 BIOTECHDS
 AB Cationic liposomes complex to negatively charged naked DNA resulting in a net positive charge. Transfection is highly efficient. To improve gene delivery, cationic **cholesterol** derivatives were synthesized. Results showed a connection between their structure, toxic effects, transfection activity, and effect on protein-kinase-C. Tertiary amines were most efficient but had a reduced shelf life. This led to synthesis of a derivative termed **3 beta** [N-(N',N'-dimethylaminoethane)-carbamoyl] **cholesterol** (DC-Chol). DNA carriers were developed. The level, onset and termination of gene expression was studied. T7 RNA polymerase and HIV virus trans-activator (tat) protein were tested. Little cytoplasmically derived DNA reached the nucleoplasm. Cytoplasmic transcription in mammalian cells was substantiated using bacteriophage T7 RNA polymerase. tat Protein delivery to cultured cells was tested, codelivery with DNA coding for a reporter gene was efficient. Tumor cells selected for cis-platin resistance were transfectable with cationic liposomes. In vivo delivery of DC-Chol liposomes for treatment of melanoma was recently approved. (29 ref)
 L9 ANSWER 30 OF 39 BIOTECHDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 93-06139 BIOTECHDS
 TI Method for delivering nucleic acid into cell;
 liposome composition containing cationic lipid with cholesterol group, linker, spacer arm, cationic amino group, for use in mammal cell culture transfection by lipofection
 PA Univ.Tenn.Res.Corp.
 PI WO 9305162 18 Mar 1993
 AI WO 92-US7290 28 Aug 1992
 PRAI US 91-751873 28 Aug 1991
 DT Patent
 LA English
 OS WPI: 93-100985 [12]
 AN 93-06139 BIOTECHDS

AB A new method for transfer of nucleic acids into mammal cells via transfection (lipofection) involves treating cells with a dispersion containing nucleic acids and a mixed lipid dispersion of a cationic lipid with a co-lipid in a solvent. The cationic lipid includes a lipophilic **cholesterol** group, a carboxamide or **carbamoyl** linker, a linear or branched C1-20 alkyl spacer arm, and a cationic primary, secondary, tertiary or quaternary amino group. The cationic lipid is a weak protein-kinase-C-inhibitor, and the co-lipid may be lecithin, phosphatidylethanolamine or dioleoyl phosphatidylethanolamine. The cationic lipid dispersion preferably has particles with an average diameter of 150 nm. The solvent may be distilled water, normal saline or buffered saline. The cationic lipid may be

cholesteryl- 3-beta-

carboxyamidoethylene trimethylammonium iodide, **cholesteryl** - 3-**beta**-carboxyamidoethyleneamine,

cholesteryl- 3-beta-

oxysuccinamidoethylene trimethylammonium iodide, 3-

beta-(N-(N'N'-dimethylaminoethane) **carbamoyl**)

cholesterol or 3-**beta**

-(N-(polyethyleneimine)- **carbamoyl**) **cholesterol**

. (40pp)

L9 ANSWER 31 OF 39 BIOTECHDS COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 93-11003 BIOTECHDS

TI Cationic liposomes and polymers for gene transfer; cationic liposome and polylysine polymer application in transfection, lipofection for e.g. gene therapy; a review

AU Gao X; *Huang L

LO Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

SO J.Liposome Res.; (1993) 3, 1, 17-30

CODEN: JLREE7

DT Journal

LA English

AN 93-11003 BIOTECHDS

AB Cationic liposome and polylysine polymer application in transfection for e.g. gene therapy is reviewed with respect to: (1) dioleoyl-phosphatidylethanolamine (DOPE):quaternary amino detergent cationic liposomes; (2) DOPE:DC-Chol (3-

beta-(N',N'-dimethylaminoethane)**carbamoyl** cholesterol) cationic liposomes; (3) protein-kinase-C inhibitory activity, toxicity and transfection activity of other

cholesterol derivatives; and (4) targeted polycations as

DNA delivery vehicles (lipopolysine and lipopolysine-containing liposome-mediated gene transfection, and N-terminal modified polylysine-antibody conjugates as carriers for targeted gene delivery in vitro and in vivo). The cationic liposome formulation DC-chol:DOPE is being used in clinical trials for ca

Searcher : Shears 308-4994

ncer gene therapy. (27 ref)

L9 ANSWER 32 OF 39 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 92-42284 DRUGU B P G
 TI Cationic Liposomes Enhance Targeted Delivery and Expression of
 Exogenous DNA Mediated by N-Terminal Modified Poly(L-lysine)-
 Antibody Conjugate in Mouse Lung Endothelial Cells.
 AU Trubetskoy V S; Torchilin V P; Kennel S; Huang L
 LO Knoxville, Oak Ridge, Tennessee, United States
 SO Biochim.Biophys.Acta N (1131, No. 3, 311-13, 1992) 3 Fig. 11 Ref.
 CODEN: BBGSD5 ISSN: 0167-4781
 AV Center for Imaging and Pharmaceutical Research, Massachusetts
 General Hospital, Building 149, 13th Street, Charlestown, MA 02129,
 U.S.A.
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature
 AN 92-42284 DRUGU B P G
 AB A ternary complex composed of anti-thrombomodulin antibody,
 34A-N-terminal modified poly(L-lysine) (NPLL) carrying pUCSV2
 chloramphenicol acetyltransferase (CAT) plasmids and cationic
 liposomes (CL) showed significantly enhanced transfection activity
 in mouse lung endothelial cells increasing the non-specific
 transfection level. The binary complex containing only
 34A-NPLL/DNA exhibited only low transfection activity. The results
 indicate that inclusion of CL into the complex enhances the
 frequency of endosome destabilization which results in an increased
 amount of DNA release into the cytoplasm and may be useful in
 transgene delivery and gene therapy.
 ABEX CL containing 65 mol% 3 **beta** (N-(N',N'-dimethyl
 aminoethane)**carbamoyl**) **cholesterol** and 35 mol%
 dioleoylphosphatidyl ethanolamine were prepared. Addition of
 34A-NPLL to the CL/DNA binary complex increased the binding of
 32P-DNA to mouse lung endothelial cells, which was partially
 inhibited by the presence of free 34A antibody. Addition of
 Ig14-NPLL to the CL/DNA complex decreased the non-specific binding
 of DNA to the cells. The CAT activity of cells transfected with
 the binary complex was low. Increasing the amount of CL increased
 CAT activity 10- to 20-fold in the transfected cells. When the
 ratio of Ab-NPLL to CL was 1.2, there was a 10-fold difference in
 the CAT activity between cells transfected with specific
 34A-NPLL/CL/DNA and those with the non-specific 14-NPLL/CL/DNA
 complexes. (M59/TOB)

L9 ANSWER 33 OF 39 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 17
 AN 91:478176 BIOSIS
 DN BA92:111936
 TI A NOVEL CATIONIC LIPOSOME REAGENT FOR EFFICIENT TRANSFECTION OF
 Searcher : Shears 308-4994

MAMMALIAN CELLS.

AU GAO X; HUANG L

CS DEP. BIOCHEM., UNIV. TENN., KNOXVILLE, TENN. 37996-0840.

SO BIOCHEM BIOPHYS RES COMMUN 179 (1). 1991. 280-285. CODEN: BBRCA9

ISSN: 0006-291X

LA English

AB A novel cationic derivative of **cholesterol**, 3.
beta.[N-(N',N'-dimethylaminoethane)-**carbamoyl**]
cholesterol (DC-Chol), has been synthesized and used to
 prepare sonicated liposomes with dioleoylphosphatidylethanolamine.
 This novel cationic liposome reagent facilitates efficient DNA
 mediated transfection in A431 human epidermoid carcinoma cells, A549
 human lung carcinoma cells, L929 mouse fibroblast cells, and YPT
 minipig primary endothelial cells. The activity was greater than that
 of a commercial reagent, Lipofectin, and was approximately 4-fold
 less toxic than Lipofectin when assayed with A431 cells. The reagent
 is easy to synthesize and stable for at least 6 weeks.

L9 ANSWER 34 OF 39 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 83-24512 DRUGU B

TI C-22-Substituted Steroid Derivatives as Substrate Analogues and
 Inhibitors of Cytochrome P-450scc.

AU Sheets J J; Vickery L E

LO Irvine, California, United States

SO J.Biol.Chem. (258, No. 3, 1720-25, 1983) 8 Fig. 40 Ref.
 CODEN: JBCHA3 ISSN: 0021-9258

AV Department of Physiology and Biophysics, University of California,
 Irvine, California 92717, U.S.A.

LA English

DT Journal

FA AB; LA; CT; MPC

FS Literature

AN 83-24512 DRUGU B

AB The cholesterol analog 22-amino- 23,24-bisnor- 5-cholen-3-beta-ol
 (22 -ABC) was a potent inhibitor of the side chain cleavage of
 cholesterol to produce pregnenolone catalyzed by purified
 adrenocortical cytochrome P-450scc. Spectral and kinetic data
 concerning 22-ABC, the 5-alpha-cholan- 3-beta-ol derivative
 (5-alpha -22-ABC) and the 22-hydroxy analog (22-diol) supported the
 previously published model in which the inhibitor interacted with
 the substrate and with the heme catalytic site simultaneously.

ABEX Cytochrome P-450scc, adrenodoxin and adrenodoxin reductase were
 purified from bovine adrenal cortex. **Cholesterol** side
 chain cleavage was measured in mixtures containing Tween 20,
 adrenodoxin, adrenodoxin reductase and an NADPH-generating system.
 Pregnenolone was determined by RIA. 22-ABC was prepared from
 23,24-bisnor-5 -cholenic acid-3-**beta**-ol acetate
 (Steraloids) via the acid chloride, **carboxamide** acetate
 and **carboxamide**. 5-Alpha-22-ABC was prepared from
 Searcher : Shears 308-4994

23,24-bisnor- 5-alpha- cholan-3-**beta**-ol
 (Steraloids). Binding of 22-ABC or 5-alpha-22-ABC to cytochrome P-450scc caused a shift in the Soret absorption maximum to 422 nm. A similar shift was observed for the interaction of enzyme and 4 -phenylimidazole. Binding of 22-diol to the enzyme produced a Soret peak at 417 nm. In the presence of 70 uM **cholesterol**, K_m values for 22-ABC, 5-alpha-22-ABC and 22-diol were 0.1, 3 and 15 uM, respectively. Difference spectra produced during titration of 5 -alpha-22-ABC and enzyme in the presence of Tween 20 yielded a spectral dissociation constant of 9 uM, reduced to 3.8 uM in the presence of adrenodoxin. The data were consistent with coordination of the 22-amino group leading to formation of the 422 nm spectral species. The 5-androstene ring determined affinity but not the type of spectral complex. The lower potency of 22-diol emphasized the importance of the 22-amino group for high affinity binding and the formation of the 422 nm spectral species.

L9 ANSWER 35 OF 39 DRUGB COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 80-02394 DRUGB C P S
 TI POTENTIAL ANTICANCER AGENTS, XIX. NEW URETHANIC TYPE NITROGEN MUSTARDS DERIVED FROM STEROIDIC STRUCTURES.
 AU NICULESCU DUVAZ I; ELIAN I; IONESCU M; TARNAUCEANU E
 LO BUCHAREST, RUM.
 SO J.PRAKT.CHEM. (321, NO.3, 522-28, 1979)
 LA German
 DT Journal

L9 ANSWER 36 OF 39 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.
 AN 77047132 EMBASE
 TI Identification by physical means of organic moieties of conjugates produced from carbaryl by tobacco cells in suspension culture.
 AU Locke R.K.; Chen J.Y.T.; Damico J.N.; et al.
 CS Div. Toxicol., Food Drug Adm., USDHEW, Washington, D.C. 20204, United States
 SO ARCH.ENVIRON.CONTAM.TOXICOL., (1976) 4/1 (60-100).
 CODEN: AECTCV
 LA English
 AB Carbaryl (1 naphthyl methylcarbamate), labeled with ^{14}C in the C1 naphthyl, carbonyl, or N methyl position, was introduced into the culture medium to tobacco cells in suspension culture. Following incubation, cells were homogenized in water, centrifuged, and supernatants hydrolyzed with β . glucosidase or HCl. Organic moieties (moieties) were characterized by two dimensional thin layer chromatography (TLC), and many were subsequently identified by infrared and mass spectrometry. On the basis of the data obtained with ^{14}C 1 naphthyl labeled carbaryl, it appeared that 18.4% of the total characterized metabolites represented unconjugated N CH₂OH carbaryl [1 naphthyl N (hydroxymethyl)**carbamate**], excreted by the cells into the culture medium. The metabolites found in the

Searcher : Shears 308-4994

cells primarily consisted of conjugates of 1 naphthol (73.6% of the total characterized metabolites) and N CH₂OH carbaryl (2.5%). Conjugates of 7 hydroxycarbaryl (7 hydroxy 1 naphthyl methylcarbamate), 4 hydroxycarbaryl (4 hydroxy 1 naphthyl methylcarbamate), and 5 hydroxycarbaryl (5 hydroxy 1 naphthyl methylcarbamate) were also detected in small amounts. Of five unknown 14C1 naphthyl labeled carbaryl metabolites, three were tentatively characterized as: O 1 naphthylcholesterol (cholest 5 en 3.**beta.** yl 1 naphthol; 3.0%); an unconjugated hydroxylated 1,4 dihydro 1,4 epiperoxynaphthalene (1.4%); and an acid labile, .**beta.** glucosidase resistant conjugate of a cis dihydrodiol of 1 naphthol (0.3%; other than the trans 5,6 dihydrodiol). The **cholesterol** derivative may represent a new 'detoxification mechanism' in plants; the epiperoxide may help to elucidate plant oxidation mechanisms. A new TLC procedure was developed which successfully separated the acetate derivative of N hydroxycarbaryl (1 naphthyl N hydroxy N methylcarbamate) from 12 other common moieties of carbaryl metabolites and their acetate derivatives. A new two dimensional TLC system was developed for the separation of underivatized N hydroxycarbaryl from 14 other moieties of carbaryl metabolites; two additional two dimensional TLC systems were utilized for moiety separations. With these TLC procedures, no conjugated or unconjugated N hydroxycarbaryl could be detected in any tobacco cell culture fraction after incubation of cells in medium containing radiolabeled carbaryl. Authentic 14C1 naphthyl labeled N CH₂OH carbaryl was shown to be converted to desmethylcarbaryl (1 naphthylcarbamate) (97%) and 1 naphthol (3%) by 0.1N HCl hydrolysis.

L9 ANSWER 37 OF 39 DRUGB COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 76-25673 DRUGB C
 TI 3-BROMO-4,4-DIMETHYL-2-OXAZOLIDINONE PREPARATION AND INVESTIGATION
 OF A NEW BROMINATING AGENT.
 AU KAMINSKI J J; BODOR N
 CS INTERX
 LO LAWRENCE, KANS., USA.
 SO TETRAHEDRON (32, NO.10, 1097-99, 1976)
 DT Journal

 L9 ANSWER 38 OF 39 DRUGB COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 68-07542 DRUGB C
 TI REACTIONS OF LEAD TETRAACETATE. I. FORMATION OF ACYLMINES FROM
 PRIMARY CARBOXAMIDES. II. FORMATION OF CARBAMIC ACID ESTERS FROM
 PRIMARY CARBOXAMIDES.
 AU ACOTT B; BECKWITH A L J; HASSANALI A
 LO ADELAIDE, AUSTR.
 SO AUSTRALIAN J.CHEM. (21, NO.1, 185-205, 1968)
 DT Journal

08/836576

L9 ANSWER 39 OF 39 DRUGB COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 66-25945 DRUGB B
TI MYOTONIC RESPONSE INDUCED BY INHIBITORS OF CHOLESTEROL
BIOSYNTHESIS.
AU WINER N; KLACHKO D M; BAER R D; Langley P L; BURNS T W
LO COLUMBIA, MO.
SO SCIENCE (153, NO.3733, 312-13, 1966)
DT Journal

FILE 'USPATFULL' ENTERED AT 16:25:59 ON 15 DEC 1997
CA INDEXING COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Dec 1997 (19971209/PD)
FILE LAST UPDATED: 10 Dec 1997 (971210/ED)
HIGHEST PATENT NUMBER: US5697097
CA INDEXING IS CURRENT THROUGH 10 Dec 1997 (971210/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Dec 1997 (19971209/PD)
REVISED CLASS FIELDS (/NCL) CURRENT THROUGH: AUG 1997
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: JUN 1997

>>> Page images are available for patents from 1/1/94. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

13667 CHOLESTER?
2208423 3
160616 BETA
377 BETAS
160693 BETA
(BETA OR BETAS)
1098828 B
36212 CARBAM?

Searcher : Shears 308-4994

10978 CARBOXAMID?
 188230 CARBOX?
 106677 AMID?
 1557 CARBOX? AMID?
 (CARBOX? (W) AMID?)
 L10 59 L7(S) (CARBAM? OR CARBOXAMID? OR CARBOX? AMID?)
 => s l10 and (immuniz? or immunis? or adjuvant# or vaccin?)
 8205 IMMUNIZ?
 517 IMMUNIS?
 31146 ADJUVANT#
 7381 VACCIN?
 L11 5 L10 AND (IMMUNIZ? OR IMMUNIS? OR ADJUVANT# OR VACCIN?)
 => d 1-5 bib abs; fil hom

L11 ANSWER 1 OF 5 USPATFULL
 AN 97:56335 USPATFULL
 TI Methods for the suppression of neu mediated tumors by adenoviral
 E1A and SV40 large T antigen
 IN Hung, Mien-Chie, Houston, TX, United States
 Yu, Di-Hua, Houston, TX, United States
 Matin, Angahin, Houston, TX, United States
 Zhang, Yujiao Joe, Houston, TX, United States
 PA Board of Regents, The University of Texas System, Austin, TX,
 United States (U.S. corporation)
 PI US 5643567 970701
 AI US 94-276359 940715 (8)
 RLI Continuation-in-part of Ser. No. US 93-162406, filed on 3 Dec 1993
 which is a continuation-in-part of Ser. No. US 93-70410, filed on
 4 Jun 1993 which is a continuation-in-part of Ser. No. US
 90-621465, filed on 4 Dec 1990, now abandoned
 DT Utility
 EXNAM Primary Examiner: Crouch, Deborah
 LREP Arnold, White & Durkee
 CLMN Number of Claims: 22
 ECL Exemplary Claim: 1
 DRWN 69 Drawing Figure(s); 40 Drawing Page(s)
 LN.CNT 3385
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Disclosed are methods and compositions for the suppression of
 expression of the neu oncogene, as well as suppression of neu
 oncogene-mediated transformation, tumorigenesis and metastasis.
 The method disclosed involves introduction of adenovirus early 1A
 gene (the E1A gene) products, or the large T antigen (the LT gene
 product), or both into affected cells. These products, which are
 preferably introduced by transfection of the E1A gene into
 Searcher : Shears 308-4994

affected cells, serve to suppress neu gene expression as measured by a reduction of p185 expression. Furthermore, the E1A gene products surprisingly serve to suppress the oncogenic phenotype, as indicated by a reduction in cell growth, growth in soft agar, as well as tumorigenic and metastatic potential in vivo. The inventors propose that E1A gene products, LT gene products or derivatives therefrom, may ultimately be employed a treatment modalities for neu-mediated cancers, such as cancers of the female genital tract and breast. The inventors also propose methods of transfecting cells with either the E1A or the LT gene products using adenoviral vectors or liposomes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 5 USPATFULL
 AN 97:53936 USPATFULL
 TI Methods for the suppression of neu mediated tumors by adenoviral
 E1A and SV40 large T antigen
 IN Hung, Mien-Chie, Houston, TX, United States
 Yu, Di-Hua, Houston, TX, United States
 Matin, Angabin, Houston, TX, United States
 PA Board of Regents, The University of Texas System, Austin, TX,
 United States (U.S. corporation)
 PI US 5641484 970624
 AI US 93-162406 931203 (8)
 RLI Continuation-in-part of Ser. No. US 93-70410, filed on 4 Jun 1993
 which is a continuation-in-part of Ser. No. US 90-621465, filed on
 4 Dec 1990, now abandoned
 DT Utility
 EXNAM Primary Examiner: Crouch, Deborah
 LREP Arnold, White & Durkee
 CLMN Number of Claims: 43
 ECL Exemplary Claim: 1
 DRWN 54 Drawing Figure(s); 31 Drawing Page(s)
 LN.CNT 3192

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods and compositions for the suppression of expression of the neu oncogene, as well as suppression of neu oncogene-mediated transformation, tumorigenesis and metastasis. The method disclosed involves introduction of adenovirus early 1A gene (the E1A gene) products, so to large T antigen (the LT gene product), or both into affected cells. These products, which are preferably introduced by transfection of the E1A gene into affected cells, serve to suppress neu gene expression as measured by a reduction of p185 expression. Furthermore, the E1A gene products surprisingly serve to suppress the oncogenic phenotype, as indicated by a reduction in cell growth, growth in soft agar, as well as tumorigenic and metastatic potential in vivo. The inventors propose that E1A gene products, LT gene products or

Searcher : Shears 308-4994

derivatives therefrom, may ultimately be employed a treatment modalities for neu-mediated cancers, such as cancers of the female genital tract and breast. The inventors also propose methods of transfecting cells with either the E1A or the LT gene products using liposomes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 5 USPATFULL
 AN 95:94826 USPATFULL
 TI Production of immunoproximity catalysts
 IN Kim, Peter S., Brookline, MA, United States
 Kallenbach, Neville R., New York, NY, United States
 PA IGEN, Inc., Gaithersburg, MD, United States (U.S. corporation)
 PI US 5460960 951024
 AI US 94-187810 940127 (8)
 RLI Continuation of Ser. No. US 92-857683, filed on 25 Mar 1992, now abandoned which is a continuation of Ser. No. US 87-92230, filed on 2 Sep 1987, now abandoned
 DT Utility
 EXNAM Primary Examiner: Patterson, Jr., Charles L.
 LREP Curtis, Morris & Safford; Evans, Barry
 CLMN Number of Claims: 28
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 645
 AB Process for producing an immunoproximity catalyst for a chemical reaction. Chemical reactions in which the immunoproximity catalyst can be used are also disclosed.

L11 ANSWER 4 OF 5 USPATFULL
 AN 95:34082 USPATFULL
 TI Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
 IN Dubler, Robert E., Gurnee, IL, United States
 Frintner, Mary P., Elk Grove, IL, United States
 Grote, Jonathan, Grayslake, IL, United States
 Hadley, Gregg A., St. Louis, MO, United States
 Hawksworth, David J., Vernon Hills, IL, United States
 Hopkins, Hal D., Chicago, IL, United States
 Nam, Daniel S., Lake Elsinore, CA, United States
 Ungemach, Frank S., Lake Villa, IL, United States
 Wray, Larry K., Highland Park, IL, United States
 PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
 PI US 5407834 950418
 AI US 92-831762 920427 (7)
 RLI Division of Ser. No. US 90-529988, filed on 29 May 1990, now
 Searcher : Shears 308-4994

patented, Pat. No. US 5155212 which is a continuation-in-part of Ser. No. US 86-866193, filed on 21 May 1986, now abandoned

DT Utility
 EXNAM Primary Examiner: Kim, Kay K. A.
 LREP Pope, Lawrence S.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 32 Drawing Figure(s); 5 Drawing Page(s)
 LN.CNT 1662

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 5 USPATFULL
 AN 92:84969 USPATFULL
 TI Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
 IN Dubler, Robert E., Gurnee, IL, United States
 Frintner, Mary P., Elk Grove, IL, United States
 Grote, Jonathan, Grayslake, IL, United States
 Hadley, Gregg A., St. Louis, MO, United States
 Hawksworth, David J., Vernon Hills, IL, United States
 Hopkins, Hal D., Chicago, IL, United States
 Nam, Daniel S., Lake Elsinore, CA, United States
 Ungemach, Frank S., Lake Villa, IL, United States
 Wray, Larry K., Highland Park, IL, United States
 PA Abbott Laboratories, Abbott Park, IL, United States (U.S.
 corporation)
 PI US 5155212 921013
 AI US 90-529988 900529 (7)
 RLI Continuation-in-part of Ser. No. US 86-866193, filed on 21 May
 1986, now abandoned
 DT Utility
 EXNAM Primary Examiner: Nucker, Christine; Assistant Examiner: Kim, Kay
 K.
 LREP Breininger, Thomas M.
 CLMN Number of Claims: 3

Searcher : Shears 308-4994

ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'HOME' ENTERED AT 16:27:37 ON 15 DEC 1997

=> fil ca,caplus

FILE 'CA' ENTERED AT 16:30:55 ON 15 DEC 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:30:55 ON 15 DEC 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

=> s dc chol

L12 79 DC CHOL

=> s l12(s)cholest?

L13 32 L12(S) CHOLEST?

=> s l13 not 15

L14 1 L13 NOT L5

=> d .bevstr1

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1997 ACS
AN 1997:674204 CAPLUS
TI Anti-inflammatory activity of cationic lipids
AU Filion, Mario C.; Phillips, Nigel C.
CS Faculte de Pharmacie, Universite de Montreal, Montreal, PQ, H3C 3J7,
Can.
SO Br. J. Pharmacol. (1997), 122(3), 551-557
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton
DT Journal
LA English
AB The effect of liposome phospholipid compn. has been assumed to be relatively unimportant because of the presumed inert nature of phospholipids. We have previously shown that cationic liposome formulations used for gene therapy inhibit, through their cationic component, the synthesis by activated macrophages of the pro-inflammatory mediators nitric oxide (NO) and tumor necrosis factor-.alpha. (TNF-.alpha.). In this study, we have evaluated the ability of different cationic lipids to reduce footpad inflammation induced by carrageenan and by sheep red blood cell challenge. Parenteral (i.p. or s.c) or local injection of the pos. charged lipids dimethyldioctadecylammomium bromide (DDAB), dioleyoltrimethylammonium propane (DOTAP), dimyristoyltrimethylammonium propane (DMTAP) or dimethylaminoethanecarbamoyl **cholesterol (DC-Chol)** significantly reduced the inflammation obsd. in both models in a dose-dependent manner (max. inhibition: 70-95%). Cationic lipids assocd. with dioleyol- or dipalmitoyl-phosphatidylethanolamine retained their anti-inflammatory activity while cationic lipids assocd. with dipalmitoylphosphatidylcholine (DPPC) or dimyristoylphosphatidylglycerol (DMPG) showed no anti-inflammatory activity, indicating that the release of cationic lipids into the macrophage cytoplasm is a necessary step for anti-inflammatory activity. The anti-inflammatory activity of cationic lipids was abrogated by the addn. of dipalmitoylphosphatidylethanolamine-poly(ethylene)glycol-2000 (DPPE-PEG2000) which blocks the interaction of cationic lipids with macrophages. Because of the significant role of protein kinase C (PKC) in the inflammatory process we have detd. whether the cationic lipids used in this study inhibit PKC activity. The cationic lipids significantly inhibited the activity of PKC but not the activity of a non-related protein kinase, PKA. The synthesis of interleukin-6 (IL-6), which is not dependent on PKC activity for its induction in macrophages, was not modified in vitro or in situ by cationic lipids. The synthesis of NO and TNF-.alpha. in macrophages, both of which are PKC-dependent, was downregulated by cationic lipids. These results demonstrate that cationic lipids can be considered as novel anti-inflammatory agents. The downregulation of pro-inflammatory mediators through interaction of cationic lipids

Searcher : Shears 308-4994

with the PKC pathway may explain this anti-inflammatory activity. Furthermore, since cationic lipids have intrinsic anti-inflammatory activity, cationic liposomes should be used with caution to deliver nucleic acids for gene therapy in vivo.

IT Gene therapy
(anti-inflammatory activity of cationic lipids in relation to liposome-mediated gene therapy)

IT Anti-inflammatory drugs
(anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT Tumor necrosis factor .alpha.
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT Liposomes (drug delivery systems)
(cationic; anti-inflammatory activity of cationic lipids in relation to liposome-mediated gene therapy)

IT Lipids
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic; anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT Macrophage
(cytoplasm, interaction with; anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT Cytoplasm
(macrophage, interaction with; anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT 2390-68-3, DDAB 137056-72-5
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT 144189-73-1, DOTAP
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

IT 10102-43-9, Nitric oxide 141436-78-4, Protein kinase C
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(anti-inflammatory activity of cationic lipids through interaction with protein kinase C pathway)

=> d his 115

(FILE 'BIOSIS, MEDLINE, EMBASE, LIFESCI, BIOTECHDS, WPIDS, CONFSCI, DISSABS, SCISEARCH, JICST-EPLUS, PROMT, TOXLIT, TOXLINE, DRUGU, DRUGB, DRUGNL, DRUGLAUNCH' ENTERED AT 16:32:49 ON 15 DEC 1997)

L15 80 S L13

=> s l15 and (immuniz? or immunis? or adjuvant# or vaccin?)

L16 1 L15 AND (IMMUNIZ? OR IMMUNIS? OR ADJUVANT# OR VACCIN?)

=> s l16 not 18

L17 1 L16 NOT L8

=> d bib abs; fil uspat; s l13

L17 ANSWER 1 OF 1 SCISEARCH COPYRIGHT 1997 ISI (R)

AN 97:752114 SCISEARCH

GA The Genuine Article (R) Number: XZ409

TI Anti-inflammatory activity of cationic lipids

AU Filion M C; Phillips N C (Reprint)

CS UNIV MONTREAL, FAC PHARM, CP 6128, SUCC CTRVILLE, MONTREAL, PQ H3C 3J7, CANADA (Reprint); UNIV MONTREAL, FAC PHARM, MONTREAL, PQ H3C 3J7, CANADA

CY A CANADA

SO BRITISH JOURNAL OF PHARMACOLOGY, (OCT 1997) Vol. 122, No. 3, pp. 551-557.

Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS.

ISSN: 0007-1188.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 59

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB 1 The effect of liposome phospholipid composition has been assumed to be relatively unimportant because of the presumed inert nature of phospholipids.

2 We have previously shown that cationic liposome formulations used for gene therapy inhibit, through their cationic component, the synthesis by activated macrophages of the pro-inflammatory mediators nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha).

3 In this study, we have evaluated the ability of different cationic lipids to reduce footpad inflammation induced by carrageenan and by sheep red blood cell challenge.

4 Parenteral (i.p. or s.c) or local injection of the positively charged lipids dimethyldioctadecylammomium bromide (DDAB), dioleyoltrimethylammonium propane (DOTAP),

Searcher : Shears 308-4994

dimyristoyltrimethylammonium propane (DMTAP) or dimethylaminoethanecarbamoyl **cholesterol (DC-Chol)** significantly reduced the inflammation observed in both models in a dose-dependent manner (maximum inhibition: 70-95%).

5 Cationic lipids associated with dioleyol- or dipalmitoyl-phosphatidylethanolamine retained their antiinflammatory activity while cationic lipids associated with dipalmitoylphosphatidylcholine (DPPC) or dimyristoylphosphatidylglycerol (DMPG) showed no anti-inflammatory activity, indicating that the release of cationic lipids into the macrophage cytoplasm is a necessary step for anti-inflammatory activity. The anti-inflammatory activity of cationic lipids was abrogated by the addition dipalmitoylphosphatidylethanolamine-poly(ethylene)glycol-2000 (DPPE-PEG(2000)) which blocks the interaction of cationic lipids with macrophages.

6 Because of the significant role of protein kinase C (PKC) in the inflammatory process we have determined whether the cationic lipids used in this study inhibit PKC activity. The cationic lipids significantly inhibited the activity of PKC but not the activity of a non-related protein kinase, PKA. The synthesis of interleukin-6 (IL-6), which is not dependent on PKC activity for its induction in macrophages, was not modified in vitro or in situ by cationic lipids. The synthesis of NO and TNF-alpha in macrophages, both of which are PKC-dependent, was downregulated by cationic lipids.

7 These results demonstrate that cationic lipids can be considered as novel anti-inflammatory agents. The downregulation of pro-inflammatory mediators through interaction of cationic lipids with the PKC pathway may explain this anti-inflammatory activity. Furthermore, since cationic lipids have intrinsic anti-inflammatory activity, cationic liposomes should be used with caution to deliver nucleic acids for gene therapy in vivo.

FILE 'USPATFULL' ENTERED AT 16:34:43 ON 15 DEC 1997
CA INDEXING COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Dec 1997 (19971209/PD)

FILE LAST UPDATED: 10 Dec 1997 (971210/ED)

HIGHEST PATENT NUMBER: US5697097

CA INDEXING IS CURRENT THROUGH 10 Dec 1997 (971210/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Dec 1997 (19971209/PD)

REVISED CLASS FIELDS (/NCL) CURRENT THROUGH: AUG 1997

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: JUN 1997

>>> Page images are available for patents from 1/1/94. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

Searcher : Shears 308-4994

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
 >>> is included in file records. A thesaurus is available for the <<<
 >>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
 >>> fields. This thesaurus includes catchword terms from the <<<
 >>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
 >>> available for the WIPO International Patent Classification <<<
 >>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
 >>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
 >>> the /IC5 and /IC fields include the corresponding catchword <<<
 >>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

126373 DC
  1075 DCS
  127180 DC
    (DC OR DCS)
  417 CHOL
    11 DC CHOL
      (DC (W) CHOL)
  14155 CHOLEST?
L18      11 L12(S) CHOLEST?

=> s l18 not l11

L19      9 L18 NOT L11

=> s l19 and (immuniz? or immunis? or adjuvant# or vaccin?)

  8205 IMMUNIZ?
  517 IMMUNIS?
  31146 ADJUVANT#
  7381 VACCIN?
L20      3 L19 AND (IMMUNIZ? OR IMMUNIS? OR ADJUVANT# OR VACCIN?)

=> d 1-3 bib abs; fil ca,caplus

```

```

L20 ANSWER 1 OF 3  USPATFULL
AN  97:75843  USPATFULL
TI  Lipid constructs for targeting to vascular smooth muscle tissue
IN  Male-Brune, Roxanne, Hillsborough, NC, United States
PA  California Institute of Technology, Pasadena, CA, United States
  (U.S. corporation)
PI  US 5660855  970826
AI  US 95-386579  950210 (8)
Searcher : Shears  308-4994

```

DT Utility
 EXNAM Primary Examiner: Jordan, Kimberly
 LREP NeXstar Pharmaceuticals
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 1110

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A lipid construct comprising an aminomannose derivatized cholesterol suitable for targeting smooth muscle cells and tissue. Preferred formulations contain 6-(cholest-5-en-3. β .-yloxy)hexyl-6-amino-6-deoxy-1-thio-. α .-D-mannopyranoside in liposome formulations wherein the formulations are delivered generally to arteries using percutaneous transluminal coronary angioplasty procedures. These formulations have applications in the reduction of restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 3 USPATFULL
 AN 97:73283 USPATFULL
 TI Inducible nitric oxide synthase gene for treatment of disease
 IN Billiar, Timothy R., Pittsburgh, PA, United States
 Tzeng, Edith, Pittsburgh, PA, United States
 Nussler, Andreas K., Neu-Ulm, Germany, Federal Republic of
 Geller, David A., Pittsburgh, PA, United States
 Simmons, Richard L., Pittsburgh, PA, United States
 PA University of Pittsburgh of the Commonwealth System of Higher
 Education, Pittsburgh, PA, United States (U.S. corporation)

PI US 5658565 970819

AI US 94-265046 940624 (8)

DT Utility

EXNAM Primary Examiner: Low, Christopher S.F.

LREP Leydig, Voit & Mayer, Ltd.

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 2444

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Searcher : Shears 308-4994

L20 ANSWER 3 OF 3 USPATFULL
 AN 94:59724 USPATFULL
 TI Treatment of diseases by site-specific instillation of cells or
 site-specific transformation of cells and kits therefor
 IN Nabel, Elizabeth G., Ann Arbor, MI, United States
 Nabel, Gary J., Ann Arbor, MI, United States
 PA The Regents of the University of Michigan, Ann Arbor, MI, United
 States (U.S. corporation)
 PI US 5328470 940712
 AI US 91-741244 910726 (7)
 RLI Continuation-in-part of Ser. No. US 91-724509, filed on 28 Jun
 1991 which is a continuation-in-part of Ser. No. US 89-331336,
 filed on 31 Mar 1989, now abandoned
 DT Utility
 EXNAM Primary Examiner: Rosenbaum, C. Fred; Assistant Examiner:
 Alexander, V.
 LREP Oblon, Spivak, McClelland, Maier & Neustadt
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 1438
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for the direct treatment towards the specific sites of a
 disease is disclosed. This method is based on the delivery of
 proteins by catheterization to discrete blood vessel segments
 using genetically modified or normal cells or other vector
 systems. Endothelial cells expressing recombinant therapeutic
 agent or diagnostic proteins are situated on the walls of the
 blood vessel or in the tissue perfused by the vessel in a patient.
 This technique, provides for the transfer of cells or vectors and
 expression of recombinant genes in vivo and allows the
 introduction of proteins of therapeutic or diagnostic value for
 the treatment of diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'CA' ENTERED AT 16:35:38 ON 15 DEC 1997
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:35:38 ON 15 DEC 1997
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

Searcher : Shears 308-4994

L21 2133 SEA CHOLESTER? (10A) (3 (W) (BETA OR B))
 L22 12 SEA L21 AND (IMMUNIZ? OR IMMUNIS? OR ADJUVANT# OR VACCIN
 ?)

=> s l22 not (l5 or l14)

L23 10 L22 NOT (L5 OR L14)

=> dup rem 123

PROCESSING COMPLETED FOR L23
 L24 5 DUP REM L23 (5 DUPLICATES REMOVED)

=> d 1-5 .bevstr1

L24 ANSWER 1 OF 5 CA COPYRIGHT 1997 ACS DUPLICATE 1
 AN 126:308676 CA
 TI Extracts of Ginkgo biloba leaves and **Vaccinium myrtillus**
 fruits prevent photo induced oxidation of low density lipoprotein
 cholesterol
 AU Francesca Rasetti, M.; Caruso, D.; Galli, G.; Bosisio, E.
 CS Faculty Pharmacy, University Milan, Milan, I-20133, Italy
 SO Phytomedicine (1997), 3(4), 335-338
 CODEN: PYTOEY; ISSN: 0944-7113
 PB Fischer
 DT Journal
 LA English
 AB G. biloba and V. myrtillus exts. inhibited dose-dependently the
 formation of cytotoxic oxysterol. Protection against oxidn. was
 confirmed by partial restoration of normal electrophoretic mobility
 of low d. lipoprotein. Therapeutic aspects on pathol. conditions
 due to free radicals including atherosclerosis were discussed.
 IT Natural products (pharmaceutical)
 RL: BOC (Biological occurrence); THU (Therapeutic use); BIOL
 (Biological study); OCCU (Occurrence); USES (Uses)
 (prevention of LDL cholesterol oxidn. by G. biloba and V.
 myrtillus exts.)
 IT Low-density lipoproteins
 RL: BOC (Biological occurrence); MFM (Metabolic formation); BIOL
 (Biological study); FORM (Formation, nonpreparative); OCCU
 (Occurrence)
 (prevention of LDL oxidn. by G. biloba and V. myrtillus exts.)
 IT Ginkgo biloba
 (prevention of LDL oxidn. by Gingko ext.)
 IT **Vaccinium myrtillus**
 (prevention of LDL oxidn. by **Vaccinium** ext.)
 IT 566-27-8, 7.beta.-Hydroxycholesterol
 Searcher : Shears 308-4994

RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (prevention of LDL cholesterol oxidn. by *G. biloba* and *V. myrtillus* exts.)

IT 566-26-7, Cholest-5-ene-3.**beta.**,7.**alpha.**-diol
 RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (prevention of LDL **cholesterol** oxidn. by *G. biloba* and *V. myrtillus* exts.)

IT 117-39-5, Quercetin
 RL: BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (prevention of LDL cholesterol oxidn. by quercetin)

L24 ANSWER 2 OF 5 CA COPYRIGHT 1997 ACS DUPLICATE 2
 AN 125:165557 CA
 TI Interaction of anti-cholesterol antibodies with human lipoproteins
 AU Dijkstra, Jan; Swartz, Glann M, Jr.; Raney, Jennifer J.; Aniagolu, Jacinta; Toro, Luis; Nacy, Carol A.; Green, Shawn J.
 CS EntreMed, Inc., Rockville, MD, 20850, USA
 SO J. Immunol. (1996), 157(5), 2006-2013
 CODEN: JOIMA3; ISSN: 0022-1767
 DT Journal
 LA English
 AB Inoculation of mice with cholesterol-rich liposomes contg. the **adjuvant** monophosphoryl lipid A results in the prodn. of antiserum contg. IgM to cholesterol. The specificity of the Ab was to **cholesterol** and structurally similar sterols contg. a 3.**beta.**-hydroxyl group. Anti-**cholesterol** binding activity was significantly diminished if the 3.**beta.**-hydroxyl was altered by either epimerization, substitution, oxidn., or esterification. A similar specificity for 3.**beta.**-hydroxy-sterols was obsd. for an anti-**cholesterol** IgM mAb. Both hyperimmune serum and the mAb reacted with intact human very-low-/intermediate-d. lipoprotein (VLDL/IDL) and low-d. lipoproteins (LDL), but not high-d. lipoproteins (HDL), in an ELISA, but could react with total lipid exts. contg. cholesterol that were prep'd. from all three lipoprotein classes. Functionally, immune serum or the mAb aggregated and induced a fusion-like reaction with VLDL/IDL and LDL at low temps.: these aggregates result in spherical structures visible with light microscopy. Similarly, binding of anti-cholesterol Ab to small cholesterol-rich liposomes resulted in the appearance of vesicular structures with approx. 20- to 200-fold increased diams. These data demonstrate that the anti-cholesterol Ab recognize unesterified cholesterol in VLDL/IDL and IDL; high-d. lipoprotein cholesterol in the intact lipoprotein, however, appears to be protected from reaction with these Ab.

IT Immunoglobulins

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (M, interaction of anti-cholesterol antibodies with human lipoproteins)
 IT Arteriosclerosis
 (atherosclerosis, interaction of anti-cholesterol antibodies with human lipoproteins in relation to)
 IT Lipoproteins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (intermediate-d., interaction of anti-cholesterol antibodies with human lipoproteins)
 IT Glycophospholipids
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (lipid A, **adjuvant**; interaction of anti-cholesterol antibodies with human lipoproteins)
 IT Lipoproteins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (low-d., interaction of anti-cholesterol antibodies with human lipoproteins)
 IT Antibodies
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (monoclonal, interaction of anti-cholesterol antibodies with human lipoproteins)
 IT Lipoproteins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (very-low-d., interaction of anti-cholesterol antibodies with human lipoproteins)
 IT 57-88-5, Cholesterol, biological studies
 RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (interaction of anti-cholesterol antibodies with human lipoproteins)

L24 ANSWER 3 OF 5 CA COPYRIGHT 1997 ACS DUPLICATE 3
 AN 117:205483 CA
 TI Maintenance or stimulation of steroidogenic enzymes and testosterone production in rat Leydig cells by continuous and pulsatile infusions of luteinizing hormone during passive **immunization** against gonadotropin-releasing hormone
 AU Chase, D. J.; Karle, J. A.; Fogg, R. E.
 CS Dep. Biol. Sci., State Univ. New York, Binghamton, NY, 13902-6000, USA
 SO J. Reprod. Fertil. (1992), 95(3), 657-67
 CODEN: JRPFA4; ISSN: 0022-4251
 Searcher : Shears 308-4994

DT Journal

LA English

AB The importance of the pulsatility of LH secretion in maintaining key enzymes in the testosterone biosynthetic pathway in Leydig cells was studied using rats in which LH secretion was suppressed by passive **immunization** against gonadotropin-releasing hormone (GnRH) and replaced by continuous or pulsatile i.v. infusions of exogenous LH (all delivering the same daily dose of the hormone). Continuous infusions (12.5 ng/100 g/h) were compared with infusions of 1 min pulses every 2 h (25 ng/100 g) and every 4 h (50 ng/100 g). After 5 days of treatment *in vivo* with sheep anti-GnRH serum (or normal sheep serum) and with LH (or vehicle), Leydig cells were purified and assayed *in vitro* for max. prodn. of testosterone stimulated by human chorionic gonadotropin (hCG) or supported by 25-hydroxycholesterol and for the activities of **cholesterol side-chain cleavage, .DELTA.5-3.**beta**** .-hydroxysteroid dehydrogenase-.DELTA.5-4-isomerase (3.**beta**.-HSD-isomerase), and 17.**alpha**.-hydroxylase. Activity of 3.**beta**.-HSD-isomerase was reduced by about 40% by anti-GnRH treatment and was increased by all LH regimens in anti-GnRH-treated animals, with no consistent pattern in the effects of the different LH regimens. Results for testosterone-producing capacity and the other two enzymes differed in several respects. Treatment with anti-GnRH serum markedly reduced basal, hCG-stimulated, and 25-hydroxycholesterol-supported testosterone prodn. (by 80-90%) and the activities of cholesterol side-chain cleavage (about 80%) and 17.**alpha**.-hydroxylase (about 65%). Infusion of exogenous LH in any of the regimens tested prevented these changes or increased the activities to values greater than those in normal serum-treated controls. There was a consistent trend in the effects of LH replacement regimens on these parameters of steroidogenic activity: continuous infusions were more effective than pulses at 2-h intervals, and these in turn were more effective than pulses at 4-h intervals, suggesting that the frequency of LH exposure is more important than the amplitude of individual exposures in maintaining Leydig cell steroidogenic function. Consistent differences among groups in hCG-stimulated relative to 25-hydroxycholesterol-supported testosterone prodn. suggest that some constituents of Leydig cells prior to cholesterol side-chain cleavage enzyme are more sensitive to LH withdrawal and deviations from optimal LH exposure than are the side-chain cleavage and subsequent enzymes in the testosterone biosynthetic pathway.

IT Testis, composition

(Leydig cell, steroidogenic enzymes of and testosterone formation by, LH effect on)

IT Enzymes

RL: BIOL (Biological study)
(steroid-forming, of testis Leydig cell, LH effect on)

IT 58-22-0, Testosterone

Searcher : Shears 308-4994

RL: FORM (Formation, nonpreparative)
 (formation of, by testis Leydig cell, LH effect on)
 IT 9029-67-8, Steroid 17.alpha.-hydroxylase 9031-36-1 37292-81-2,
 Cholesterol side-chain-cleaving enzyme
 RL: BIOL (Biological study)
 (of testis Leydig cell, LH effect on)
 IT 9044-85-3, .DELTA.5-3.beta.-Hydroxy steroid dehydrogenase
 RL: BIOL (Biological study)
 (of testis, LH effect on)
 IT 9002-67-9, LH
 RL: BIOL (Biological study)
 (steroid formation by testis Leydig cells response to)

L24 ANSWER 4 OF 5 CA COPYRIGHT 1997 ACS DUPLICATE 4
 AN 117:187206 CA
 TI Expansion of the mammalian **3.beta**.-hydroxysteroid dehydrogenase/plant dihydroflavonol reductase superfamily to include a bacterial **cholesterol** dehydrogenase, a bacterial UDP-galactose-4-epimerase, and open reading frames in **vaccinia** virus and fish lymphocystis disease virus
 AU Baker, Michael E.; Blasco, Rafael
 CS Dep. Med. 0623B, Univ. California, San Diego, La Jolla, CA,
 92093-0623, USA
 SO FEBS Lett. (1992), 301(1), 89-93
 CODEN: FEBLAL; ISSN: 0014-5793
 DT Journal
 LA English
 AB Mammalian **3.beta**.-hydroxysteroid dehydrogenase and plant dihydroflavonol reductases are descended from a common ancestor. Here, evidence is presented that *Nocardia* cholesterol dehydrogenase, *Escherichia coli* UDP-galactose-4-epimerase, and open reading frames (ORFs) in **vaccinia** virus and fish lymphocystis disease virus are homologous to **3.beta**.-hydroxysteroid dehydrogenase and dihydroflavonol reductase. Anal. of a multiple alignment of these sequences indicates that viral ORFs are most closely related to the mammalian **3.beta**.-hydroxysteroid dehydrogenases. The ancestral protein of this superfamily is likely to be one that metabolized sugar nucleotides. The sequence similarity between **3.beta**.-hydroxysteroid dehydrogenase and the viral ORFs is sufficient to suggest that these ORFs have an activity that is similar to **3.beta**.-hydroxysteroid dehydrogenase or **cholesterol** dehydrogenase, although the putative substrates are not yet known.
 IT *Escherichia coli*
 (UDP-galactose epimerase of, sequence homol. of, with hydroxysteroid dehydrogenase/dihydroflavonol reductase superfamily)
 IT *Nocardia*

(cholesterol dehydrogenase of, sequence homol. of, with hydroxysteroid dehydrogenase/dihydroflavonol reductase superfamily)

IT Protein sequences
(of dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily, of mammals and bacteria and viruses, homologies among)

IT Evolution
(divergent, of dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily)

IT Virus, animal
(lymphocystis disease of fish, hydroxysteroid dehydrogenase-like enzyme encoded by ORF of, sequence homol. of, with dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily)

IT Virus, animal
(**vaccinia**, hydroxysteroid dehydrogenase-like enzyme encoded by ORF of, sequence homol. of, with dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily)

IT 143927-70-2
RL: BIOL (Biological study)
(ORF-encoded, of fish lymphocytis disease virus, sequence homol. of, with hydroxysteroid dehydrogenase/dihydroflavonol reductase superfamily)

IT 143927-65-5
RL: BIOL (Biological study)
(ORF-encoded, of **vaccinia** virus, sequence homol. of, with hydroxysteroid dehydrogenase/dihydroflavonol reductase superfamily)

IT 98743-49-8
RL: BIOL (Biological study)
(evolution and sequence homologies of enzyme superfamily contg.)

IT 9032-89-7, UDP-galactose-4-epimerase
RL: BIOL (Biological study)
(sequence homol. of, of *Escherichia coli*, with dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily)

IT 67775-34-2, Cholesterol dehydrogenase
RL: BIOL (Biological study)
(sequence homol. of, of *Nocardia*, with dihydroflavonol reductase/hydroxysteroid dehydrogenase superfamily)

L24 ANSWER 5 OF 5 CA COPYRIGHT 1997 ACS DUPLICATE 5
AN 70:9183 CA
TI Clinical experiences with aminoglutethimide (Elipten), a new inhibitor of steroid biosynthesis in the adrenal
AU Horky, K.; Kuechel, Otto; Gregorova, Inge; Jirankova, J.; Matys, Zdenek
CS III. Med. Klin., Karlova Univ., Prague, Czech.
SO Schweiz. Med. Wochenschr. (1968), 98(47), 1843-51
Searcher : Shears 308-4994

DT CODEN: SMWOAS
 DT Journal
 LA German
 AB Aminoglutethimide (I), which inhibits steroid synthesis by blocking the conversion of **cholesterol** to **3.beta**.-hydroxypregn-5-en-20-one, was studied in 36 patients with various adrenal gland disorders. The best results during I therapy were observed in autonomous hypercortisolism of the Cushing type in patients with adenoma or adrenal carcinoma. Protein breakdown and electrolyte disturbances were improved in presurgical patients by conservative therapy with I, improving the surgical prognosis. I administration to patients with ACTH-dependent Cushing's syndrome was less effective. Good results were also observed in patients with hyperaldosteronism secondary to idiopathic edema, with ascitic cirrhosis of the liver, and with renal-vascular or severe essential hypertension. I exhibited marked saluretic and diuretic effects in edema and was an effective hypotensive **adjuvant** drug in patients with severe hypertension.
 IT Diuretics
 (aminoglutethimide as)
 IT Cirrhosis
 Hypertension
 Adrenal cortex, diseases or disorders
 (aminoglutethimide in treatment of)
 IT Salivary glands
 (aminoglutethimide stimulation of secretion by)
 IT 125-84-8
 RL: BIOL (Biological study)
 (in adrenocortical disorder treatment)

=> fil
 biosi,medl,embas,lifesci,biotechd,wpid,confsci,dissabs,scisearch,jicst,promt,t
 oxlit,toxlin,drugu,drugb,drugnl,druglaunch

FILE 'BIOSIS' ENTERED AT 16:37:24 ON 15 DEC 1997
 COPYRIGHT (C) 1997 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 16:37:24 ON 15 DEC 1997

FILE 'EMBASE' ENTERED AT 16:37:24 ON 15 DEC 1997
 COPYRIGHT (C) 1997 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 16:37:24 ON 15 DEC 1997
 COPYRIGHT (C) 1997 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:37:24 ON 15 DEC 1997
 COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

08/836576

FILE 'WPIDS' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

FILE 'CONFSCI' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 Cambridge Scientific Abstracts (CSA)

FILE 'DISSABS' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 UMI Company

FILE 'SCISEARCH' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 Institute for Scientific Information (ISI) (R)

FILE 'JICST-EPLUS' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 Japan Science and Technology Corporation (JST)

FILE 'PROMT' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 Information Access Company. All rights reserved.

FILE 'TOXLIT' ENTERED AT 16:37:24 ON 15 DEC 1997

FILE 'TOXLINE' ENTERED AT 16:37:24 ON 15 DEC 1997

FILE 'DRUGU' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

FILE 'DRUGB' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

FILE 'DRUGNL' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 IMSWORLD Publications Ltd

FILE 'DRUGLAUNCH' ENTERED AT 16:37:24 ON 15 DEC 1997
COPYRIGHT (C) 1997 IMSWORLD Publications Ltd

=> s 122

2 FILES SEARCHED...

5 FILES SEARCHED...

6 FILES SEARCHED...

12 FILES SEARCHED...

L25 11 L22

=> s 125 not (l8 or l17)

L26 11 L25 NOT (L8 OR L17)

=> dup rem 126

DUPLICATE IS NOT AVAILABLE IN 'DRUGLAUNCH'.
Searcher : Shears 308-4994

08/836576

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L26
L27 3 DUP REM L26 (8 DUPLICATES REMOVED)

=> d 1-3 bib abs; fil uspat; s 122

L27 ANSWER 1 OF 3 MEDLINE DUPLICATE 1
AN 96355004 MEDLINE
TI Interaction of anti-cholesterol antibodies with human lipoproteins.
AU Dijkstra J; Swartz G M Jr; Raney J J; Aniagolu J; Toro L; Nacy C A;
Green S J
CS EntreMed, Inc., Rockville, MD 20850, USA.
SO JOURNAL OF IMMUNOLOGY, (1996 Sep 1) 157 (5) 2006-13.
Journal code: IFB. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 9701
EW 19970104
AB Inoculation of mice with cholesterol-rich liposomes containing the **adjuvant** monophosphoryl lipid A results in the production of antiserum containing IgM Ab to cholesterol. The specificity of the Ab was to **cholesterol** and structurally similar sterols containing a **3 beta**-hydroxyl group. Anti-**cholesterol** binding activity was significantly diminished if the **3 beta**-hydroxyl was altered by either epimerization, substitution, oxidation, or esterification. A similar specificity for **3 beta**-hydroxy-sterols was observed for an anti-**cholesterol** IgM mAb. Both hyperimmune serum and the mAb reacted with intact human very-low-/intermediate-density lipoprotein (VLDL/IDL) and low-density lipoproteins (LDL), but not high-density lipoproteins (HDL), in an ELISA, but could react with total lipid extracts containing cholesterol that were prepared from all three lipoprotein classes. Functionally, immune serum or the mAb aggregated and induced a fusion-like reaction with VLDL/IDL and LDL at low temperatures: these aggregates result in spherical structures visible with light microscopy. Similarly, binding of anti-cholesterol A to small cholesterol-rich liposomes resulted in the appearance of vesicular structures with approximately 20- to 200-fold increased diameters. These data demonstrate that the anti-cholesterol Ab recognize unesterified cholesterol in VLDL/IDL and LDL; high-density lipoprotein cholesterol in the intact lipoprotein, however, appears to be protected from reaction with these Ab.

L27 ANSWER 2 OF 3 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 2
AN 92:522350 BIOSIS

Searcher : Shears 308-4994

DN BA94:130425
TI MAINTENANCE OR STIMULATION OF STEROIDOGENIC ENZYMES AND TESTOSTERONE PRODUCTION IN RAT LEYDIG CELLS BY CONTINUOUS AND PULSATILE INFUSIONS OF LUTEINIZING HORMONE DURING PASSIVE **IMMUNIZATION AGAINST GONADOTROPHIN-RELEASING HORMONE**.
AU CHASE D J; KARLE J A; FOGG R E
CS DEP. BIOLOGICAL SCIENCES, STATE UNIV. NEW YORK, BINGHAMTON, N.Y. 13902-6000, USA.
SO J REPROD FERTIL 95 (3). 1992. 657-667. CODEN: JRPFA4 ISSN: 0022-4251
LA English
AB The importance of the pulsatility of luteinizing hormone (LH) secretion in maintaining key enzymes in the testosterone biosynthetic pathway in Leydig cells was studied using rats in which LH secretion was suppressed by passive **immunization** against gonadotrophin-releasing hormone (GnRH) and replaced by continuous or pulsatile i.v. infusion of exogenous LH, all delivering the same daily dose of the hormone (300 ng per 100 g NIDDK-ovine LH-24). Continuous infusions (12.5 ng per 100 g h⁻¹) were compared with infusions of 1 min pulses every 2 h (25 ng per 100 g) and every 4 h (50 ng per 100 g). After 5 days of treatment *in vivo* with sheep anti-GnRH serum (or normal sheep serum) and LH (or vehicle), Leydig cells were purified and assayed *in vitro* for maximum production of testosterone stimulated by human chorionic gonadotrophin (hCG) and supported by 25-hydroxycholesterol and for the activities of **cholesterol** side-chain cleavage, .**DELTA.5-3.**
beta.-hydroxysteroid dehydrogenase-.**DELTA.5-4-isomerase** (3.**beta.**-HSD-isomerase) and 17.**alpha.**-hydroxylase. Relative contents of **cholesterol** side-chain cleavage and 17.**alpha.**-hydroxylase were also quantified by western and immunoblotting analysis. Activity of 3.**beta.**-HSD-isomerase was reduced by about 40% by anti-GnRH treatment and was increased by all LH regimens in anti-GnRH-treated animals, with no consistent pattern in the effects of the different LH regimens. Results for testosterone-producing capacity and the other two enzymes differed in several respects. Treatment with anti-GnRH serum markedly reduced basal, hCG-stimulated and 25-hydroxycholesterol-supported testosterone production (by 80-90%) and the activities of cholesterol side-chain cleavage (about 80%) and 17.**alpha.**-hydroxylase (about 65%). Infusion of exogenous LH in any of the regimens tested prevented these changes or increased the activities to values greater than those in normal serum-treated controls. Differences in immunodetectable contents of the two enzymes generally paralleled those in enzyme activities. There was a consistent trend in the effects of LH replacement regimens on these parameters of steroidogenic activity: continuous infusions were more effective than pulses at 2 h intervals and these in turn were more effective than pulses at 4 h intervals, suggesting that the frequency of LH exposure is more important than the amplitude of individual exposures in maintaining Leydig cell steroidogenic function. Consistent

Searcher : Shears 308-4994

differences among groups in hCG-stimulated relative to 25-hydroxycholesterol-supported testosterone production suggest that some constituents of Leydig cells prior to cholesterol side-chain cleavage enzyme are more sensitive to LH withdrawal and deviations from 'optimal' LH exposure than are the side-chain cleavage and subsequent enzymes in the testosterone biosynthetic pathway.

L27 ANSWER 3 OF 3 BIOSIS COPYRIGHT 1997 BIOSIS DUPLICATE 3
 AN 92:322624 BIOSIS
 DN BA94:24465
 TI EXPANSION OF THE MAMMALIAN **3-BETA** HYDROXYSTEROID DEHYDROGENASE PLANT DIHYDROFLAVONOL REDUCTASE SUPERFAMILY TO INCLUDE A BACTERIAL **CHOLESTEROL** DEHYDROGENASE A BACTERIAL UDP-GALACTOSE-4-EPIMERASE AND OPEN READING FRAMES IN **VACCINIA** VIRUS AND FISH LYMPHOCYSTIS DISEASE VIRUS.
 AU BAKER M E; BLASCO R
 CS DEP. MED., 0623B, UNIV. CALIFORNIA, SAN DIEGO, 9500 GILMAN DRIVE, LA JOLLA, CALIF. 92093-0623, USA.
 SO FEBS (FED EUR BIOCHEM SOC) LETT 301 (1). 1992. 89-93. CODEN: FEBLAL
 ISSN: 0014-5793
 LA English
 AB Mammalian 3.**beta.**-hydroxysteroid dehydrogenase and plant dihydroflavonol reductases are descended from a common ancestor. Here we present evidence that Nocardia cholesterol dehydrogenase, Escherichia coli UDP-galactose-4 epimerase, and open reading frames in **vaccinia** virus and fish lymphocystis disease virus are homologous to 3.**beta.**-hydroxysteroid dehydrogenase and dihydroflavonol reductase. Analysis of a multiple alignment of these sequences indicates that viral ORFs are most closely related to the mammalian 3.**beta.**-hydroxysteroid dehydrogenases. The ancestral protein of this superfamily is likely to be one that metabolized sugar nucleotides. The sequence similarity between 3.**beta.**-hydroxysteroid dehydrogenase and the viral ORFs is sufficient to suggest that these ORFs have an activity that is similar to 3.**beta.**-hydroxysteroid dehydrogenase or **cholesterol** dehydrogenase, although the putative substrates are not yet known.

FILE 'USPATFULL' ENTERED AT 16:41:02 ON 15 DEC 1997
 CA INDEXING COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Dec 1997 (19971209/PD)
 FILE LAST UPDATED: 10 Dec 1997 (971210/ED)
 HIGHEST PATENT NUMBER: US5697097
 CA INDEXING IS CURRENT THROUGH 10 Dec 1997 (971210/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Dec 1997 (19971209/PD)
 REVISED CLASS FIELDS (/NCL) CURRENT THROUGH: AUG 1997
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: JUN 1997
 Searcher : Shears 308-4994

>>> Page images are available for patents from 1/1/94. Current <<<
 >>> week patent text is typically loaded by Thursday morning and <<<
 >>> page images are available for display by the end of the day. <<<
 >>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
 >>> is included in file records. A thesaurus is available for the <<<
 >>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
 >>> fields. This thesaurus includes catchword terms from the <<<
 >>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
 >>> available for the WIPO International Patent Classification <<<
 >>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
 >>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
 >>> the /IC5 and /IC fields include the corresponding catchword <<<
 >>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

13667 CHOLESTER?
2208423 3
160616 BETA
  377 BETAS
160693 BETA
  (BETA OR BETAS)
1098828 B
  133 CHOLESTER?(10A) (3(W) (BETA OR B))
  8205 IMMUNIZ?
  517 IMMUNIS?
  31146 ADJUVANT#
  7381 VACCIN?
L28      19 L21 AND (IMMUNIZ? OR IMMUNIS? OR ADJUVANT# OR VACCIN?)

=> s l28 not (l11 or l20)

L29      16 L28 NOT (L11 OR L20)
```

=> d 1-16 bib abs; fil hom

```

L29  ANSWER 1 OF 16  USPATFULL
AN  97:112593  USPATFULL
TI  Glycoside derivatives of acetaminophen
IN  Klemke, R. -Erich, Hilzingen, Germany, Federal Republic of
     Koreeda, Masato, Ann Arbor, MI, United States
     Houston, Todd A., Timonium, MD, United States
     Shull, Brian K., Ann Arbor, MI, United States
     Searcher : Shears 308-4994
```

PA Tuinman, Roeland J., Fenton, MI, United States
 PA Harrier Inc., Hermosa Beach, CA, United States (U.S. corporation)
 PI US 5693767 971202
 AI US 94-251869 940601 (8)
 RLI Continuation-in-part of Ser. No. US 93-6447, filed on 21 Jan 1993,
 now abandoned which is a continuation-in-part of Ser. No. US
 92-815691, filed on 24 Jan 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 91-733915, filed on 22 Jul
 1991, now abandoned which is a continuation-in-part of Ser. No. US
 91-644002, filed on 22 Jan 1991, now patented, Pat. No. US
 5278296, issued on 11 Jan 1994
 DT Utility
 EXNAM Primary Examiner: Kight, John; Assistant Examiner: Lee, Howard C.
 LREP Medlen & Carroll, LLP
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
 LN.CNT 1043
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel glycosides, especially steroidal and non-steroidal
 glycosides are provided. The steroidal and non-steroidal
 glycosides preferably are prepared from aglycons which possess
 valuable properties such as pharmacological properties. The
 glycosides are prepared from useful aglycons and possess useful
 properties which are the same as those of their respective
 unglycosylated aglycons. The glycosides are provided in acylated
 and deacylated form. The acylated glycosides after hydrolysis of
 the acyl groups possess enhanced water solubility properties, as
 illustrated in the case where the aglycon is acetominophen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 2 OF 16 USPATFULL
 AN 96:116123 USPATFULL
 TI Method of preparing gas and gaseous precursor-filled microspheres
 IN Unger, Evan C., Tucson, AZ, United States
 Fritz, Thomas A., Tucson, AZ, United States
 Matsunaga, Terry, Tucson, AZ, United States
 Ramaswami, VaradaRajan, Tucson, AZ, United States
 Yellowhair, David, Tucson, AZ, United States
 Wu, Guanli, Tucson, AZ, United States
 PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S.
 corporation)
 PI US 5585112 961217
 AI US 93-159687 931130 (8)
 RLI Continuation-in-part of Ser. No. US 93-160232, filed on 30 Nov
 1993, now abandoned And a continuation-in-part of Ser. No. US
 93-159674, filed on 30 Nov 1993, now abandoned , each Ser. No. US
 - which is a continuation-in-part of Ser. No. US 93-76239, filed
 Searcher : Shears 308-4994

on 11 Jun 1993, now patented, Pat. No. US 5469854 which is a continuation-in-part of Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 91-716899, filed on 18 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned, said Ser. No. US -717084 which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499

DT Utility
 EXNAM Primary Examiner: Kishore, Gollamudi S.
 LREP Woodcock Washburn Kurtz Mackiewicz & Norris
 CLMN Number of Claims: 21
 ECL Exemplary Claim: 1
 DRWN 14 Drawing Figure(s); 12 Drawing Page(s)
 LN.CNT 3161

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 3 OF 16 USPATFULL
 AN 96:19079 USPATFULL
 TI Glycoside compounds and production and use thereof
 IN Klemke, R. Erich, D-78247 Hilzingen, Germany, Federal Republic of
 PA Klemke, R. Erich, Germany, Federal Republic of (non-U.S.
 individual)
 PI US 5496806 960305
 AI US 94-239373 940506 (8)
 RLI Division of Ser. No. US 93-6447, filed on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-815691, filed on 24 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-733915, filed on 22 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-644002, filed on 22 Jan 1991, now patented, Pat. No. US 5278296
 PRAI DE 90-4001895 900123
 DT Utility
 EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Lee, Howard C.
 LREP Young, MacFarlane & Wood
 CLMN Number of Claims: 4
 ECL Exemplary Claim: 1
 DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
 LN.CNT 412

Searcher : Shears 308-4994

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel glycosides 7-ketosteryl di-O-acyl-pyranoside and 7-.beta.-hydroxycholesteryl 2,3-dideoxy-.alpha.-D-erythro-hex-2-enopyranoside. The glycosides possess valuable pharmacological properties as a medicament. In particular, the cholesterol glycoside in vivo exhibits a selective cell-destructive activity on malignant cells which activity is substantially free of side effects on normal cells. The glycosides possess useful properties, especially pharmacological properties which are the same as the respective unglycosylated aglycon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 4 OF 16 USPATFULL
 AN 95:99184 USPATFULL
 TI Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
 IN Kun, Ernest, Mill Valley, CA, United States
 Mendeleyev, Jerome, San Francisco, CA, United States
 Kirsten, Eva, Daly City, CA, United States
 PA Octamer, Inc., Sausalito, CA, United States (U.S. corporation)
 PI US 5464871 951107
 AI US 93-76313 930611 (8)
 RLI Continuation-in-part of Ser. No. US 93-60409, filed on 12 May 1993
 DT Utility
 EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Mach, D. Margaret M.
 LREP Halluin, Albert P. Pennie & Edmonds
 CLMN Number of Claims: 6
 ECL Exemplary Claim: 1
 DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 906

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and suppressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and suppression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro nitroso compounds and their metabolites are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 5 OF 16 USPATFULL
 AN 94:3918 USPATFULL
 TI Production of hydroxysterol glycoside compounds
 IN Klemke, R.-Erich, Hilzingen, Germany, Federal Republic of
 Searcher : Shears 308-4994

PA Gelman Sciences Inc., Ann Arbor, MI, United States (U.S. corporation)

PI US 5278296 940111

AI US 91-644002 910122 (7)

PRAI DE 90-4001895 900123

DT Utility

EXNAM Primary Examiner: Husarik, Nancy S.

LREP Krass & Young

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 504

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel glycosides, especially steroidal glycosides, and a novel method of their production, are provided. For the novel method of producing novel glycosides, hydroxysterol compounds are glycosylated with tri-O-acyl glucal using molecular iodine as a reaction catalyst. In this method an alcohol or phenol, especially a hydroxy-steroid such as a water-insoluble cholesterol, is glycosylated, such that the glycosylation is performed in a single step. The resulting steryl pyranoside is by oxidation converted to the corresponding 7-ketosteryl di-O-acyl-pyranoside. The latter pyranoside is selectively reduced to provide the corresponding 7-.beta.-hydroxysterol 2,3-dideoxy-.alpha.-D-erythro-hex-2-enopyranoside. The steroidal glycosides obtained in this way possess valuable pharmacological properties. In particular, the glycosides in vivo exhibit a selective cell-destructive activity on malignant cells which activity is substantially free of side effects on normal cells. The glycosides also possess a drive-enhancing (stimulating) activity and an anti-inflammatory (immunosuppressive or immunoregulatory) activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 6 OF 16 USPATFULL

AN 91:42708 USPATFULL

TI Steroidal glycolipids as host resistance stimulators against viral infection

IN Durette, Philippe L., New Providence, NJ, United States

Hagmann, William K., Westfield, NJ, United States

Ponpipom, Mitree M., Branchburg, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5019568 910528

AI US 89-370058 890621 (7)

DCD 20071113

RLI Continuation of Ser. No. US 87-63197, filed on 18 Jun 1987, now abandoned

DT Utility

EXNAM Primary Examiner: Friedman, Stanley J.; Assistant Examiner: Searcher : Shears 308-4994

Criares, Theodore J.

LREP Harbour, John W.; Pfeiffer, Hesna J.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are pharmaceutical compositions for enhancing human host resistance against opportunistic infection in an individual immunocompromised by an AIDS-related virus, consisting essentially of an anti-viral, anti-AIDS drug selected from the group consisting of ansamycin, ribavirin, dideoxycytidine, HPA-23, AL-721, foscarnet, and azidothymidine and a glycolipid compound consisting essentially of the formula: ##STR1## where: R.sup.1 is .alpha. or .beta.-D-1-thiomannopyranoside, .alpha. or .beta.-L-1-thiogucopyranoside.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 7 OF 16 USPATFULL

AN 90:87331 USPATFULL

TI Steroidal glycolipids as host resistance stimulators against viral infection

IN Durette, Philippe L., New Providence, NJ, United States
Hagmann, William K., Westfield, NJ, United States
Ponpipom, Mitree M., Branchburg, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4970199 901113

AI US 89-378424 890710 (7)

RLI Continuation of Ser. No. US 87-63000, filed on 18 Jun 1987, now abandoned

DT Utility

EXNAM Primary Examiner: Griffin, Ronald W.; Assistant Examiner: Carson, Nancy S.

LREP Harbour, John W.; North, Robert J.; Pfeiffer, Hesna J.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1189

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are steroidal derivatives of glycolipids, in which steroids are bridged, via a medium length hydrocarbon chain, to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses in combination with an anti-AIDS drug, that protect an immunocomprised host, particularly resulting from an AIDS-related virus, against opportunistic infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 8 OF 16 USPATFULL
 AN 90:56217 USPATFULL
 TI Steroidal glycolipids as host resistance stimulators against viral
 infection
 IN Durette, Philippe L., New Providence, NJ, United States
 Ponpipom, Mitree M., Branchburg, NJ, United States
 Hagmann, William K., Westfield, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 4942154 900717
 AI US 87-62997 870618 (7)
 DCD 20040324
 DT Utility
 EXNAM Primary Examiner: Griffin, Ronald W.; Assistant Examiner: Carson,
 Nancy S.
 LREP Harbour, John W.; North, Robert J.; Pfeiffer, Hesna J.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are steroidal derivatives of glycolipids, in which
 steroids are bridged, via a medium length hydrocarbon chain, to
 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses that protect an
 immunocompromised host, particularly resulting from an
 AIDS-related virus, against opportunistic infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 9 OF 16 USPATFULL
 AN 87:20717 USPATFULL
 TI Steroidal glycolipids
 IN Hagmann, William K., Westfield, NJ, United States
 Ponpipom, Mitree M., Branchburg, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 4652637 870324
 AI US 85-801905 851125 (6)
 DT Utility
 EXNAM Primary Examiner: Brown, Johnnie R.; Assistant Examiner: Peselev,
 Elli
 LREP North, Robert J.; Speer, Raymond M.; Pfeiffer, Hesna J.
 CLMN Number of Claims: 2
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 805

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described are derivatives of glycolipids with substituted steroids
 bridged via a medium length hydrocarbon chain to
 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses. These compounds
 protect an immunocompromised human or animal host against
 Searcher : Shears 308-4994

08/836576

opportunistic infection by virtue of their immunostimulant properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 10 OF 16 USPATFULL
AN 87:20633 USPATFULL
TI Steroidal glycolipids as host resistance stimulators
IN Hagmann, William K., Westfield, NJ, United States
Durette, Philippe L., New Providence, NJ, United States
Ponpipom, Mitree M., Branchburg, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4652553 870324
AI US 85-801906 851125 (6)

DT Utility
EXNAM Primary Examiner: Brown, Johnnie R.
LREP North, Robert J.; Speer, Raymond M.; Pfeiffer, Hesna J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1,9
DRWN No Drawings
LN.CNT 839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described are derivatives of glycolipids with substituted steroids bridged via a medium length hydrocarbon chain to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses. These compounds protect an immunocompromised human or animal host against opportunistic infection by virtue of their immunostimulant properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 11 OF 16 USPATFULL
AN 87:20485 USPATFULL
TI Synthesis of 1.alpha.,25-dihydroxy-24R-fluorocholecalciferol and 1.alpha.,25-dihydroxy-24S-fluorocholecalciferol
IN Partridge, John J., Upper Montclair, NJ, United States
Shiuey, Shian-Jan, Nutley, NJ, United States
Uskokovic, Milan R., Upper Montclair, NJ, United States
PA Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 4652405 870324
AI US 82-405854 820806 (6)
RLI Continuation-in-part of Ser. No. US 81-297446, filed on 28 Aug 1981, now abandoned
DT Utility
EXNAM Primary Examiner: Roberts, Elbert L.
LREP Saxe, Jon S.; Leon, Bernard S.; Boxer, Mathew
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
Searcher : Shears 308-4994

DRWN No Drawings

LN.CNT 1215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1.alpha.,25-Dihydroxy-24R-fluorocholecalciferol and 1.alpha.,25-dihydroxy-24S-fluorocholecalciferol, analogs of 1.alpha.,25-dihydroxy-cholecalciferol which is physiologically the most active metabolite of vitamin D_{sub.3}, are synthesized in a multistep process from the known substance 1.alpha.,3.beta.-dihydroxyandrost-5-en-17-one. The new analogs are characterized by the ability to increase intestinal calcium transport, increase serum calcium and phosphate concentrations and to increase the deposition of these minerals in bones. These compounds will find a ready application as substitutes for natural 1.alpha.,25-dihydroxycholecalciferol in the treatment of disease states characterized by metabolic calcium and phosphate deficiencies. Exemplary of such disease states are the following: osteosclerosis, anticonvulsant treatment, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism, cirrhosis, obstructive jaundice, drug induced metabolism, medullary carcinoma, chronic renal disease, hypophosphatemic VDRR, vitamin D-dependent rickets, sarcoidosis, glucocorticoid antagonism, malabsorption syndrome, steatorrhea, tropical sprue, idiopathic hypercalcemia and milk fever.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 12 OF 16 USPATFULL

AN 87:6433 USPATFULL

TI Method for the immunoanalysis of cholesterol epoxides

IN Schaffner, Carl P., 10 Youngs Rd., Trenton, NJ, United States
08619

PI US 4639420 870127

AI US 84-673768 841121 (6)

DT Utility

EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner:
DeSantis, Patricia L.

LREP Flehr, Hohbach, Test, Albritton & Herbert

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1301

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An immunoassay is provided for cholesterol epoxide. To prepare the antibodies used in the immunoassay, novel immunogens, are prepared which comprise a 3,5(6)-transdiaxial-dihydroxycholestane-6(5)-yl-hapten adduct linked to a covalently bonded bridge to a carrier protein. To detect cholesterol epoxide in the sample, it is converted to the hapten adduct, then contacted with the selected

Searcher : Shears 308-4994

antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 13 OF 16 USPATFULL
 AN 87:1313 USPATFULL
 TI Synthesis of 1.alpha.,25-dihydroxy-24R-fluorocholecalciferol and
 1.alpha.,25-dihydroxy-24S-fluorocholecalciferol
 IN Partridge, John J., Upper Montclair, NJ, United States
 Shiuey, Shian-Jan, Nutley, NJ, United States
 Uskokovic, Milan R., Upper Montclair, NJ, United States
 PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S.
 corporation)
 PI US 4634692 870106
 AI US 84-599086 840411 (6)
 RLI Continuation-in-part of Ser. No. US 82-405854, filed on 6 Aug 1982
 which is a continuation-in-part of Ser. No. US 81-297446, filed on
 28 Aug 1981, now abandoned
 DT Utility
 EXNAM Primary Examiner: Schenkman, Leonard; Assistant Examiner:
 Lipovsky, Joseph A.
 LREP Saxe, Jon S.; Leon, Bernard S.; Boxer, Matthew
 CLMN Number of Claims: 3
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1182

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1.alpha.,25-Dihydroxy-24R-fluorocholecalciferol and
 1.alpha.,25-dihydroxy-24S-fluorocholecalciferol, analogs of
 1.alpha.,25-dihydroxy-cholecalciferol which is physiologically the
 most active metabolite of vitamin D₃, are synthesized in a
 multistep process from the known substance 1.alpha.,3.beta.-
 dihydroxyandrost-5-en-17-one. The new analogs are characterized by
 the ability to increase intestinal calcium transport, increase
 serum calcium and phosphate concentrations and to increase the
 deposition of these minerals in bones. These compounds will find a
 ready application as substitutes for natural 1.alpha.,25-
 dihydroxycholecalciferol in the treatment of disease states
 characterized by metabolic calcium and phosphate deficiencies.
 Exemplary of such disease states are the following: osteomalacia,
 osteoporosis, rickets, osteitis fibrosa cystica, renal
 osteodystrophy, osteosclerosis, anti-convulsant treatment,
 osteopenia, fibrogenesis-imperfecta ossium, secondary
 hyperparathyroidism, hypoparathyroidism, hyperparathyroidism,
 cirrhosis, obstructive jaundice, drug induced metabolism,
 medullary carcinoma, chronic renal disease, hypophosphatemic VDRR,
 vitamin D-dependent rickets, sarcoidosis, glucocorticoid
 antagonism, malabsorption syndrome, steatorrhea, tropical sprue,
 idiopathic hypercalcemia and milk fever.

Searcher : Shears 308-4994

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 14 OF 16 USPATFULL
 AN 86:2096 USPATFULL
 TI 23,23-Difluoro-25-hydroxy-vitamin D._{sub.3} and process for
 preparing same
 IN DeLuca, Hector F., Madison, WI, United States
 Tanaka, Yoko, Madison, WI, United States
 Ikekawa, Nobuo, Tokyo, Japan
 Kobayashi, Yoshiro, Tokyo, Japan
 PA Wisconsin Alumni Research Foundation, Madison, WI, United States
 (U.S. corporation)
 PI US 4564474 860114
 AI US 84-639776 840813 (6)
 DCD 20020219
 RLI Continuation-in-part of Ser. No. US 83-524269, filed on 18 Aug
 1983
 DT Utility
 EXNAM Primary Examiner: Roberts, Elbert L.
 LREP Bremer, Howard W.
 CLMN Number of Claims: 3
 ECL Exemplary Claim: 1,3
 DRWN No Drawings
 LN.CNT 489

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new derivatives of vitamin D,
 23,23-difluoro-25-hydroxycholecalciferol and the acylates thereof,
 a method for preparing said compounds and various new
 intermediates utilized in such process.

The derivative compounds are characterized by vitamin D-like
 activity as evidenced by their ability to increase intestinal
 calcium transport and serum calcium. The compounds are further
 characterized by resistance to hydroxylation at C-23, which is
 recognized as an essential metabolic step to the inactivation of
 vitamin D. The compounds should, therefore, provide vitamin D-like
 activity of greater time duration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 15 OF 16 USPATFULL
 AN 82:22686 USPATFULL
 TI 24-Cyclopropylcholene-3. β ., 22-diols and esters thereof
 IN Chorvat, Robert J., Arlington Heights, IL, United States
 PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
 PI US 4329295 820511
 AI US 81-278276 810629 (6)
 DT Utility

Searcher : Shears 308-4994

08/836576

EXNAM Primary Examiner: Roberts, Elbert L.
LREP Drehkoff, W. Dennis; Passe', James G.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 259

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 24-Cyclopropylcholene-3.**beta.**, 22-diols and
esters thereof which control serum **cholesterol** levels
and their preparation are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 16 OF 16 USPATFULL

AN 81:23334 USPATFULL

TI Contraceptive methods and compositions

IN Burck, Philip J., Indianapolis, IN, United States

Zimmerman, Ronald E., Danville, IN, United States

Thakkar, Arvind L., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)

PI US 4264578 810428

AI US 80-138394 800408 (6)

RLI Continuation-in-part of Ser. No. US 79-57931, filed on 16 Jul
1979, now abandoned which is a continuation of Ser. No. US
78-973252, filed on 26 Dec 1978, now abandoned

DT Utility

EXNAM Primary Examiner: Rose, Shep K.

LREP Rowe, James L.; Whale, Arthur R.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 602

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Introduction of a pharmaceutically acceptable non-toxic cation
salt of a sterol sulfate into the uterine lumen or vaginal cavity
prevents conception. Potassium or pyridinium .beta.-sitosteryl
sulfate is preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'HOME' ENTERED AT 16:41:52 ON 15 DEC 1997

Searcher : Shears 308-4994